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New life of higher organized organisms like vertebrates starts from one cell upon fertilization. 
The cell divides and after a couple cell division rounds, cells start specifying their functions. 
In a relative short time, they give rise to different organs with distinct tissues and many 
unique cell types that together form an organism. When all body parts have formed, it will 
further grow until an adult stage is reach. At this stage, cells are still dividing to replenish 
old cells and to maintain all the different tissues (Gilbert, Scott F. et al. 2010). Tissue 
maintenance requires well-balanced stem cell self-renewal and differentiation by tissue stem 
cells. Deregulation of this balance can result in malfunctioning of the tissue or diseases such 
as cancer. All cells of an organism share the same genetic information and is called their 
genome. The human genome contains 46 chromosomes, which are big DNA molecules that 
are tightly folded to fit in the nucleus of the cell. To mediate the packaging of the DNA many 
proteins are associated with the DNA and together they are called the chromatin. The DNA 
molecules are actually large sequences of four different nucleotides that either contain an 
adenine, thymine, guanine or cytosine base. Through this, the human genome encodes 
approximately 18,000 genes. The set of genes expressed in a cell determines its fate and 
function. From actively expressed genes, RNA molecules are transcribed that can be translated 
to make the functional gene product, a gene specific protein. The RNA molecules function as 
intermediate gene product and are therefore termed messenger RNAs (mRNAs) (Lodish et 
al. 2013). The gene expression profile of self-renewing stem cells changes when they decide 
to differentiate into somatic cells with a specific cell fate and function. The decision of a stem 
cell to start differentiation requires a trigger from the environment. Via a receptor, signals 
are transmitted into the cell to activate or inactivate signal transduction pathways in the stem 
cell leading to activation of specific transcription programs. This also involves transcription 
factors important to activate genes and chromatin factors to unfold tightly packed genes to 
make them accessible. From the trigger towards the changed gene expression profile many 
different factors are essential to initiate differentiation successfully and loss of function of 
these factors will make it difficult for the stem cell to initiate differentiation. A trigger can 
be a ligand inducing pathways and transcription of genes involved in differentiation, but can 
also be the depletion of a growth factor essential for self-renewal leading to inactivation 
of pathways and genes important for cell proliferation. An interesting model to study self-
renewal and differentiation are human epidermal stem cells. They form the epidermis –the 
outer layer of the skin– and represent a robust model with well-established markers for self-
renewal and differentiation. They are easily obtained from surgical material and they allow 
long-term culturing in vitro. It is also a clinically relevant tissue stem cell model, because 
deregulation of these cells can contribute to cancer development and skin diseases such as 
psoriasis (Green, 2008; Rheinwald and Green, 1975). 
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Chapter 1
Epidermal skin homeostasis
The skin covers our body and has an important role to protect us against pathogens and 
excessive water loss, but is also essential for maintaining the body temperature and the 
sensation of environmental temperature and pressure. The skin has three layers based 
on structure and function (FiG. 1). The first layer is the subcutaneous layer or hypodermis 
which is made of soft connective tissue and adipose tissue. This layer has several functions: 
1) Serves for insulation of the body, 2) Connects the skin with other body parts such as 
bones 3) Supplies the skin with blood vessels and nerves. The second layer is the dermis 
which is tighter and makes the skin elastic. It contains fibroblasts and an extracellular 
matrix (ECM) with elastic fibers, but also several glands, such as the sweat glands and 
sebaceous glands as well as nerve endings. The third and outer layer is the epidermis (Hsu 
et al., 2014). The epidermis forms the actual barrier with the environment. In hairy skin, 
hair follicles are appendages of the epidermis. Their main role is generation of hairs, but 
they also form an anchor for nerves, blood vessels and muscles. In the hair follicle reside 
multipotent stem cells that form hair in a cyclic manner and upon wounding, these stem cells 
are also important for skin repair (Hsu et al., 2014). The maintenance of the epidermal skin 
is regulated by other stem cells and will be further discussed. 
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Figure 1. Schematic overview of the human skin. The structure of the skin has three different layers 
hypodermis, dermis and epidermis (left). The epidermis further highlighted and is subdivided in 4 
additional layers (right). A proliferative basal layer and 3 differentiating suprabasal layers: spinous layer, 
granular layer and stratum cornea.
The epidermis is a stratified layer which is renewed every month (Figure 1). This ongoing 
process is regulated by the Inter follicular stem cells which reside on the border between the 
dermis and epidermis known as the basal lamina and on this border, they form the basal cell 
layer. These stem cells or basal cells are connected to the basal lamina with integrins which 
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keeps them in close contact with the fibroblasts from the dermal layer. The fibroblasts are 
thought to form an important source of growth factors for the basal cells demonstrated by 
the colony formation they facilitate in vitro (Rheinwald and Green, 1975; Zhu et al., 2014). 
Basal cells are continuously dividing to form new stem cells as well as mitotically inactive 
cells that start differentiating to give rise to the different surabasal layers of the epidermis 
(Figure 1). Upon initiation of differentiation cells de-attach from the basal lamina. They 
become transit-amplifying cells with limited cell divisions left and migrate upwards into the 
suprabasal layer. This differentiating layer of cells can be subdivided in three structurally 
distinct layers: spinous layer, granular layer and stratum conea. In the spinous layer 
different pathways are triggered and transcriptional programs are re-organized resulting in 
further maturation and migration to the granular layer. From here, the cells also lose their 
nuclei, die and form the stratum cornea, the outer layer where cells shed off and need to be 
replenished. To maintain the epidermal layers, good regulation of the balance between self-
renewal and differentiation is important in the basal cells. When this balance is disturbed the 
structure of the skin barrier is lost and diseases will develop
Regulation of epidermal stem cell renewal 
The division of stem cells can occur in three different ways. 1) Two self-renewing daughter 
cells are formed. 2) A self-renewing and differentiating daughter cell is formed. 3) Both 
daughter cells are differentiating. Label tracing studies have shown that basal cells are long 
lived stem cells giving rise to a new stem cell and a transient amplifying (TSA) cell in a 
hierarchical manner. TSA’s or progenitor cells in turn show a more stochastic pattern which 
means progenitors can randomly give rise to differentiating and proliferating cells with a 
fixed probability to get both cell types (Hsu et al., 2014; Mascré et al., 2012). Through this 
the replenishment of different epidermal layers is kept in balance.    
Integrins are essential for self-renewal capacity
In basal cells, the ECM of the basal lamina and growth factors from the dermal fibroblasts are 
important external regulators for maintaining the self-renewal capacity. To respond to these 
factors, intrinsic regulators in the basal cells are also essential such as the expression of 
Integrins and growth factor receptors. Of the multiple expressed Integrins, Integrin beta-1 
(ITGB1) and -alpha-6 (ITGA6) are considered as the most important Integrins (Watt, 2002) 
and ITGB1 in particular represents a strong marker for basal cells. When ITGB1 expression 
drops, cells go into a transit amplifying state and after commitment to differentiation ITGB1 
expression is completely inactive (Watt, 2002). Integrins are important for self-renewal 
via the anchor they form with the ECM, but they also function as receptor connected 
with intracellular signaling routes associated with cell proliferation including the mitogen-
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activated protein kinase (MAPK) signaling (Figure 2). Evidence for this was demonstrated in 
mice with active ITGB1 expression in the suprabasal layer leading to hyper proliferation and 
activation of the MAPK signaling. (Haase et al., 2001; Mercurio and Rabinovitz, 2001; Zhang 
et al., 2013; Zhu et al., 1999). 
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Figure 2. Overview of several signaling routes in epidermal cells regulating proliferation and differentiation. 
Arrows indicate activation and blunt arrows inactivation events.
EGF signaling and transcription in epidermal stem cells 
Activation of proliferation associated signaling routes also highly depend on growth factors, 
including insulin like growth factors (IGFs) and epidermal growth factor receptor (EGFR) 
ligands (Hsu et al., 2014). For self-renewal, the EGFR in particular is a potent regulator 
of epidermal growth. In mice studies, activation of ligands such as transforming growth 
factor alpha (TGFa) or inactivation of a negative regulator leads to hyper proliferation in the 
epidermis (Ferby et al., 2006; Vassar and Fuchs, 1991) and in vitro EGFR inhibition induces 
differentiation in epidermal stem cells (Kolev et al., 2008; Mulder et al., 2012). Altogether, 
growth factors and Integrins in particular are important to keep the cells in a proliferative 
environment and via intracellular signaling and specific gene transcription programs the self-
renewal capacity is regulated intrinsically. 
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Most of the intracellular signaling via receptors such as the EGFR is mediated by protein 
kinases. Kinases are enzymes that add phosphate-groups to their substrates, a chemical 
reaction termed phosphorylation. Phosphorylation leads to a conformational change of 
the substrate making it active or inactive. Through this actions, kinases control multiple 
cellular processes, including metabolism, transcription, cell cycle progression, cytoskeletal 
rearrangement and cell movement, apoptosis, and differentiation (Manning, 2002). 
Signaling routes downstream the EGFR are important for maintaining the proliferative state 
in basal cells. The MAPK signaling is one of these routes (Figure 2) (Wee and Wang, 2017). 
MAPK activation involves EGFR binding with adaptor proteins Sos2 and Grb2 causing a 
conformational change in Sos2. This activates Ras which in turn stimulates the classic MAPK 
cascade consisting of Raf, MEK and ERK. Via ERK many other factors are stimulated including 
transcription factors that promote survival and proliferation (Liebmann, 2001). Beside the 
classical MAPK route via ERK, two other MAPK subfamilies exist: JNKs (Jun amino-terminal 
kinases), and p38/SAPKs (stress-activated protein kinases), however these routes are more 
responsive to oxidative-stress and cytokines (Cobb, 2012). Another signaling protein that 
acts via EGFR on cell proliferation and multiple other processes is Akt (Manning and Toker, 
2017; Wee and Wang, 2017). After EGFR stimulation, PI3K is activated first via GAB1/2 or 
alternatively via IRS1/2 and subsequently, Akt is activated by PI3K (Knowlden et al., 2008; 
Manning and Toker, 2017). Akt is a central player in signal transduction and has many 
targets, including several transcription factors and other signaling proteins such as mTOR, 
one of the most important regulators in protein translation. MAPK signaling and Akt-mTOR 
signaling represent two prominent signaling arms in the EGF signaling network that also 
have common targets exemplified by Ribosomal protein S6 (RPS6). This a protein involved 
in protein translation and is phosphorylated by the kinases p90RSK and p70S6K downstream 
ERK and Akt-mTOR, respectively (Mendoza et al., 2011). Via these arms and also alternative 
routes, the EGF signaling is connected to a network with multiple other signaling pathways. 
Examples of well described cross-talks represents the interaction of MAPK with STAT3 from 
the Jak-STAT signaling and Akt with Wnt signaling protein GSK3b. 
To maintain self-renewal, the EGF signaling pathway regulates transcription factors that 
control transcription programs. One of these transcription factors is cMyc. This factor can 
be stimulated by the EGF signaling via ERK and controls cell proliferation and cell cycle 
progression in many cell types (Kern et al., 2010; Oskarsson et al., 2006). Another 
transcription factor more specific for the skin is TP63. TP63 expression in the epidermis is 
highest in basal cells and Its downregulation is thought to be required for withdrawal from 
the cell cycle and subsequent differentiation (Kouwenhoven et al., 2010; Pellegrini et al., 
2001; Truong et al., 2006). In addition, TP63 expression also depends on EGF signaling and 
has been shown to go via STAT3 and PI3K (Yoh and Prywes, 2015).
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Epidermal differentiation and signaling
Initiation of differentiation is governed by two mechanisms: 1) loss of contact with the 
basal lamina termed delamination in which Integrin downregulation has a prominent role 
(Brakebusch et al., 2000; Watt, 2002). 2) Asymmetric cell division giving rise to a basal 
cell attached to the basal lamina and a committed cell pointing towards the suprabasal 
layer (Lechler and Fuchs, 2005). An essential pathway for further entry into the spinous 
layer is the Notch signaling pathway (Figure 2) (Blanpain et al., 2006; Hsu et al., 2014). 
In the epidermis of mice, the Notch receptors (Notch1, -2, -3) are expressed suprabasally 
together with one of their ligands Jagged1. When the Notch receptors interact with their 
ligand, the internal domain of Notch receptor is cleaved and released. The presence of the 
Notch intracellular domain (NICD) is a hallmark of active Notch signaling and enables the 
transcription of Notch target genes of the Hes/Hey family via inactivation of transcriptional 
repressor RBP-J. Nuclear presence of NICD, active transcription of Hes1 and expression of 
a Notch reporter gene regulated by RBP-J and NICD have been used to demonstrate active 
Notch signaling in the spinous layer (Blanpain et al., 2006). Moreover, in vitro differentiation 
induced with EGFR inhibition in human epidermal stem cells leads to increased expression of 
Notch1 and Hes transcription factors (Kolev et al., 2008) and constitutive activation of Notch 
signaling in the basal mouse epidermis results in massive expansion of the spinous layer 
(Blanpain et al., 2006). Conversely, when components important in asymmetric cell division 
are affected, Notch signaling is less activated and the cell numbers in the spinous layer 
decline (Williams et al., 2011). These findings indicate the importance of Notch signaling for 
the formation of the spinous layer. 
Another pathway active in epidermal differentiation represents the BMP signaling pathway. 
BMPs are members of TGFb family which includes 33 members in mammals and among these 
molecules more than a dozen belong to the BMP subfamily (Miyazono et al., 2010). The BMP 
ligands act via a combination of type I and type II receptors. In epidermal differentiation 
roles have been described for BMP2, BMP4, BMP6 and BMP7, based on their expression levels 
and ability to induce differentiation (Ahmed et al., 2011; Gosselet et al., 2007; Mulder et al., 
2012). They all act via the type II receptor BMPR2 and type I BMPR1A or BMPR2A. Binding 
of the BMPs with the receptors activates the intracellular SMAD signaling. This implies the 
phosphorylation of SMAD1, SMAD5 and SMAD9 and subsequent complex formation following 
translocation to the nucleus leading to transcriptional activation of target genes. The Id 
genes (Id1-4), MSX2 and DLX3 are examples of BMP target genes that have also been used 
to demonstrate an active BMP response in epidermal differentiation. (Ahmed et al., 2011; 
Gosselet et al., 2007; Miyazono and Miyazawa, 2002). Most studies demonstrating a role 
for BMP signaling in epidermal differentiation are done in mice and hair follicle cells. BMPs 
also contribute to human epidermal differentiation, but our understanding is still modest. 
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BMP2 and BMP7 have been demonstrated as potent inducers of epidermal differentiation and 
BMP2 and 6 were shown to control growth arrest and terminal differentiation. The genes and 
transcription programs activated by BMPs and the timing of their expression during human 
epidermal differentiation are still poorly understood and requires further investigation.
Transcription events during epidermal differentiation
Transcription programs are regulated by transcription factors. Transcription factors are 
activated to coordinate cellular processes that lead to changes such as the switch from stem 
cell to differentiating cell in the epidermis. In this process different transcription factors 
regulate each other to down-regulate the genes important for self-renewal and activate 
genes important for differentiation in the right order. Notch signaling is thought to act 
early in differentiation and its target genes (Hey/Hes genes) seem therefore important for 
commitment toward differentiation (Williams et al., 2011). Another target gene of Notch is 
IRF6 (Richardson et al., 2006). Interestingly, IRF6 is also regulated by TP63 and mutations 
in both genes lead to similar phenotypes in human syndromes. Moreover, IRF6 is down-
regulated when TP63 is mutated (Ingraham et al., 2006; Richardson et al., 2006) and 
in adult epidermal skin, TP63 was shown to activate IRF6 via enhancers regulating IRF6 
expression (Nguyen et al., 2006; Truong et al., 2006). TP63 is regulated by IRF6 as well, 
but IRF6 inactivates TP63. In line with this, an IRF6 knock-down study showed increased 
TP63 expression in epidermal stem cells induced for differentiation through activation of the 
Notch signaling. In these cells, self-renewal markers were also increase including several 
Integrins and diminished expression was observed for differentiation marker Involucrin. 
Furthermore, it was demonstrated that this effect of IRF6 on differentiation was induced 
in parallel of other Notch target genes such as Hes1, indicating that these Notch target 
genes do not depend on each other for their expression (Restivo et al., 2011). IRF6 also 
regulates other transcription factors with known to regulate differentiation, including GRHL3 
and Ovol1 (Garza et al., 2013; Kwa et al., 2014). Another transcription factor identified in 
epidermal differentiation and regulated by TP63 is ZNF750. Like IRF6, ZNF750 activates 
GRHL3, but also other factors including transcription factor KLF4 which is considered as 
marker for late differentiation and known to regulate many other genes (Boxer et al., 2014; 
Sen et al., 2012). ZNF750 is therefore an important regulator in epidermal differentiation. 
However, two other transcription factors have been identified that regulate ZNF750. Also, 
many other genes targeted by ZNF750 such as KLF4 were depended on activity of MAF/
MAFB. The regulation of MAF/MAFB is not completely understood. At least two long non-
coding RNAs (lncRNAs) have been identified to regulate them. ANCR down-regulates MAF/
MAFB and TINCR up-regulates them (Lopez-Pajares et al., 2015), but pathways involved in 
their regulation have not been identified yet. In addition, it remains unclear in which order 
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transcription factors act during differentiation and whether they are all necessary or whether 
there are parallel routes to regulate differentiation.
Genetic screening in epidermal differentiation
For the identification of novel factors important in processes such as epidermal differentiation 
genetic screens can be applied. This generally involves the perturbation of many genes 
and subsequent analysis of a specific and robust read-out that can tell whether a gene 
perturbation has a significant effect on differentiation or proliferation. A commonly used 
strategy for gene perturbations makes use of RNA interference (RNAi) (Kim, 2005; Kim et 
al., 2009; Meister and Tuschi, 2004). This is based on the mechanism behind the activity of 
micro RNAs (miRNAs) which are known to fine tune gene expression. They are transcribed 
form larger transcript and processed by nucleases into hairpins. The hairpin structured 
RNA molecules are transported out of the nucleus and further processed in the cytoplasm 
into double-stranded RNA molecules of approximately 21 nucleotides long. In this form, 
they are loaded into a protein complex that uses the miRNA as guide to target specific 
mRNAs for degradation or inhibition of translation. In this protein complex, Argonaute 2 is 
responsible for targeting the mRNA for degradation, but this only occurs when the miRNA 
sequence is fully complementary to the target mRNA sequence. This principle is used in 
RNAi based genetic screens in which double-stranded RNA molecules are brought into the 
cell to knock-down gene activity through targeting specific mRNAs for degradation. For the 
identification of genes in epidermal differentiation, two similar RNAi screens have been 
performed that covered hundreds of genes targeting chromatin factors and transcription 
factors (Mulder et al., 2012; Tanis et al., 2018). These genes were screened for an effect on 
the protein expression of late differentiation marker Transglutaminase 1 (TGM1) induced by 
a variety of differentiation triggers, including stimulation with recombinant BMPs, inhibition 
of the EGFR or addition of serum. This gave the screens an extra dimension as it is not 
evident that all differentiation triggers require the same genes and through this it was also 
possible to link different genes in the screen with a similar effect on the differentiation 
triggers. The chromatin factor screen discovered several factors including EZH2 that led to 
increased differentiation upon knock-down (Mulder et al., 2012). Interestingly, EZH2 is also 
thought to act in complex with the lncRNA ANCR which was shown to down-regulate the 
MAF/MAFB transcription factors and therefore seems a good explanation for the increased 
differentiation phenotype in the screen upon EZH2 knock-down  (Lopez-Pajares et al., 2015). 
The Transcription factor screen identified known regulators in differentiation such as IRF6 
and several Hes genes. Gene knock-downs leading to increased differentiation were found 
as well including splice factor ZMAT2. Further research showed that ZMAT2 is important for 
the transcript processing of several genes that mediate cell adhesion including ITGB1 (Tanis 
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et al., 2018). These two screens nicely show the power of genetic screening to find novel 
regulators in self-renewal and differentiation. However, these screens rely on the use of 
small interfering RNAs (siRNAs) with a variable efficiency and cover only hundreds of genes 
while the genome contains ~18,000 genes. 
Genetic screening with CRISPR-Cas9
A recent and revolutionary technology to perturb genes emerged with the discovery of 
the mechanism behind CRISPR-Cas9 (Jinek et al., 2012; Mali et al., 2013). Through this, 
an accessible application for targeted gene-editing became available for many scientists 
and opened new doors in the field of genetic engineering (Knott and Doudna, 2018). The 
rationale is based on the CRISPR RNA that guides the Cas9 protein to a specific genomic 
DNA sequence to introduce a cut in the DNA, but only if the guide RNA (gRNA) sequence of 
the CRISPR is fully complementary to its target. The cell does have repair mechanisms, but 
often the repair of a DNA-break leads to insertion or deletion mutations that can inactivate 
the gene completely through destroying the gene code. With CRISPR-Cas9, introducing site 
specific mutations in the genome has become very simple and it is therefore a versatile 
tool to inactivate genes on the genomic level. However, it should be taken in account that a 
mutation not always inactivates the gene. Proteins are like DNA a sequence of building blocks 
termed amino acids. In contrast with the DNA building blocks, there are not four but twenty 
different amino-acids. To make translation towards a protein sequence possible, amino acids 
encode for specific combinations of 3 nucleotides called codons. To successfully introduce an 
inactivating mutation, the repair of a DNA break should not lead to an insertion or deletion 
of nucleotides that only lead to the addition or removal of codons as these keeps the rest of 
the protein sequence intact. Furthermore, all genes have two copies that need to be mutated 
properly to inactivate the gene completely. Like RNAi, gene inactivation efficiency can be 
variable with CRISPR-Cas9, but the chance to completely and permanently inactivate a gene 
is higher compared to RNAi based strategies. It is therefore not surprising that CRISPR-cas9 
is also applied in genetic screens. The first reported CRISPR screens covered all annotated 
genes allowing identification of genes in all kinds of processes in the cell (Shalem et al., 
2014). The targeting of CRISPR-Cas9 is conferred by short gRNA sequences and therefore, 
libraries can be easily produced with multiple gRNAs per gene (Peng et al., 2015; Sanjana 
et al., 2014; Shalem et al., 2014). To cover all annotated genes, the scale of the screen is 
enormous and forced to develop a pooled genome-scale CRISPR screen. Delivery into the 
cell of the genetic information to express Cas9 and the CRISPR RNA was accomplished with 
a lentiviral expression system. The viruses easily infect the cells and are stably maintained 
over the course of multiple cell divisions as they integrate in the host genome. A puromycin-
resistance gene was delivered as well to allow selection with puromycin for cells that have 
the virus integrated. Using lentiviral vectors, a library was constructed of vectors that all 
express the Cas9 and the puromycin-resistance gene, but differ in the gRNA they express. 
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The selection pressure of this pooled lentiviral CRISPR screen relies on the effect that gRNAs 
and thus gene knock-outs have on cell growth and survival. With the right titer allowing 
not more than one knock-out per cell, the screen rationale is that short after infection the 
representation of the gRNAs in the cell population will be different compared to a later time-
point. Some gRNAs will be depleted as they knock-out genes essential for survival and others 
are increased, because they knock-out a gene that represses cell proliferation. Because 
gRNA sequences are integrated in the genome of the cells, the difference in representation 
of the gRNAs between time points can be addressed with high-throughput sequencing. For 
this, genomic DNA is extracted from the samples and processed in a way that only gRNA 
sequences are sequenced. After sequencing, the number of sequenced gRNAs is counted 
in the different samples. Per gene multiple gRNAs are present in the library (>3) allowing 
statistical analysis. Through this, statistically substantiated decisions can be made for the 
selection of gene knock-outs with an effect on cell growth and survival.
CRISPR screening can be done in two directions. With negative selection the focus is on 
under-represented and depleted gRNAs and with positive selection on over-represented 
gRNAs. With cell growth as selection pressure, the positive selection is most robust and 
has been demonstrated as powerful approach for identification of gene knock-outs that 
make cancer cells resistant to drugs (Ruiz et al., 2016; Shalem et al., 2014). These 
genes are important for the response to the drug that blocks cell proliferation. When 
these genes are inactivated, cells are less sensitive to the drug allowing them to keep 
growing leading to over-representation of the responsible gRNAs. When epidermal stem 
cells commit towards differentiation, they also stop proliferating. CRISPR screening 
would therefore be an interesting genome-wide screening approach to find novel genes 
important for the commitment towards differentiation. In the previously described RNAi 
differentiation screens, the EGFR inhibitor AG1478 was used as differentiation trigger and 
would be interesting to apply in a CRISPR screen. (Kolev et al., 2008; Mulder et al., 2012; 
Tanis et al., 2018). These RNAi screens with differentiation marker expression as read-out 
were capable to find genes affecting differentiation, but not necessarily genes essential 
for differentiation. With cell growth as selection pressure genes will be screened for less 
sensitivity to AG1478 resulting in delayed differentiation or continued cell proliferation. 
The most essential genes in differentiation are the ones important for the commitment 
towards differentiation. Withdrawal from the cell cycle is one of the most important steps in 
commitment, which makes CRISPR screening with AG1478 a suitable approach to generate 
hits essential in epidermal differentiation. Furthermore, the genome-wide coverage will also 
be able to identify other genes than chromatin- and transcription factors such as receptors 
or signaling proteins. Therefore, this approach has the potential to show which processes or 
pathways are important in differentiation when multiple genes in one of these processes are 
identified as hit. Altogether, the technical difference compared to the RNAi screening, the 
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difference in selection pressure/ read-out and the genome-wide scale of the CRISPR makes 
it an interesting screening approach to find novel regulators in epidermal differentiation.   
ID-seq enables novel strategies to study cellular signaling in 
epidermal differentiation
CRISPR screening using EGFR inhibition is an interesting way to find novel regulators in 
differentiation. The EGFR inhibitor AG1478 blocks the EGF signaling which is an established 
differentiation trigger. However, the EGF signaling downstream the EGFR has different 
routes, including routes via Akt, ERK and other connected routes like STAT3 from the JAK-
STAT signaling and GSK3b from the Wnt signaling (Figure 2). It is a complex signaling 
network and therefore important to investigate what exactly occurs downstream EGFR 
upon inhibition in epidermal cells. Questions to address are for instance, which signaling 
routes are most important for differentiation and how are other signaling routes affected? 
A good way to approach these questions would be measuring multiple proteins of interest 
simultaneously to follow their expression upon treatment with AG1478. To understand which 
downstream signaling routes have a significant role in triggering differentiation, it would be 
even more informative to perturb multiple downstream signaling components and address 
their ability to induce differentiation. Recently, Immuno-detection sequencing (ID-seq) was 
presented as novel and innovative technique to address these questions (van Buggenum 
et al., 2018). This technique is based on antibodies. These are proteins produced by the 
immune system to specifically bind and recognize pathogen associated molecules. In science, 
antibodies are developed and used to bind and detect specific proteins or even specific 
modifications such as phosphorylation site. ID-seq was developed to allow detection of > 100 
antibodies simultaneously within one cell population of 10,000 cells. This was accomplished 
by a strategy in which antibodies are conjugated with unique DNA sequences facilitating 
detection with high-throughput sequencing (van Buggenum et al., 2018, 2016). Detection 
of 84 (phospho-) antibodies in AG1478 treated cells showed an increase of differentiation 
associated factor Notch1, but also a substantial decrease in signal of phosphorylated RPS6, 
the signaling protein downstream EGF regulated by the ERK and the Akt-mTOR signaling 
routes. Furthermore, a kinase inhibitor drug screen was demonstrated with ID-seq to 
perturb many kinases in order to find inhibitors with similar effects as AG1478. This also 
identified inhibitors of the RPS6 kinases p70S6K and p90RSK. Further investigation with the 
p70S6K inhibitor PF4708671 and p90RSK inhibitor BI-D1870 showed that both inhibitors 
led to decreased cell proliferation and BI-D1870 did also induce the expression of late 
differentiation marker TGM1. ID-seq therefor represents a great technique to screen drugs 
based on their effect on signaling and phenotypes such as differentiation. 
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Single cell analysis provides insights in cellular heterogeneity 
and signaling dynamics
A limitation of ID-seq is the cell population-based measuring. For instance, if half the 
population shows an effect in one pathway and the other half in another pathway, the 
population-based measurement will indicate that both pathways are affected while it is 
either one of the two. Therefore, a single cell approach would be beneficial to determine how 
heterogeneous a drug response is within a population through the observation of individual 
cells. Single cell multi-protein detection methods are available, but they also have their 
limitations.
A powerful technology is CyTOF combining flow cytometry with mass spectrometry. Flow 
cytometry is originally a single cell analysis method that uses antibodies with fluorescent-
labels for detection and can processes millions of cells. This method is well established, but 
distinguishing distinct fluorescent signals becomes very complex when the number of labels 
increases. Combining flow cytometry with mass spectrometry enabled the use of metal 
labels allowing the use of more antibodies (Lun et al., 2017). With a panel of 35 antibodies, 
this mass-cytometry based method has previously been demonstrated in combination with 
overexpression of tagged signaling proteins to study the relationship between different 
signaling components (Lun et al., 2017). Mass-cytometry is therefore a good method to 
study the effects of targeted drug treatments on signaling, but the number of pathway 
components that can be measured remains limiting with 35 antibodies. Single cell multi-
protein detection is a new and fast developing field that recently led to the introduction of 
other strategies than mass-cytometry. These strategies, including REAP-seq, CITE-seq and 
Abseq (Peterson et al., 2017; Shahi et al., 2017; Stoeckius et al., 2017) are more similar 
to ID-seq as they also use DNA barcoding of antibodies with high-throughput sequencing 
as read-out. Interestingly, the REAP-seq and CITE-seq methods both were developed to 
measure proteins and transcripts allowing the comparison of protein and mRNA expression 
in single cells. However, compared to ID-seq and mass-cytometry, none of them has been 
demonstrated to detect intracellular signaling proteins. In addition, when ID-seq is applied 
for drug screening, it is convenient when the approach used for follow-up on single cells has 
a compatible antibody-DNA conjugate panel with the same barcoding strategy. 
For a single cell ID-seq application, implementing a flow cytometry step could suffice it. 
To accomplish this, development of an in-solution staining is required and the sample 
preparation for sequencing will need down-scaling and optimization to detect biological 
signals from single cells. Moreover, the combination of population-based and single-cell 
multi protein detection with the same technique will be an interesting toolbox allowing 
drug screening and subsequent characterization of interesting candidates in single cells. 
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From the demonstrated kinase drug screen with ID-seq, PF4708671 and BI-D1870 would be 
interesting candidates for single-cell analysis. The targeted kinases are both stimulated by 
EGF, but via different signaling routes (ERK and Akt-mTOR) and both phosphorylate RPS6. 
Single-cell analysis could nicely show how different the effects of inhibiting these kinases 
are on signaling. The screen already showed diminished downstream RPS6 phosphorylation 
upon treatment with the inhibitors. However, through single-cell analysis, questions can also 
be addressed about their effects on signaling upstream the p70S6K and p90RSK kinases 
and possibly other signaling pathways as well. The use of single cell ID-seq can also be 
focused on the heterogeneity of a cell population, such as different differentiation stages. 
Through this signaling activity can be studied at different stages during differentiation. In 
addition, the implementation of flow cytometry can be an advantage here, as it could be 
used to pre-sort and enrich different stages using antibodies with fluorescent labels against 
differentiation or self-renewal markers. Development of a single cell ID-seq approach would 
therefore be beneficial to further investigate function and activity of genes and pathways in 
processes such as epidermal self-renewal and differentiation. 
Aim of thesis and outline
Molecular biology is a fast and highly dynamic field with technical developments that constantly 
enable deeper understanding of biology on the molecular level. Recent developments with 
great impact on the field include applications based on the targeted genome engineering 
with CRISPR-Cas9 and innovations with single cell resolution to study gene regulation, 
signaling and other cellular processes. The research of this thesis aimed to gain new insights 
in human epidermal self-renewal and differentiation while using this well-established model 
for the development of novel and innovative molecular research techniques representing 
CRISPR screening and ID-seq in single cells. 
In chapter 2, I aimed to adapt ID-seq for single cell analysis and use it for the study of 
signaling in epidermal differentiation. To accomplish this, the staining procedure was changed 
into an in-solution staining to allow flow cytometry for single cell sorting and the sample 
preparation for sequencing was improved to allow sensitive detection of many antibodies in 
single cells. We took advantage of the flow cytometry step to pre-sort cells with high and 
low expression of self-renewal marker ITGB1 and scID-seq analysis of other self-renewal 
and differentiation markers was used to fine tune the differentiation status of the cells. This 
enabled expression and activity analysis of multiple measured signaling proteins in many 
cells with distinct differentiation stages. This highlighted several changes in signaling during 
differentiation including BMP signaling. Further analysis was therefore aimed to dissect the 
role of BMP signaling in regulating epidermal differentiation.
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Genome-wide CRISPR screens require many cells for a good coverage of the gRNA library 
and long-term cell culture to generate robust hits with cell growth as selection pressure. 
Expansion of primary epidermal stem cells is relatively easy and they can be cultured for 
multiple weeks. For this reason, epidermal stem cells were considered as suitable primary 
stem cell model for genome-wide CRISPR screening. With EGFR inhibitor AG1478 terminal 
differentiation is triggered effectively in a controlled manner giving rise to non-dividing 
maturating cells. In chapter 3, I therefore aimed to develop an AG1478 induced epidermal 
differentiation assay for genome-wide CRISPR screening to find novel regulators of epidermal 
differentiation.
The kinase inhibitor screen previously demonstrated with ID-seq demonstrated a link 
between epidermal differentiation and decreasing levels of RPS6-p. The inhibitors PF4708671 
and BI-D1870 of RPS6 kinases p70S6K and p90RSK both have a negative effect on clonal 
expansion of epidermal stem cells and BI-D1870 also induced terminal differentiation (van 
Buggenum et al., 2018). These phenotypic inhibitory effects on epidermal cells together 
with their regulation via EGF, but via distinct signaling routes makes it appealing to further 
analyse the inhibition of p70S6K and p90RSK in single cells. In chapter 4, scID-seq was 
applied to study the changes on epidermal signaling introduced by RPS6 kinase inhibitors 
PF4708671 and BI-D1870. In this study, the signaling blockade introduced by the inhibitors 
was expected to inactivate downstream signaling, and was therefore aimed to address the 
effects upstream of the inhibited kinases and on other pathways? 
In chapter 5, I initially aimed to study the nuclear role of miRNA associated protein AGO2. Its 
classical role takes place outside the nucleus in the cytoplasm and involves association with 
miRNAs and subsequent targeting of specific mRNA molecules for degradation. To investigate 
its nuclear role, AGO2 associated chromatin was isolated through immunoprecipitation 
with the AGO2 11A9 antibody (Rüdel et al., 2008). We addressed the immunoprecipitated 
chromatin with high-throughput sequencing to identify potential genomic binding sites and 
mass spectrometry to reveal the associated proteins. To validate the findings from this 
experiment with the AGO2 11A9 antibody, I engineered an AGO2 knock-out using CRISPR-
Cas9. This showed that the SWI/SNF proteins identified in immunoprecipitated chromatin 
were also identified in the absence of AGO2. With the data I already collected with the AGO2 
11A9 antibody, it was decided to change the aim of the chapter and focus it on the cross-
reactivity of the AGO2 11A9 antibody with the SWI/SNF complex.
In chapter 6, I will further discuss the work from chapter 2, 3 and 4.
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Abstract
Epidermal homeostasis requires balanced and coordinated adult stem cell renewal and 
differentiation. These processes are controlled by both extracellular signaling and by cell 
intrinsic transcription regulatory networks, yet how these control mechanisms are integrated 
to achieve this is unclear. Here, we developed single-cell ID-seq and simultaneously 
measured 69 proteins (including 34 phosphorylated epitopes) at single-cell resolution to 
study the activation state of signaling pathways during human epidermal differentiation. 
Computational pseudo-timing inference revealed dynamic activation of the JAK-STAT, WNT 
and BMP pathways along the epidermal differentiation trajectory. We found that during 
differentiation, cells start producing BMP2-ligands and activate the canonical intracellular 
effectors SMAD1/5/9. Mechanistically, the BMP pathway is responsible for activating the 
MAF/MAFB/ZNF750 transcription factor network to drive late stage epidermal differentiation. 
Our work indicates that incorporating signaling pathway activation into this transcription 
regulatory network enables coordination of transcription programs during epidermal 
differentiation.
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Introduction
The human epidermis is continuously turned-over throughout life, a process that requires 
precise control and coordination of stem cell renewal and differentiation. During epidermal 
homeostasis, proliferating stem/progenitor cells residing in the basal layer replenish terminally 
differentiated cells that are shed from the skin surface (Blanpain and Fuchs, 2006; Solanas 
and Benitah, 2013; Watt et al., 2006). Human epidermal stem cells can be maintained in 
culture and used to regenerate functional epidermis in vivo upon transplantation and retain 
their capacity to differentiate in vitro (Barrandon et al., 2012; Green, 2008; Hirsch et al., 
2017; Rheinwald and Green, 1975). The process of differentiation is driven forward by 
consecutive activation of transcriptional programs, yet the mechanisms underlying their 
sequence and timing are not well understood. In the epidermal basal layer, cells receive 
proliferative signals, predominantly via the epidermal growth factor receptor, and contact 
the underlying basement membrane (Watt, 2002; Watt and Huck, 2013). These contacts 
are mediated by focal adhesions and hemi-desmosomes that contain integrin b1 and integrin 
a6, respectively (Watt, 2002; Watt and Huck, 2013). As cells stop proliferating and initiate 
differentiation, these structures are resolved, allowing the cells to detach from the basement 
membrane and migrate up towards the epidermal surface. During this migration, the cells 
undergo major transitions in transcriptional programs, eventually producing the terminally 
differentiated keratinocytes that form the outermost protective layer of our skin.
TP63 is a key DNA-binding transcription factor in epidermal stem cell renewal and upon 
differentiation its expression is decreased (Kouwenhoven et al., 2010; Truong et al., 2006). 
In contrast, other transcription factors, including KLF4, OVOL2, GRHL3, MAF/MAFB and 
ZNF750, are induced (Bhaduri et al., 2015; Koster and Roop, 2004; Lopez-Pajares et al., 
2015; Sen et al., 2012; Wells et al., 2009). Of these, MAF and MAFB cooperatively regulate 
a transcription program that includes ZNF750, which subsequently drives expression of 
terminal differentiation genes (Lopez-Pajares et al., 2015). This concept of sequential 
activation of transcription factors (also called transcription regulatory networks) explains cell 
intrinsic progression of epidermal differentiation. Indeed, human keratinocytes differentiate 
when placed in conditions where they are not in contact with other cells, for instance in 
suspension in methylcellulose or on micro-patterned islands, (Adams and Watt, 1989; 
Connelly et al., 2010). However, this does not take into account the need for regional 
coordination of differentiation in a tissue context. For instance, the basal, spinous, granular 
and cornified layers of the epidermis are morphologically distinct and can be distinguished 
using specific markers, reflecting differences in transcriptional programs. The fact that these 
are sequentially formed layers indicates the need for a form of coordination that is not 
immediately explained by the function of cell intrinsic transcription factor networks.
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Extracellular signaling pathways generally depend on binding of a peptide ligand to the 
extracellular part of a transmembrane receptor. This receptor then relays this interaction 
into an intracellular cascade, usually involving multiple kinases and phosphorylation events 
to regulate specific transcription programs. As such, activation of extracellular signaling 
pathways may serve as a self-contained timing mechanism to drive differentiation forward 
in a tissue and safeguard the irreversibility of the process. Several signaling pathways (e.g. 
Integrins, EGF, TGFb, Notch and BMP) have been implicated in epidermal biology, yet their 
temporal dynamics and mechanistic contributions to the control of specific transcription 
programs are largely unknown, especially in the context of human epidermis (Beck and 
Blanpain, 2012; Blanpain and Fuchs, 2006; Li et al., 2003; Watt, 2002; Watt et al., 2006). 
For example, the importance of the Bone Morphogenetic Protein (BMP) pathway in the 
embryonic morphogenesis of mouse hair follicles and bulge stem cell behavior during 
postnatal hair differentiation and cycling in mice is well established (Blanpain and Fuchs, 
2006; Botchkarev and Sharov, 2004; Guha et al., 2004; Lewis et al., 2014; Mou et al., 
2016), yet the contribution of this pathway to human epidermal renewal and differentiation 
is still poorly understood (Fessing et al., 2010; Gosselet et al., 2007; Yang et al., 2006).
To study the role of signaling in human epidermal differentiation, we recently described 
the Immuno-Detection by sequencing (ID-seq) technology to simultaneously quantify >70 
(phospho-)proteins in many cell populations in parallel (van Buggenum et al., 2018; van 
Buggenum et al., 2016). This allowed us to screen hundreds of small molecule kinase inhibitors 
for their impact on keratinocyte biology. The ID-seq technology entails highly multiplexed 
immuno-staining with DNA-barcoded antibodies followed by signal quantification through 
high-throughput sequencing. A 10nt antibody-specific barcode enables deconvolution of the 
measured epitope, whereas inclusion of unique molecular identifiers allows accurate count-
based quantification. The fact that these 10nt barcodes are discrete and specific for each 
antibody facilitates multiplexed detection of 70 (or more) epitopes per treated population 
of cells. Thus, using ID-seq, the activity of a range of processes and signaling pathways 
can be monitored through the activated (phosphorylated) states of its components (van 
Buggenum et al., 2018). However, populations of cells rarely display homogeneous timing 
of differentiation (Altschuler and Wu, 2010; Wu and Singh, 2012), making it difficult to 
investigate the signaling dynamics underlying this process. We therefore set out to study 
signaling pathway activity and dynamics during human epidermal cell differentiation at the 
single-cell level.
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Results
scID-seq allows robust, reproducible and highly multiplexed protein detection in 
single cells.
To reach single-cell sensitivity and resolution, we redesigned and significantly modified 
our original ID-seq technology. Our final single cell (sc) ID-seq workflow includes immuno-
staining of cells in suspension followed by flow cytometry-based single-cell distribution 
into 96-wells PCR plates to prepare samples for sequencing (Figure 1A and Figure S1). 
A key improvement was the addition of a preamplification step prior to adding the cell-
specific barcode. Again, the inclusion of a 15-nt unique molecular identifier (UMI) allowed 
counting-based quantification and ensured that potential duplication artifacts introduced 
during sample preparation could be accounted for (Kivioja et al., 2012). We found that 
unique barcode counts from wells containing a single sorted cell were 100-fold higher 
than empty wells, indicating that only 1% of the signal constituted technical background 
(Figure 1B). Next, we sought to characterize the reproducibility/confidence of quantification 
of antibody-derived UMI-counts within single cells. For this, we generated a panel of five 
antibodies against cell surface (ITGA6 and ITGB1), cytoplasmic (Actin and TGM1) and 
nuclear (RNApol2) epitopes, each of which were independently conjugated to 9 distinct DNA-
barcodes, generating a total pool of 45 antibody-DNA conjugates. Each of these barcodes 
serves as a technical replicate and their concordance therefore reflects the reproducibility 
of single cell ID-seq measurements. All of the barcodes for each of these five antibodies 
showed very good correlation across cells (R=0.95-0.99), indicating a low level of noise in 
scID-seq measurements (Figure 1C and S2). To further validate scID-seq, we stained human 
epidermal stem cells simultaneously with ITGB1 antibodies containing either a fluorescent 
group, or the DNA-barcode. We recorded the FACS-based ITGB1 signal, as well as the ITGB1 
DNA-barcode counts for individual cells. This revealed that scID-seq counts indeed reflect 
standard FACS measurements for the same cell (R=0.76, Figure 1D). Together, these results 
establish single-cell ID-seq as a robust and reproducible method to measure proteins at 
individual cell resolution. Moreover, the fact that each DNA-barcode is unique to a specific 
antibody allows antibodies to be multiplexed and measured in each individual cell at an 
unprecedented level. 
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Figure 1: Single-cell Immuno-Detection by Sequencing (scID-seq) enables robust and reproducible 
protein detection in individual cells. (A) Schematic overview of the scID-seq workflow. (B) Single cell 
derived antibody counts indicate low technical noise levels in scID-seq. Single cells stained with antibody-
DNA conjugates sorted into individual wells of a 96-well plate and compared to wells were no cells 
were sorted into using scID-seq (n=132 with 84 cells and 48 empty wells). (C) scID-seq reproducibly 
measures antibody signals in single cells. Independently generated antibody-DNA conjugates were used 
to stain human epidermal stem cells. Barcode counts derived from the two barcodes were plotted against 
each other, indicating high reproducibility of the protein measurements from the same cell. (D) scID-
seq reflects Fluorescent Activated Cell Sorting measurements. ITGB1 levels were measured in human 
epidermal stem cells using FACS and scID-seq. Fluorescent signal and scID-seq counts for each cell 
(n=84) showed a good correlation (R=0.76).
scID-seq distinguishes renewing and differentiated epidermal cells.
We applied single-cell ID-seq to monitor the activity of signaling pathways and other cellular 
processes during epidermal differentiation using a panel of 70 antibody-DNA conjugates 
(van Buggenum et al., 2018; van Buggenum et al., 2016). These antibodies cover a broad 
range of cellular processes including cell cycle, DNA damage, epidermal self-renewal 
and differentiation, as well as the intracellular signalling status for the EGF, G-protein 
coupled receptors, calcium signalling, TNFα, TGFβ, Notch, WNT and BMP pathways (van 
Buggenum et al., 2018 and supplemental Table 1). This panel includes 34 antibodies against 
phosphorylated epitopes and was extensively validated (van Buggenum et al., 2018). For 11 
of the phosphorylated epitopes we also measured the non-phosphorylated protein, allowing 
us to correct for total protein levels by calculating the phosphorylated to total protein ratio 
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per cell. Most of the targeted processes are measured using multiple (3-5) independent 
validated antibodies (van Buggenum et al., 2018).
The surface level of ITGB1, reflects a cell’s potential to proliferate and self-renew (Adams 
and Watt, 1989; Jones and Watt, 1993; Jones et al., 1995; Watt, 2002; Watt and Jones, 
1993). We used FACS isolation of single cells based on their ITGB1 levels to capture the 
transitions that underlie the differentiation process (Figure 2A, see Figure S3 for details of 
the FACS-isolation). Colony formation assays confirmed the loss of proliferative capacity in 
cells expressing low levels of ITGB1 (Figure S4A). After staining with the 70 antibody-DNA 
conjugates, cells were sorted into ITGB1 positive (ITGB+) and ITGB1low populations based 
on their fluorescent ITGB1 antibody signal and subjected to scID-seq. After quality control 
and filtering (see methods for details) we obtained a dataset of 220 single cells (163 ITGB1+ 
and 57 ITGB1low, respectively) in which 69 antibody-DNA conjugates were quantified. For 
each cell, antibody-DNA counts were normalized for differences in sequencing depth by 
subsampling. To avoid downstream analyses from being dominated by the most abundant 
epitopes, we scaled all antibody counts between 0 and 1 across all cells. Unsupervised 
principal component analysis separated the ITGB1low (differentiated) cells from the ITGB1+ 
cells, confirming the notion that these represent distinct cell states (Figure S4B). Although 
we isolated cells only with respect to their cell surface expression of ITGB1, we found that 
other proteins displayed concordant dynamics. For instance, the basal cell markers ITGA6 
and TP63 were also decreased in the ITGB1low population (Figure 2B). In contrast, this 
population exhibited higher expression of the differentiation-associated proteins TGM1, 
Notch1 Intracellular Domain (NICD) and KLF4 (Figure 2B). Furthermore, cell cycle markers, 
such as Rb-p and cdc2 (reflecting the G1-S and G2-M transitions, respectively), distinguished 
these populations very well (Figure 2B). This is consistent with the loss of proliferative 
capacity during differentiation as observed in our colony formation assay (Figure S4A) and 
demonstrates that scID-seq captures molecular events underlying cellular function. Indeed, 
other antibodies in our panel also showed quantitative differences between these two cell 
states in either all, or in a subset of the cells (Figure S4C). Interestingly, many of the 
measured proteins displayed multimodal distributions, suggesting underlying subpopulation 
structures that could reflect transitions over the course of differentiation. This highlights the 
richness and complexity of our dataset and indicates the need to incorporate information on 
multiple parameters simultaneously in further analyses.   
Pseudo-timing reveals dynamic signaling pathway activity over the course of 
differentiation.
To obtain insight into the progressive changes in signaling pathway activity that occur over 
the course of epidermal cell differentiation, we aimed to order the cells by their relative 
differentiation state. We hypothesized that this state can be inferred by examining the 
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combination of expression of known basal and differentiation markers. We performed PCA 
on selected markers (ITGB1, ITGA6, TP63, NICD, KLF4 and TGM1) with established roles 
and dynamics during epidermal differentiation, and ranked the cells based on the resulting 
principal components. This revealed that principal component 1 (PC1; explaining 50% of 
the variance) recapitulated the expected trajectory of the epidermal differentiation process 
(Figure 2C). We calculated the average of 10 cell bins to smoothen the data, revealing 
that the basal markers ITGA6 and TP63 are indeed down regulated with distinct kinetics 
(Figure 2D). Immunohistochemical analysis of human epidermis showed that this PCA-
derived ordering of the cells closely resembles the relative order and timing of changes of 
these markers in vivo (Figure S5). Thus, we interpret the scaled and binned PC1-score as a 
‘pseudo-time’ approximation of epidermal differentiation dynamics (Figure 2D). 
Next, we mined our data for signaling pathways of which the included antibodies showed 
concordant effects over pseudo-time and were statistically significantly different between 
the ITGB1low and ITGB1+ (Figure S4C, Kolmogorov-Smirnov (K-S) test, p<0.001). This 
uncovered several signaling pathways that displayed dynamic behaviour over pseudo-time. 
For instance, PKB/Akt phosphorylation, measured by two independent antibodies, was 
increased upon differentiation as previously described (Figure 2E, (Janes et al., 2009)). 
Besides these expected effects, we found previously unappreciated dynamics in 3 additional 
pathways. The JAK-STAT pathway was activated during differentiation, as evident from 
increased phosphorylation of JAK1, STAT1 and STAT5, but not the EGFR activated STAT3 
(Figure 2F). In addition, the level of the WNT receptor Frizzled-3 gradually increased with 
differentiation, as did the activated/phosphorylated form of its co-receptor LRP6 (Figure 
2G). Moreover, the inactivating serine-9 phosphorylation of GSK3-b increased and then 
reached a plateau. This modification helps stabilize cytoplasmic b-catenin in response to 
WNT-pathway activation (van Kappel and Maurice, 2017). Finally, the Bone Morphogenetic 
Protein (BMP) pathway was activated at multiple levels (Figure 2H). Our scID-seq panel 
included antibodies for the BMP2/4 ligand, the type 2 BMP receptor, total SMAD1 levels, as 
well as two distinct antibodies against phosphorylated SMAD1/5/9. Over pseudo-time we 
observed increasing levels of the ligand, the receptor, as well as phosphorylated SMADs, 
reflecting activation of the BMP pathway during differentiation (Figure 2H). As our cells are 
cultured in a defined medium in the absence of feeder cells the signals that activate these 
pathways are therefore likely to be generated by the cells themselves. Indeed, the increase 
of the BMP2/4 ligand is consistent with such regulation by the BMP pathway (Figure 2H). 
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Figure 2: Pseudo-timing reveals dynamic signaling pathway activity over the course of epidermal 
differentiation. (A) Combining scID-seq with FACS-based sorting on ITGB1 levels. Cells were immuno-
stained with fl uorescent ITGB1 antibodies in combination with a panel of 70 Ab-DNA conjugates, FACS 
sorted based on their ITGB1 levels and subjected to scID-seq. (B) scID-seq distinguishes ITGB1+ 
and ITGB1low sorted cells based on known epidermal basal, differentiation and cell-cycle markers. 
Distributions of normalised and scaled scID-seq counts of selected proteins verifi ed the separation of 
the ITGB1+ and ITGB1low populations. (C) Principal Component Analysis on known markers orders 
epidermal cells on their renewal and differentiation status. Top panel - markers used for the temporal 
ordering, color intensity represents scaled antibody counts. Bottom panel - cells were ranked on their 
(scaled) PC1 loading. Vertical lines indicate the 10-cell bins used to smoothen the data in subsequent 
analyses. (D) Dynamics of the markers used for PCA, ordered by pseudo-time (scaled PC1 loading) after 
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smoothening. Data points indicate 10-cell bin mean and solid lines represent model fit of the data (3rd 
order polynomial regression). (E) Dynamics of two independent phosphorylated Akt/PKB antibodies over 
pseudo-time. (F,G,H) Dynamics of antibodies reflecting the JAK-STAT, WNT and BMP signaling pathways 
over pseudo-time.
BMP signaling stimulates a terminal epidermal differentiation transcription 
program.
To validate our findings on the activation of the BMP pathway, we induced differentiation 
of proliferating epidermal cells in culture by inhibiting EGF signaling (Kolev et al., 2008; 
Mulder et al., 2012). Samples were collected at 6, 12, 24 and 48 hours after the addition of 
either vehicle (DMSO) or the EGFR inhibitor AG1478. RT-qPCR analysis showed that mRNA 
expression of the early differentiation marker periplakin (PPL) and the late differentiation 
marker TGM1 reflected the progression of differentiation over time (Figure 3A). In line with 
our scID-seq results, mRNA expression of the BMP2 ligand was activated upon induction of 
differentiation (after the 12-hour time-point), whereas the classical BMP-pathway target 
gene ID2 was induced at a subsequent stage (after 24 hours, Figure 3A). This induction 
was dependent on both BMP-ligand binding to the extracellular part of the receptor and on 
intracellular BMPR kinase activity, as a recombinant version of the natural BMP-antagonist 
noggin and the small molecule kinase inhibitor DMH1 blocked ID2 expression (Figure S6A 
and B). Moreover, the observed induction of BMP2 and ID2 was further validated in cells 
undergoing calcium induced differentiation (Figure S6C, data from (Kretz et al., 2012)). 
Thus, the BMP pathway is indeed activated during epidermal differentiation in vitro. To 
investigate BMP pathway activity in vivo, we performed immuno-staining with antibodies 
against phosphorylated SMAD1/5/9 on human skin. The epidermal basal layer was visualised 
through co-staining with a keratin-14 antibody and we counterstained the DNA of all cells 
with DAPI (Figure 3B). Consistent with our scID-seq and RT-qPCR results, the signal from 
the p-SMAD1/5/9 antibody was increased in the differentiated (keratin-14 negative) layers 
of human epidermis, confirming that BMP signaling is activated during differentiation in vivo. 
These results suggest that BMP signaling may serve as a positive feed-forward loop to 
stimulate epidermal differentiation gene expression. To test this hypothesis, we treated 
cells with AG1478 for 96 hours in the absence or presence of the small molecule BMP 
receptor inhibitor DMH1 and monitored global gene expression by RNA-sequencing. 
Vehicle treated cells -/+ DMH1 were included as controls. Principal component analysis 
(PCA) indicated that the transcriptomes of non-differentiated and differentiated cells were 
markedly different (Figure 3C, PC1; explaining 76% of the variance). In addition, PC2 (5% 
of variance) distinguished the DMH1 treated and non-treated differentiated cells, reflecting 
a transcription program that depends on the BMP pathway (Figure 3C). Notably, vehicle 
control cells were virtually indistinguishable from control cells treated with DMH1, indicating 
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Figure 3: BMP signaling stimulates a terminal epidermal differentiation transcription program. (A) BMP2 
ligand and its downstream target gene ID2 are activated during in vitro keratinocyte differentiation. 
Human keratinocytes were induced to differentiate with AG1478 (or DMSO as a control) and samples were 
harvested at the indicated time-points. RT-qPCR analysis was performed for PPL, TGM1, BMP2 and ID2 
(n=3, data represented as mean-/+SD). (B) BMP signaling is activated during epidermal differentiation 
in vivo. Sections of human foreskin were stained with antibodies against phosphorylated SMAD1/5/9. 
DAPI and K14 antibodies were used to counterstain all nuclei and basal cells, respectively. Scale bar 
denotes 50 μm. Dashed line indicates the basement membrane separating the dermis and epidermis. (C) 
Activation of BMP signaling regulates a transcriptional program during epidermal differentiation. Principal 
component analysis of human keratinocytes induced to differentiate with AG1478 (or the DMSO control) 
for 96 hours in the presence of the BMP receptor inhibitor DMH1, followed by RNA-sequencing analysis 
(n=3, except DMSO control n=2). (D) BMP dependent genes are involved in late differentiation processes. 
Top enriched terms from a gene ontology overrepresentation analysis (hypergeometric test, FDR<0.01) 
of differentially expressed genes between the AG1478 and AG1478+DMH1 samples.
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that BMP signaling specifi cally regulates differentiation, but not proliferation/renewal 
programs. Moreover, the genes that were dependent on the BMP pathway activity showed 
highly signifi cant enrichment of genes involved epidermal keratinization and cornifi cation, 
indicating that BMP signaling drives transcriptional changes towards terminal differentiation 
(Figure 3D). 
The terminal differentiation transcription factors MAF/MAFB are downstream 
targets of the BMP pathway.
We further explored the mechanistic role of the BMP pathway in epidermal differentiation by 
investigating the gene expression program that is infl uenced by stimulation with recombinant 
BMPs. First, we treated cells with different BMP ligands and measured the induction of the 
late differentiation marker transglutaminase I (TGM1) at the protein level. This indicated 
that most recombinant ligands led to a robust increase of TGM1 (Figure S7A). Moreover, 
simultaneous treatment of cells with the EGFR inhibitor AG1478 and BMP ligands resulted in 
a synergistic increase of TGM1 protein levels, highlighting opposing roles for these pathways 
in epidermal biology (Figure S7B). Next, we performed RNA-sequencing analysis on cultured 
human epidermal cells treated with vehicle, AG1478, BMP2/7 or AG1478+BMP2/7 for 48 
hours (Figure S7C,D). Comparing the mRNA profi les of these conditions revealed the genes 
that were responsive to the addition of recombinant BMP2/7 and were also dynamically 
expressed during AG1478 induced differentiation (S7E). As expected, the top most BMP 
responsive genes included the ID gene family. Moreover, genes involved in terminal 
differentiation, including TGM1, MAF, MAFB and ZNF750 displayed BMP induced expression 
changes (Figure S7F), confi rming the results obtained with the BMP pathway inhibitor DMH1 
(Figure 3D). The MAF/MAFB and ZNF750 transcription factor axis drives the epidermal 
terminal differentiation transcription program (Lopez-Pajares et al., 2015). These results 
imply that activation of BMP signaling functions upstream of this axis.
To identify potential transcriptional targets downstream of the BMP pathway, we performed 
chromatin immunoprecipitation followed by sequencing (ChIP-seq), using H3K4me3 ChIP-
seq signals at the transcription start site (TSS) as a proxy for changes in transcriptional 
activity of a gene. We did not manage to obtain high quality SMAD1 ChIP-seq profi les and 
reasoned that the changes in H3K4me3 signals might provide a fi rst indication of downstream 
BMP signaling targets. Proliferating epidermal stem cells were treated with vehicle or 
recombinant BMP2/7 (in combination with AG1478) for 6 hours, after which they were 
harvested for ChIP-seq analysis.  This identifi ed 135 genes that showed a signifi cant increase 
in H3K4me3 signal (FPKM, p<0.01, outlier statistics) at their transcription start site (TSS), 
suggestive of increased transcriptional activity (Figure 4A and B). De novo motif discovery 
on the 2.5 kb up and downstream of these TSS regions revealed enrichment of a SMAD-like 
motif (p<10-31, Figure 4A). This is in line with the notion that these genes are responsive 
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Figure 4: The terminal differentiation transcription factors MAF/MAFB are downstream targets of the BMP 
pathway. (A) ChIP-sequencing of the active gene mark H3K4me3 identifies potential downstream targets 
after BMP stimulation. Scatter plot of normalised, log-transformed H3K4me3 ChIP-seq signals from cells 
incubated with and without recombinant BMP2/7 in the context of EGFR inhibition. Genes with increased 
or decreased H3K4me3 signals (p<0.01, outlier statistics) at their transcription start site are highlighted 
in red and blue, respectively. Examples of relevant activated and inhibited genes are indicated. (B) Gene 
promoters of genes with induced H3K4me3 levels are enriched in a SMAD-like motif. The sequences (TSS 
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-/+ 2.5 kb) of the genes with induced H3K4me3 levels were subjected to a de novo motif enrichment 
search. One of the enriched motifs showed high similarity to a known SMAD motif. (C) H3K4me3 genome-
browser tracks of ID2, MAF, MAFB and ZNF750. (D) MAF and MAFB, but not ZNF750, are immediate early 
responding genes downstream of BMP stimulation. RT-qPCR analysis of the indicated genes two hours 
after treatment with vehicle, or recombinant BMP2/7 (n=3, data represented as mean-/+SD). (E) Model 
of the transcription regulatory network activated by BMP signaling during epidermal differentiation.
to BMP signaling. This set included the classical BMP targets ID1, 2 and 3, demonstrating 
that our experimental approach identified known direct BMP pathway target genes (Figure 
4B). Additional to this, the terminal differentiation regulating transcription factors GRHL3, 
MAF and MAFB were among the top set of immediate BMP targets (Figure 4B and C). In 
contrast, the key MAF/MAFB target gene ZNF750 was not directly regulated downstream of 
the BMP pathway as determined by H3K4me3 ChIP-seq signal (Figure 4C). A limitation of 
this experiment is that we performed ChIP-seq analysis after 6 hours of treatment. Some of 
the observations may therefore reflect secondary effects of BMP treatment. In general, we 
would expect direct BMP target genes to show an immediate early response to activation of 
the pathway. We tested this by treating proliferating keratinocytes with recombinant BMP2/7 
for 2 hours followed by RT-qPCR analysis. This revealed that both MAF and MAFB mRNA 
levels were induced at this early timepoint, as was the classical BMP target gene ID2 (Figure 
4D). In contrast, ZNF750 was not induced, nor were the differentiation markers periplakin 
(PPL) and TGM1. These results place BMP pathway activation immediately upstream of the 
MAF/MAFB transcription factors. These factors subsequently drive terminal differentiation 
programs through, among others, ZNF750 (Figure 4E, (Lopez-Pajares et al., 2015).
Discussion
We developed single-cell Immuno-Detection by sequencing (scID-seq) as a highly 
multiplexed single-cell (phospho-)proteomics approach based on our previously published 
ID-seq method. The combination of these two related techniques constitutes a toolbox 
spanning cell population-based drug screens to single-cell follow-up. This allows exploration 
of the heterogeneity of drug effectivity within a cell population, as well as effects on 
signaling and other cellular processes within individual cells after drug treatment. In 
principle, scID-seq can be applied to any biological system where single cells can be 
obtained and high-quality antibodies are available. Moreover, scID-seq in combination 
with FACS-based sorting allows enrichment of specific and/or rare cell types a priori. Using 
this approach, we enriched for spontaneously differentiating cells based on their surface 
ITGB1 levels to study signaling pathway activity in individual human epidermal cells with 
distinct differentiation states. Measuring 69 (phospho-)proteins per cell demonstrated that, 
amongst others, Bone Morphogenetic Protein signaling is activated along the differentiation 
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trajectory. Mechanistically, the BMP pathway stimulates the MAF/MAFB/ZNF750-axis to 
induce a transcriptional program during late stage epidermal differentiation. Previous studies 
provided indications that stimulation with exogenous BMP ligands increases the expression 
of cell cycle inhibitory factors and selected differentiation associated genes, suggesting 
involvement of this pathway in human epidermal differentiation (Botchkarev, 2003; Fessing 
et al., 2010; Gosselet et al., 2007; Li et al., 2003; Yang et al., 2006). However, its timing 
and function during the differentiation process remained unclear. Using RNA-sequencing 
and H3K4me3 ChIP-seq analysis in combination with inhibition and stimulation, we found 
that BMP signaling activation drives a terminal differentiation transcription program and 
the MAF/MAFB/ZNF750 transcription factor axis (Figures 3 and 4). Our findings have 
implications for our view on the progressing nature of keratinocyte differentiation. First, 
regional signaling pathway activity plays crucial roles in patterning and tissue specification 
during (early) development. Our findings implicate BMP pathway activation as an integral 
part of the transcription factor network stimulating epidermal differentiation. As the BMP 
ligand is produced and excreted by the cells into their local environment, our results provide 
a mechanistic explanation for coordinated expression program progression in a zonated 
fashion in a tissue context. Second, the identification of the cell intrinsic activation of the 
BMP pathway through up regulation of its ligand BMP2, in combination with our observation 
that the BMP pathways is responsible for the stimulation of a specific transcriptional program 
including late differentiation regulators (e.g. MAF/MAFB, DLX3 and OVOL2), suggests that 
this pathway is involved in a self-sustaining loop that keeps driving epidermal differentiation 
forward. Taken together, our results reveal a mechanistic role for BMP signaling in human 
epidermal differentiation and indicates that activation of (potentially autocrine) signaling 
loops enables cells to coordinate their transcriptional programs and ensure progressive 
differentiation.
Methods
Cell culture and reagents
Primary pooled human epidermal stem cells derived from foreskin were obtained from 
Lonza. Cells were cultured and expanded as previously reported (Gandarillas and Watt, 
1997). Briefly, cells were cultured on a feeder layer of J2-3T3 cells in FAD medium (Ham’s 
F12 medium/Dulbecco’s modified Eagle medium (DMEM) (1:3) supplemented with 10% 
batch tested fetal calf serum (FCS) and a cocktail of 0.5 µg/ml of hydrocortisone, 5 µg/ml of 
insulin, 0.1 nM cholera enterotoxin, and 10 ng/ml of epidermal growth factor) supplemented 
with Rock inhibitor (Y-27632, 10 µM). J2-3T3 cells were cultured in DMEM containing 10% 
bovine serum and inactivated with Mitomycin C (SCBT) upon seeding the epidermal stem 
cells. For experiments epidermal stem cells were transferred to Keratinocyte Serum Free 
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Medium (KSFM) supplemented with 0.2 ng/ml Epidermal Growth Factor and 30 μg/ml bovine 
pituitary extract from Life Technology until 70% confluent. Cells were treated with AG1478 
(10 μM, Calbiochem), DMH-1 (1 µM, RND systems) or BMP2/7 (200 ng/ml, R&D systems). 
All media were supplemented with 1% penicillin/streptomycin antibiotics.
Antibody conjugation with dsDNA barcodes
Antibodies and dsDNA were functionalized and conjugated as described (van Buggenum 
et al., 2016). Antibody details are provided in supplemental Table 1. In short, antibodies 
were functionalized with NHS-s-s-PEG4-tetrazine (Jena Bioscience) in a ratio of 1:10 in 
50 mM borate buffered Saline pH 8.4 (150 mM NaCl). Then, N3-dsDNA was produced 
and functionalized with DBCO-PEG12-TCO (Jena Bioscience) in a ratio of 1:25 (oligo list). 
Finally, purified functionalized antibodies were conjugated to purified functionalized DNA 
by 4-hour incubation at room temperature in borate buffered saline pH 8.4 in a ratio of 
4:1 respectively. The reaction was quenched with an excess of 3,6-diphenyl tetrazine. 
The conjugation efficiency and quality were checked on an agarose gel, confirming that 
a substantial amount of DNA conjugated with the antibody. Ultimately, conjugates were 
equally pooled for staining’s in scID-seq.
Immunostaining and single-cell sorting
Cells (> 3 x 106) were harvested with trypsin and cross-linked in suspension by incubating for 
10 minutes with 4% paraformaldehyde (PFA) in PBS following a quenching step of 5 minutes 
with 125 mM Glycine in PBS. Removal of PFA and Glycine occurred through washing twice 
with wash buffer (0.1x Pierce™ Protein-Free Blocking Buffer from Thermo in PBS). Then, 
cells were blocked in 500µl blocking buffer (0.5x 0.1x Pierce™ Protein-Free Blocking Buffer, 
200 µg/ml boiled salmon sperm DNA, 0.1% Triton-X 100, in PBS) at room temperature for 
30-60 min. Staining with the conjugate mix occurred overnight at 4°C in 500 µl blocking 
buffer and pre-staining’s were performed at room temperature for 1-2 hours. After each 
staining, cells were washed 3x in 5ml wash buffer. Cells were sorted single cell with the 
BD FACSAria SORP flow cytometer (BD biosciences) in 96 well PCR plates containing 1µl 
release buffer (10 mM DTT in 15mM Tris, pH 8.8) and 7µl Vapor-lock (Qiagen). For selection 
of ITGB1 negative cells, a primary and secondary pre-stain was done with 2.5 µg/ml anti-
ITGB1 (P4D1) and 1:1000 Alexa488 goat anti-mouse (Life technology, 1484573). Plates 
were stored at -20°C until use.
Barcoding and library preparation for next generation sequencing
For the library preparation 3 PCR steps were performed to amplify the antibody barcodes 
and to add barcodes specific for the well and the plate of each cell. The barcoding occurred 
with the same sequences used in ID-seq (van Buggenum et al., 2018). For the first PCR step 
15 cycles were run after adding to each well a 4 µl reaction mix containing the Herculase II 
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Fusion DNA Polymerase (Agilent), dNTPs, 5x Herculase buffer and 0.1µM amplification primers 
(Forward 5′-CACGACGCTCTTCCGATCT-3′, Reverse 5′- TCGCTTATCTGTTGACTGAT-3′). 
Directly after the first PCR step, 5 extra cycles were run after adding 1 µl mix containing 
Herculase buffer 0.2 µM forward amplification primer and 0.2 µM reverse well barcoding 
primer. Then all material was pooled per plate, Vapor-lock was removed and a clean-up was 
performed with the QIAquick PCR Purification Kit, an EXO1 treatment to degrade remaining 
primers followed by another purification. Another 5 cycles were run in PCR 3 with a 20 µl 
reaction containing pooled and purified plate sample and 0.1 µM plate barcoding primers 
(Fw_long 5′- AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
-3′ and specific plate reverse). After repeating the clean-up, the libraries were checked on 
agarose gel and with the Bioanalyzer (Agilent) to confirm the size of the DNA fragments 
(expected size around 185 bp).     
scID-seq data analysis
Sequence data from the NextSeq500 (Illumina) was demultiplexed using bcl2fastq software 
(Illumina). Then, all reads were processed using our dedicated R-package (van Buggenum 
et al., 2018). In short, the sequencing reads were split using a common “anchor sequence” 
identifying the position of the UMI sequence, Barcode 1 (antibody specific) and Barcode 2 
(well specific) sequence. After removing all duplicate reads, the number of UMI sequences 
were counted per barcode 1 and 2. Finally, barcode 1 (“antibody)” and barcode 2 (‘well’) 
sequences were matched to the corresponding. For scID-seq, a threshold was set based on 
the total UMI count per well difference between high- and low-quality cells or empty wells. 
Antibodies with a median of <10 counts per cell were removed from the dataset. Cells that 
displayed strong outliers for a single antibody (cut-off > 5x standard deviation of the mean 
of the population) were removed from the analysis. After this, cells were normalized through 
subsampling and antibody counts were normalized on a scale from 0 to 1 using the formula 
(x-min(x))/(max(x)-min(x)). Principal component analysis was done with the R-package 
“pcaMethods”. Additional statistical analysis and visualization of the data was done in R and 
Excel.  
Colony formation assays
Epidermal stem cells were sparsely seeded on a feeder layer in a 6 well plate (500 cells/
well) and cultured for at least 7 days to form colonies. After colony formation, cells were 
washed with PBS and fixed by incubating 10 minutes with 4% paraformaldehyde (PFA) in 
PBS. PFA removal occurred with 3 PBS washes. For the imaging of the colonies, a DNA stain 
was performed with DRAQ5 (1:4000, Biostatus) for 1 hour at room temperature. After 3 
PBS washes, plates were scanned with the Odyssey system and the number of colonies 
quantified.
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Immunostaining of human skin sections
Frozen sections of human foreskin were a kind gift from Prof. Fiona Watt and were obtained 
with informed consent and appropriate ethical review. Sections were fixed for 15 minutes 
with 4% paraformaldehyde, followed by 3 washes with PBS and permeabilisation with 0.2% 
triton-X100 in PBS for 10 minutes at RT. After blocking with 10% Bovine Serum in PBS for 1 
hour, the sections were stained with antibodies against phosphorylated-SMAD1/5/9 (41D10, 
Cell Signaling Technologies) at 1:200 dilution in blocking buffer overnight at 4 degrees 
Celsius. Sections were washes 3x with PBS and stained with secondary antibodies (1:2000 
dilution) and DAPI (1:5000) for 90 minutes at RT. After mounting on a microscopy slide, 
images were acquired using a Leica IR laser confocal microscope.
RT-qPCR
Isolated RNA (Quicki-RNA TM MicroPrep, Zymo Research) was used for quantitative PCR 
analysis using iQTM SYBR Green Supermix with 20µM reaction volume, scanned on CFX-96 
machine. Per gene, -2^Ct values were calculated and normalized to 18S RNA levels. 
Transcriptome analysis with CEL-seq2 
Isolated RNA (Qucki-RNA TM MicroPrep, Zymo Research) was used for transcriptome 
analysis via a slightly modified CEL-seq2 procedure (Hashimshony et al., 2016). See Table 
1 primer sequences. In short, 100 pg purified RNA was used in 2 µl reverse transcription 
reactions containing Maxima H minus reverse transcriptase (ThermoFisher). The reactions 
were covered with Vapor-Lock (7 µl, Qiagen).  Different primer sequences were designed 
and used (Table 1), allowing 63 nt long read 1 of mRNA, and 14 nt long read 2 with the 
sample barcode and UMI. NextSeq500 (Illumina) was used for sequencing. 
Table 1. Primer sequences used during CEL-seq2 procedure.
Reverse transcription primer 5’GCCGGTAATACGACTCACTATAGGGGTTCAGACGTGTGCTCTTCCGATC 
TNNNNNNNN[6ntsamplebarcode]TTTTTTTTTT TTTTTTTTTTTTTTV3’
random-octamer-primer 
for reverse transcription of 
amplified RNA
5’CACGACGCTCTTCCGATCTNNNNNNNN3’
library PCR Primers 5’AATGATACGGCGACCACCGAGATCTACA 
CTCTTTCCCTACACGACGCTCTTCCGATCT3’
5’CAAGCAGAAGACGGCATACGAGAT[6ntind ex] 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC3’
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CEL-seq2 data analysis
CEL-seq2 sequencing data was processed using as described (Hashimshony et al., 2016). 
In brief, high quality reads were filtered, and used for mapping. In brief, the count matrix 
was loaded as Seurat object, and used to visualize number of total UMI counts, number of 
genes and number of mitochondrial genes per sample. One out of three vehicle controls in 
the DMH-1 experiment did not pass the QC checks (with 50% less reads/sample) and was 
removed from further analyses. The count matrix was loaded into DESEq2 data object, to 
allow easy normalization, filtering, PCA and differential expression analysis. For analysis of 
the CEL-seq2 data, the DESeq2 R-package (Love et al., 2014) was used to normalize UMI 
counts, perform PCA analysis and determine differential expressed genes. Gene Ontology 
overrepresentation analysis was performed using the GeneTrail webtool (Backes et al., 2007)
ChIP-sequencing
Cells in KSFM (2.5x106) were incubated with vehicle/DMSO or BMP2/7+AG1478 for 6 hours. 
After harvesting by trypsinisation, the cells were cross-linked with 1% formaldehyde in PBS 
for 10 minutes, quenched for 5 minutes with 125 mM glycine in PBS and washed in PBS 
at 4 degrees Celsius. Cross-linked cells were incubated 4 hours in lysis buffer (5 mM Tris-
HCl pH 8.0, 85mM NaCl, 0.5% NP40, 1X PIC) on ice, following 50 strokes with a dounce 
homogenizer to enrich for nuclei. Nuclei were sonicated in sonication buffer (50 mM Tris-
HCl pH 8.0, 10 mM EDTA, 0.1% SDS, 150mM NaCl and 0.5% deoxycholic acid) to get an 
average chromatin fragment length of 500 bp. Chromatin extracts were incubated with 1 
µg H3K4me3 antibody (ab8580, AbCam) overnight. Antibodies were captured for 4 hours 
with 100 µl protein G-coated magnetic beads (Life Technology). Subsequently, beads were 
washed 5X in RIPA buffer. The retrieved chromatin was reverse cross-linked overnight at 
65°C followed by a 1-hour incubation step with proteinase K (1µg/µl) and RNAse A (1µg/
µl) at 37°C. The DNA was purified with the Qiaquick PCR purification kit. Using the KAPA 
Biosystems kit (#KK8504), between 0.5 and 5ng ChIP-derived DNA was trimmed, A-tailed, 
provided with Nextflex adaptors and amplified with 10 PCR cycles. Subsequently, DNA was 
size-selected with the E-Gel® iBase Power System (Invitrogen) to purify for fragments 
between 300 and 400bp. The libraries were quantified on the Agilent 2100 Bioanalyzer and 
evaluated by qPCR to confirm representation of enrichments at specific loci. The libraries 
were sequenced with the Nextseq500. Reads were quality checked and aligned to the human 
hg19 genome with the Burrows-Wheeler Alignment tool (BWA) and processed with SAMtools 
to generate BAM files. Peaks were called from BAM files using “Model-based analysis of 
ChIP-Seq version 1.4” (MACS14) with a p-value cut-off of 1x10-8. The ratio of the fragments 
per kilobase per million reads (FPKM) values of the called H3K4me3 peaks were z-score 
transformed and subjected to outlier statistics assuming a normal distribution. De novo 
motif discovery was performed with the Trawler software (Dang et al., 2018). The enriched 
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motifs were compared to known motifs in the JASPAR database using PWMtools (http://ccg.
vital-it.ch/pwmtools).
Data and Software Availability
All sequencing data are available from GEO under series number GSE115926.
Limitations of the Study
scID-seq has the potential to quantify many antibodies can be measured with high 
sensitivity. As with any antibody-based approach, the quality of the antibodies is a limiting 
factor and should be defined carefully. Our current iteration of scID-seq, which includes 
FACS-based single cell isolation, is limited in the number of cells that can be practically 
processed in parallel.  A solution would be replacing the FACS and sample preparation 
with  droplet-microfluidics like in the Ab-seq approach (Shahi et al., 2017). With regards 
to our biological question, our data contains a comparatively low coverage of intermediate 
differentiation stages for the pseudo-timing analysis. As a consequence, the relative timing 
of the pathways that show dynamics during that stage cannot, currently, be temporally 
segregated at high resolution. Finally, the H3K4me3 ChIP-seq we performed is taken as a 
proxy for transcriptional changes and we cannot exclude some contribution of secondary 
or indirect responses that are not defacto immediately downstream of BMP activation. We 
therefore chose to include additional experiments to provide further indications of direct 
effects on the MAF/MAFB/ZNF750-axis.
Acknowledgements
We thank members of the Mulder lab for fruitful discussion and assistance and Dr. H Zhou 
and C. Albers for critical reading of the manuscript and Eva Janssen-Megens for assistance 
with sequencing. We thank Simon Broad for providing the ITGA6 and ITGB1 antibodies 
and Dr. R. Rice for hybridoma clone BC.1 (anti-TGM1). This work was supported by a VIDI 
grant from the Netherlands Organisation for Scientific Research (NWO-VIDI grant number: 
864.12.010) to K.W.M. 
Declaration of Interests
The authors declare no conflicts of interest.
Author contributions
R.A.P.M.v.E., J.A.G.L.v.B., and S.E.J.T. designed and performed experiments, analyzed and 
interpreted data, and wrote the manuscript. J.H. performed and analyzed experiments. 
K.W.M. conceived the project, designed experiments, interpreted data, and wrote the 
manuscript.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 52
52
Chapter 2
References
Adams, J.C., and Watt, F.M. (1989). Fibronectin inhibits the terminal differentiation of human keratinocytes. 
Nature 340, 307–309.
Altschuler, S.J., and Wu, L.F. (2010). Cellular heterogeneity: do differences make a difference? Cell 141, 
559–563.
Barrandon, Y., Grasset, N., Zaffalon, A., Gorostidi, F., Claudinot, S., Droz-Georget, S.L., Nanba, D., and 
Rochat, A. (2012). Capturing epidermal stemness for regenerative medicine. Semin. Cell Dev. Biol. 
23, 937–944.
Beck, B., and Blanpain, C. (2012). Mechanisms regulating epidermal stem cells. EMBO J. 31, 2067–2075.
Bhaduri, A., Ungewickell, A., Boxer, L.D., Lopez-Pajares, V., Zarnegar, B.J., and Khavari, P.A. (2015). 
Network Analysis Identifies Mitochondrial Regulation of Epidermal Differentiation by MPZL3 and 
FDXR. Dev. Cell 35, 444–457.
Blanpain, C., and Fuchs, E. (2006). Epidermal stem cells of the skin. Annu Rev Cell Dev Biol 22, 339–373.
Botchkarev, V.A. (2003). Bone morphogenetic proteins and their antagonists in skin and hair follicle 
biology. J. Invest. Dermatol. 120, 36–47.
Botchkarev, V.A., and Sharov, A.A. (2004). BMP signaling in the control of skin development and hair 
follicle growth. Differentiation 72, 512–526.
Buggenum, J.A.G. Van, Gerlach, J.P., Tanis, S.E.J., Hogeweg, M., and Pascal, W.T.C. (2018). Immuno-
Detection by sequencing (ID-seq) enables large-scale high-dimensional phenotyping in cells. Nat. 
Com. 1–12.
van Buggenum, J.A.G.L., Gerlach, J.P., Eising, S., Schoonen, L., van Eijl, R.A.P.M., Tanis, S.E.J., Hogeweg, 
M., Hubner, N.C., van Hest, J.C., Bonger, K.M., et al. (2016). A covalent and cleavable antibody-DNA 
conjugation strategy for sensitive protein detection via immuno-PCR. Sci. Rep. 6, 22675.
Connelly, J.T., Gautrot, J.E., Trappmann, B., Tan, D.W., Donati, G., Huck, W.T., and Watt, F.M. (2010). 
Actin and serum response factor transduce physical cues from the microenvironment to regulate 
epidermal stem cell fate decisions. Nat Cell Biol 12, 711–718.
Fessing, M.Y., Atoyan, R., Shander, B., Mardaryev, A.N., Botchkarev, V. V., Poterlowicz, K., Peng, Y., 
Efimova, T., and Botchkarev, V.A. (2010). BMP signaling induces cell-type-specific changes in gene 
expression programs of human keratinocytes and fibroblasts. J. Invest. Dermatol. 130, 398–404.
Gosselet, F.P., Magnaldo, T., Culerrier, R.M., Sarasin, A., and Ehrhart, J.C. (2007). BMP2 and BMP6 control 
p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human 
epidermal keratinocytes. Cell Signal 19, 731–739.
Green, H. (2008). The birth of therapy with cultured cells. Bioessays 30, 897–903.
Guha, U., Mecklenburg, L., Cowin, P., Kan, L., Guin, W.M.O., Vizio, D.D., Pestell, R.G., Paus, R., and Kessler, 
J.A. (2004). Bone Morphogenetic Protein Signaling Regulates Postnatal Hair Follicle Differentiation 
and Cycling. Am. J. Pathol. 165, 729–740.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 53
53
Signalling and transcription events during epidermal differentiation
2
Hirsch, T., Rothoeft, T., Teig, N., Bauer, J.W., Pellegrini, G., De Rosa, L., Scaglione, D., Reichelt, J., 
Klausegger, A., Kneisz, D., et al. (2017). Regeneration of the entire human epidermis using transgenic 
stem cells. Nature 551, 327–332.
Janes, S.M., Ofstad, T.A., Campbell, D.H., Eddaoudi, A., Warnes, G., Davies, D., and Watt, F.M. (2009). 
PI3-kinase-dependent activation of apoptotic machinery occurs on commitment of epidermal 
keratinocytes to terminal differentiation. Cell Res. 19, 328–339.
Jones, P.H., and Watt, F.M. (1993). Separation of human epidermal stem cells from transit amplifying cells 
on the basis of differences in integrin function and expression. Cell 73, 713–724.
Jones, P.H., Harper, S., and Watt, F.M. (1995). Stem cell patterning and fate in human epidermis. Cell 
80, 83–93.
van Kappel, E.C., and Maurice, M.M. (2017). Molecular regulation and pharmacological targeting of the 
β-catenin destruction complex. Br. J. Pharmacol. 174, 4575–4588.
Kivioja, T., Vähärautio, A., Karlsson, K., Bonke, M., Enge, M., Linnarsson, S., and Taipale, J. (2012). 
Counting absolute numbers of molecules using unique molecular identifiers. Nat. Methods 9, 72–74.
Kolev, V., Mandinova, A., Guinea-Viniegra, J., Hu, B., Lefort, K., Lambertini, C., Neel, V., Dummer, R., 
Wagner, E.F., and Dotto, G.P. (2008). EGFR signalling as a negative regulator of Notch1 gene 
transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10, 902–911.
Koster, M.I., and Roop, D.R. (2004). The role of p63 in development and differentiation of the epidermis. 
J Dermatol Sci 34, 3–9.
Kouwenhoven, E.N., van Heeringen, S.J., Tena, J.J., Oti, M., Dutilh, B.E., Alonso, M.E., de la Calle-
Mustienes, E., Smeenk, L., Rinne, T., Parsaulian, L., et al. (2010). Genome-wide profiling of p63 
DNA-binding sites identifies an element that regulates gene expression during limb development in 
the 7q21 SHFM1 locus. PLoS Genet 6, e1001065.
Kretz, M., Webster, D.E., Flockhart, R.J., Lee, C.S., Zehnder, A., Lopez-Pajares, V., Qu, K., Zheng, G.X.Y., 
Chow, J., Kim, G.E., et al. (2012). Suppression of progenitor differentiation requires the long 
noncoding RNA ANCR. Genes Dev. 26, 338–343.
Lewis, C.J., Mardaryev, A.N., Poterlowicz, K., Sharova, T.Y., Aziz, A., Sharpe, D.T., Botchkareva, N. V, and 
Sharov, A.A. (2014). Bone Morphogenetic Protein Signaling Suppresses Wound-Induced Skin Repair 
by Inhibiting Keratinocyte Proliferation and Migration. 827–837.
Li, A.G., Koster, M.I., and Wang, X.J. (2003). Roles of TGFbeta signaling in epidermal/appendage 
development. Cytokine Growth Factor Rev 14, 99–111.
Lopez-Pajares, V., Qu, K., Zhang, J., Webster, D.E., Barajas, B.C., Siprashvili, Z., Zarnegar, B.J., Boxer, 
L.D., Rios, E.J., Tao, S., et al. (2015). A LncRNA-MAF:MAFB transcription factor network regulates 
epidermal differentiation. Dev. Cell 32, 693–706.
Mou, H., Vinarsky, V., Tata, P.R., Brazauskas, K., Choi, S.H., Crooke, A.K., Zhang, B., Solomon, G.M., 
Turner, B., Bihler, H., et al. (2016). Dual SMAD Signaling Inhibition Enables Long-Term Expansion of 
Diverse Epithelial Basal Cells. Cell Stem Cell 19, 217–231.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 54
54
Chapter 2
Mulder, K.W., Wang, X., Escriu, C., Ito, Y., Schwarz, R.F., Gillis, J., Sirokmany, G., Donati, G., Uribe-
Lewis, S., Pavlidis, P., et al. (2012). Diverse epigenetic strategies interact to control epidermal 
differentiation. Nat Cell Biol 14, 753–763.
Rheinwald, J.G., and Green, H. (1975). Serial cultivation of strains of human epidermal keratinocytes: the 
formation of keratinizing colonies from single cells. Cell 6, 331–343.
Sen, G.L., Boxer, L.D., Webster, D.E., Bussat, R.T., Qu, K., Zarnegar, B.J., Johnston, D., Siprashvili, Z., and 
Khavari, P.A. (2012). ZNF750 Is a p63 Target Gene that Induces KLF4 to Drive Terminal Epidermal 
Differentiation. Dev. Cell 22, 669–677.
Shahi, P., Kim, S.C., Haliburton, J.R., Gartner, Z.J., and Abate, A.R. (2017). Abseq : Ultrahigh-throughput 
single cell protein profiling with droplet microfluidic barcoding. Nat. Publ. Gr. 1–12.
Solanas, G., and Benitah, S.A. (2013). Regenerating the skin: a task for the heterogeneous stem cell pool 
and surrounding niche. Nat. Rev. Mol. Cell Biol. 14, 737–748.
Truong, A.B., Kretz, M., Ridky, T.W., Kimmel, R., and Khavari, P.A. (2006). p63 regulates proliferation and 
differentiation of developmentally mature keratinocytes. Genes Dev 20, 3185–3197.
Watt, F.M. (2002). Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO 
J 21, 3919–3926.
Watt, F.M., and Huck, W.T.S. (2013). Role of the extracellular matrix in regulating stem cell fate. Nat. Rev. 
Mol. Cell Biol. 14, 467–473.
Watt, F.M., and Jones, P.H. (1993). Expression and function of the keratinocyte integrins. Dev Suppl 
185–192.
Watt, F.M., Lo Celso, C., and Silva-Vargas, V. (2006). Epidermal stem cells: an update. Curr Opin Genet 
Dev 16, 518–524.
Wells, J., Lee, B., Cai, A.Q., Karapetyan, A., Lee, W.J., Rugg, E., Sinha, S., Nie, Q., and Dai, X. (2009). 
Ovol2 suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing 
c-Myc and Notch1. J. Biol. Chem. 284, 29125–29135.
Wu, M., and Singh, A.K. (2012). Single-cell protein analysis. Curr. Opin. Biotechnol. 23, 83–88.
Yang, L., Yamasaki, K., Shirakata, Y., Dai, X., Tokumaru, S., Yahata, Y., Tohyama, M., Hanakawa, Y., 
Sayama, K., and Hashimoto, K. (2006). Bone morphogenetic protein-2 modulates Wnt and frizzled 
expression and enhances the canonical pathway of Wnt signaling in normal keratinocytes. J Dermatol 
Sci 111–119.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 55
55
Signalling and transcription events during epidermal differentiation
2
Supplemental Material
Sort single cells in Vapor-lock (7μl) 
and release buer (1μl)
Pre-Amplication
Add 4ul PCR mix for the pre-ampli-
cation (15 cycles, continue the 
next step right after the last cycle)
Well-barcoding
Add 1ul PCR mix for the 
Well-barcoding PCR (5 cycles)
Vapor-lock
pooled sample
Pooling and clean-up
Sample collection and clean-up 
(column purication, EXO1 
treatment, column purication)
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ed sample for plate barcoding 
(5 cycles)
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library check on agarose gel and 
Bioanalyzer. Expected size ~185bp
Plate PCR
In suspension staining on 
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with Ab-DNA conjugates 
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Figure S1: Schematic representation of the single-cell ID-seq work-flow. The scID-seq procedure entails 
crucial modifications compared to the original ID-seq protocol. First, cells are stained with the antibody-
DNA conjugates in suspension, to allow single-cell sorting. Second, a pre-amplification step increased 
the yield and complexity of the single-cell libraries. This pre-amplification is done prior to adding a cell-
specific barcode to the PCR products. From this point on, the library preparation is the same as described 
for ID-seq. Related to Figure 1.
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Figure S2: Nine technical replicates per individual cell highlight the reproducibility of scID-seq. Cells 
were stained with a mixture of 45 antibody-DNA conjugates consisting of 5 different antibodies that 
were each separately conjugated to 9 independent DNA-barcodes. The Pearson correlation among the 
9 measurements for each antibody across individual cells indicates the reproducibility of scID-seq to 
quantify relative protein levels. Related to Figure 1.
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Figure S3: ITGB1 FACS strategy. (A-C) single cells were gated using forward and side-scatter 
characteristics. (D) Cells stained with low ITGB1-FITC levels were gated and sorted into individual wells 
(ITGB1low). ITGB1+ cells were selected from the total population. (E) Secondary antibody only stained 
cells indicate the specifi city of the ITGB1-FITC staining. Related to Figure 2.  
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Figure S4: scID-seq on cells selected on ITGB1 level by FACS. (A) Cells with low ITGB1 surface levels 
represent differentiated keratinocytes. Cultured human keratinocytes were isolated based on their ITGB1 
surface expression by FACS and subjected to colony formation assays. (B) ITGB1+ and ITGB1low cells 
display distinct scID-seq profi les. Human keratinocytes were subjected to staining with a panel of 70 
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antibody-DNA conjugates, isolated based on their ITGB1 surface level by FACS and analyzed with scID-
seq. Principal component analysis separated the ITGB1+ and ITGB1low populations. (C) Individual 
antibodies display dynamics between ITGB1+ and ITGB1low cell populations. Distributions of scaled 
signals of ITGB1+ and ITGB1low populations for 70 antibody-DNA conjugates. Statistically different 
distributions are indicated (Kolmogorov-Smirnov test, p<0.001). Related to Figure 2.
ITGA6 NOTCH1TP63ITGB1
ITGB1  : basal layer & basement membrane staining, rapid decrease.
ITGA6  : basal layer & basement membrane staining, rapid decrease.
TP63  : basal layer staining, slow decrease.
NOTCH1 : throughout the epidermis, cell membrane staining in basal layer,
      the activated Notch Intracellular Domain localises to the nucleus in the
    suprabasal layers during dierentiation.
KLF4  : increased expression in suprabasal layers during dierentiation.
Dashed line indicates the separation of the dermis and the epidermis by the basement membrane.
KLF4
165766_B_5_8.jpg 39935_B_5_8.jpg 19019_B_7_1.jpg 61564_B_5_8.jpg 8748_B_7_1.jpg
Figure S5: Dynamics of known markers used to derive the pseudo-time line as assessed by 
immunohistochemical staining of human epidermis. Publicly available IHC staining of validated antibodies 
against the indicated epidermal marker proteins. Data from the human protein atlas. Related to Figure 2.
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Figure S6: The BMP pathway target gene ID2 is induced during differentiation in a BMP-BMPR interaction 
dependent manner. (A) Human keratinocytes were induced to differentiate with the EGFR inhibitor 
AG1478 in the presence or absence of recombinant noggin for 48 hours and subjected to RT-qPCR 
analysis of the ID2 gene. (B) BMP2 and ID2 mRNA expression is induced during a time-course of calcium 
induced differentiation. Related to Figure 3.
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Figure S7: Stimulation with recombinant BMPs induces differentiation gene expression. (A) Recombinant 
BMPs stimulate endogenous TGM1 protein expression. Cells were stimulated with the indicated 
recombinant BMP proteins for 48 hours and subjected to In-Cell-Western analysis using TGM1 specifi c 
antibodies. Measurements were corrected for cell density using the DNA staining agent DRAQ5. n=3 -/+ 
SD (B) Recombinant BMPs and AG1478 syngergise to stimulate endogenous TGM1 protein expression. 
Cells were stimulated with the indicated recombinant BMP proteins for 48 hours in combination with 
the EGFR inhibitor AG1478 and subjected to In-Cell-Western analysis using TGM1 specifi c antibodies. 
Measurements were corrected for cell density using the DNA staining agent DRAQ5. n=3 -/+ SD. (C) 
Recombinant BMPs, AG1478 and the combined treatment lead to distinct transcriptional responses. 
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Cells were stimulated with the indicated treatments for 48 hours and subjected to RNA-sequencing. 
Principal component analysis of differentially expressed genes indicates condition specific transcriptional 
effects. (D) Identification of differentially expressed genes per condition. Volcano plots indicate the log2 
fold-change of mRNA expression between vehicle and the indicated condition on the x-axis. The y-axis 
represents the -log10 transformed p-value (FDR corrected t-test). (E) Hierarchical clustering highlights 
condition specific differences in transcriptional responses. Heatmap of differentially expressed genes 
(z-score normalised across the samples) clustered on Pearson’s correlation with average linkage for both 
genes and samples. (F) 48 hours treatment with recombinant BMPs stimulates expression of transcription 
factors involved in late epidermal differentiation. Related to Figure 3.
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epidermal stem cells generated 
known and unknown differentiation 
regulators
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Abstract
Epidermal maintenance requires well-balanced regulation of self-renewal and differentiation 
in epidermal stem cells. Processes including signal transduction transcription and chromatin 
remodeling are essential to initiate differentiation successfully. Loss of function of specific 
factors in these processes will make it difficult for the stem cell to initiate differentiation. To 
identify these factors, screens covering hundreds of genes have been applied using small 
interfering RNAs. To find additional essential differentiation factors, we applied the GeCKO 
CRISPR library to do genome-wide screening. For this, we constructed a screen assay in 
which cell proliferation is blocked, differentiation is induced with AG1478 and unintended 
differentiation is prevented. This screening approach generated hits representing potentially 
novel regulators in epidermal differentiation as well as hits acting in epidermal differentiation 
associated pathways including BMP and Notch signaling. Decreased sensitivity for AG1478 
and gene editing was confirmed for individual guide RNAs targeting BMP4, WNT3a and 
GLIS3. Expression analysis and stimulation with recombinant BMPs indicated that BMP4 
is most likely an essential gene in epidermal differentiation. Altogether, we generated a 
genome-wide CRISPR screen data set with potential to find novel regulators in epidermal 
differentiation.
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Introduction
The epidermis is the outer layer of the skin protecting the body against dehydration and 
entry of pathogens. Every month, the epidermis is renewed by epidermal stem cells that 
have to decide between proliferation or differentiation. Epidermal stem cells locate on the 
basal membrane which separates the epidermis from the underlying dermal layer. When 
differentiation is triggered, epidermal stem cells lose contact with the basal membrane and 
they mature while they migrate upwards. Eventually, they also lose their nuclei and form a 
protective layer of tightly connected dead cells. Epidermal self-renewal and differentiation 
is regulated by firmly controlled gene expression programs. When genes or pathways in 
these processes are deregulated diseases such as cancer and psoriasis can develop due to 
uncontrolled cell growth (Blanpain and Fuchs, 2006). Several pathways are known to play a 
role in epidermal self-renewal and differentiation. EGF signaling for instance is important for 
self-renewal whereas other pathways such as BMP and notch signaling promote differentiation 
(Gosselet et al., 2007; Kolev et al., 2008; Tata et al., 2016; Watt et al., 2008). For this reason, 
EGF receptor inhibition with AG1478 and stimulation with recombinant BMPs represent 
robust and controlled strategies to trigger epidermal differentiation (Kolev et al., 2008; 
Mulder et al., 2012) For the identification of factors important during differentiation RNA 
interference (RNAi) based genetic screens have been applied using different differentiation 
methods, including EGFR inhibition with AG1478 and BMP stimulation (Mulder et al., 2012; 
Tanis et al., 2018). These screens covered hundreds of genes representing chromatin factors 
and transcription factors and used the expression of terminal differentiation marker TGM1 
as read-out. In these studies, differentiation associated notch signaling factors (IRF6 and 
HES1) were confirmed and the combination of different differentiation strategies led to the 
identification of interesting genetic interaction complexes (Kwa et al., 2014; Restivo et al., 
2011).
Since the discovery of CRISPR-cas9 as high-resolution genomic-DNA-editing tool, novel 
genetic screening approaches were developed with genome-wide coverage (Shalem et al., 
2014). In addition, in CRISPR screens, genes are completely inactivated whereas gene 
knock-down efficiencies vary in RNAi screens. The core of the CRISPR screen represents a 
lentiviral plasmid library and the selection pressure relies on cell growth. The robustness of 
CRISPR screens is therefore mainly determined by the library coverage within the screened 
cell population and the growth capacity of these cells (Peng et al., 2015). The genome-
scale CRISPR-Cas9 knock-out (GeCKO) v2 library contains plasmids that all express Cas9, 
but they differ in the gRNA they produce (Sanjana et al., 2014). The GeCKO library covers 
all annotated protein encoding genes with 6 gRNAs and the microRNA encoding genes 
with 4 gRNAs. When introducing the lentiviral library into a cell population, cells will have 
random gene knock-outs that may affect their proliferation rate or survival. Through this, 
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the representation of the guide RNA library will change over time which can be addressed 
with next generation sequencing. This CRISPR screening approach has been demonstrated 
in cancer cell lines as powerful positive selection screen for genes essential for sensitivity to 
cancer drugs that block proliferation (Ruiz et al., 2016; Shalem et al., 2014).
During differentiation, cells stop dividing as well. Therefore, we aimed here to screen for 
genes essential in AG1478 induced epidermal differentiation using the GeCKOv2 library. 
This genome-wide CRISPR screening approach is interesting as it has the potential to 
identify the most essential factors in epidermal differentiation and when multiple genes 
are found in one pathway, essential pathways may be found as well. The application of this 
AG1478 CRISPR screen on primary epidermal stem cells is challenging due to limited growth 
capacities compared to cancer cell lines and the chance of spontaneous differentiation. With 
the screen assay that we developed, we were able to overcome this. In the screen, we found 
known and potentially new regulators in epidermal differentiation. The known regulators 
represented several genes acting in the differentiation associated signaling pathways of 
Notch and BMP. The role of WNT signaling in epidermal differentiation is less well understood. 
The identification of two canonical WNT genes was therefore less expected. The strongest 
known regulator in epidermal differentiation that we found represented BMP4. We further 
validated BMP4 to demonstrate the potential of this genome-wide CRISPR screen data-set 
for identification of novel genes in epidermal differentiation.
Results
Establishment of the epidermal differentiation assay for CRISPR screening
For the search of genes important in epidermal differentiation, we aimed to apply the 
lentiviral GeCKO library screen on epidermal stem cells induced for differentiation with the 
EGFR inhibitor AG1478. This genome-wide screening approach should therefore generate 
hits that reduce sensitivity to AG1478. These hits will represent gene knock-outs that 
prevent or attenuate the cell proliferation block by AG1478 and will therefore include 
genes essential in AG1478 induced differentiation. To accomplish this screen in primary 
epidermal stem cells, we needed to set-up a screening assay with 1) a minimal chance of 
differentiation independent of AG1478, 2) maximum growth capacity and 3) an AG1478 
treatment that stops cell proliferation and induces differentiation. Triggers of unintended cell 
differentiation include overgrowing of the cell culture and transfer of the cells. To prevent 
unintended differentiation, we decided to construct a screening assay without cell transfers. 
To maximize the number of cell divisions, we determined the lowest number of cells to seed 
without affecting the growth capacity following transduction and puromycin selection. Using 
these conditions, we subsequently tested different AG1478 concentrations to find the lowest 
concentration without cell growth after at least 6 days. The cell growth and differentiation 
status of epidermal stem cells were quantified with In-cell-Western using DNA-staining with 
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DRAQ5 and late differentiation marker TGM1. After 6 days treatment, we observed a dose 
dependent effect on the confluency by AG1478 and the confluency consistently increased 
with the different vehicle concentrations. The lowest AG1478 concentration without increased 
confluency ranged between 0.31-0.63 µM (Figure 1a and S1a). For the differentiation status, 
we looked at the TGM1 levels and found that 0.31-0.63 µM AG1478 is high enough to 
induce TGM1 expression (Figure 1b and S1b). These results show that in this screen assay 
cells will differentiate in the presence of 0.5 µM and will expand in the absence of AG1478. 
Therefore, it was decided to use 0.5 µM AG1478 for inducing epidermal differentiation in 
the final screen assay as this should lead to strong inhibition of proliferation and induction 
of differentiation. 
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Figure 1: Establishment of AG1478 concentration for the AG1478 CRISPR screen. (a) Epidermal stem 
cells were grown for 6 days with different concentrations of AG1478 and vehicle. On day 0 and day 6 
confluency was measured and quantified with a DRAQ5 stain. The y-axis represents confluence over day 
0. (b) For the AG1478 treatment, 6 concentrations were also stained with anti-TGM1. TGM1 signal was 
corrected with DRAQ5 signal and all measurements were subtracted by Day 0. (c) Screen overview.
An overview of the screen assay is illustrated in figure 1C. After transduction and puromycin 
selection, cells were either harvested (baseline) or treated with 0.5 µM AG1478 for 9 days in 
duplicate. The screen was performed in duplicate and showed descent correlations between 
the replicates (R = 0.8-0.9) (Figure 2a). The library coverage in the screen was   ̴50 times 
per replicate. To increase the depth for further statistical analysis replicates were combined. 
To determine the screen quality, we addressed the change in library complexity during the 
screen. Over time, depletion or a decrease is expected for guide RNAs targeting genes 
essential for survival. We focused on genes in ribosome, proteasome, spliceosome and cell 
cycle pathways as most of these genes are essential for cell survival as shown previously 
(Shalem et al., 2014). We used the MaGECK method to determine scores for the depletion 
or enrichment of these genes based on their guide RNA dynamics. Using these scores, we 
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visualized how many essential genes were significantly depleted or enriched (Figure 2b, 2c). 
Although most cells in this screen did not proliferate due to AG1478, we clearly found more 
genes from the essential pathways back in the group of genes with a significant depletion 
score. These results indicate that the screen underwent negative selection as expected.
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Identification of hits with known and unknown roles in epidermal differentiation 
For the selection of hits with reduced sensitivity for AG1478, we focused on the positive 
selection of the screen. Guide RNAs targeting genes important reducing sensitivity for 
AG1478 should increase over time as cells having these genes inactivated are expected to 
keep proliferating. To explore the positive selection, we used MaGECK to rank the genes 
based on the MaGECK enrichment score p-values and applied gene set enrichment analysis 
(GSEA) to determine the biological processes enriched for highly ranked genes. This analysis 
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showed no significant enrichments for expected GO terms such as Notch signaling, BMP 
signaling or epidermal differentiation. However, we did find two highly significant epithelial 
GO terms that include genes from these signaling pathways, representing epithelial cell 
proliferation and columnar cuboidal epithelial cell differentiation (supplementary Table 
2). Although slightly moderate, these observations indicate that the screen did undergo 
positive selection. Therefore, we continued with the selection of the top hits.  For this, we 
used MaGECK to filter genes with the following parameters: significant MaGECK score for 
enrichment (p-value ≤ 0.05) log2 fold change ≥ 0.5 and a maximum of one good guide RNA 
in the negative selection analysis (Figure 3a). In this selection of 454 genes, we observed 
multiple genes from the two epithelial GO terms including three Notch genes (JAG1, IRF6 
and HES1) and BMP4, demonstrating that our screen is able to identify regulators with a 
background in epidermal differentiation. Surprisingly, we also found two canonical WNT 
factors (WNT3a, and DVL1). The role of WNT signaling in epidermal differentiation is still 
elusive, although canonical WNT signaling is thought to promote epidermal cell proliferation 
(Veltri et al., 2018). Noticing these genes in our screen therefore represents an interesting 
observation. The strongest hits indicated in figure 3a represent genes with diverse roles: cell 
adherence (CDH7), late cornification (LCE1E), transport in endoplasmic reticulum (YIF1A), 
metabolism (GLYAT), transcription regulation (GLIS3) and peptide cleavage (NRD1). The 
screen therefore demonstrates an interesting selection of hits consisting of known regulators 
and potentially undiscovered regulators in epidermal differentiation. For further analysis and 
validation, we proceeded with the strongest hits from the epithelial GO-terms (IRF6, BCCIP 
and BMP4) as known regulators and as potentially novel genes in epidermal differentiation 
we selected the strongest WNT hit (WNT3a) and two of the strongest hits representing 
NRD1 and GLIS3. NRD1 was selected as strongest hit and GLIS3 was chosen for its role in 
transcriptional regulation and development as well as its association with several diseases 
including diabetes and cancer (Scoville et al., 2017).
Individual guide RNAs of three hits led to gene editing and reduced sensitivity for 
AG1478
To experimentally validate the hits, several individual guide RNAs per gene should be tested. 
Therefore, we addressed the log2 fold change of the individual guide RNAs. As negative 
control we used the guide RNAs targeting the EGF receptor as they should not have added 
pressure by AG1478. Indeed, we only found one guide RNA with a substantial negative 
foldchange (Figure 3b). Strong and positive fold changes for 3-4 guide RNAs were observed 
for the three epithelial GO term genes and for the genes GLIS3 and NRD1. The foldchanges 
of the WNT3a guide RNAs were consistent and positive, but slightly lower. These indicates 
that all hits have multiple guide RNAs that can be selected for experimental validation. 
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For further experimental validation, we continued with BMP4 as strongest epithelial GO term 
gene and WNT3a, NRD1 and GLIS3 as potential novel candidates in epidermal differentiation. 
To test the individual guide RNA effect on AG1478 sensitivity, we applied the AG1478 screen 
assay. Less sensitivity to AG1478 was quantified through measuring the change in confluence 
after 9 days AG1478 treatment using in cell Western with DRAQ5. In this assay, we tested the 
two most enriched guide RNAs per gene and compared them with two non-targeting guide 
RNAs (Figure 3c, S2). The two non-targeting controls showed a very consistent decrease in 
confluence of 50-60%. For the hits, we expected an increase in confluency or at least less 
decrease in confluency than these controls. Consistent with two guide RNAs, NRD1 showed 
a strong decrease in confluency of 80-90% and was therefore not validated as hit. Cells 
treated with GLIS3 and WNT3a guide RNAs were still more confluent than cells treated with 
the non-targeting controls, but confluence still decreased with 20-40%. An actual increase 
in confluence of approximately 20-40% was observed with the BMP4 guide RNAs. These 
results indicate that a decreased sensitivity to AG1478 is introduced by the GLIS3, WNT3a 
and BMP4 guide RNAs with BMP4 as most potent hit. Next, a T7E1 assay was applied to 
confirm that all the individually tested guide RNAs indeed target the gene for which they 
were designed. We observed targeting by two WNT3a guide RNAs and for the other genes 
only by one of the two guide RNAs (Figure S3a). Based on validation experiments on two 
separate guide RNAs per hit, we show that three of the four selected genes are interesting for 
further conformation and follow-up. To demonstrate the potential of our screen, we decided 
to continue with BMP4 as it has already some background in epidermal differentiation and 
it represented the most potent hit in the screen assay validation. For further confirmation, 
we addressed two more guide RNAs with the T7E1 assay and proved that they also edit the 
BMP4 locus (Figure S3b). Altogether, four guide RNAs of BMP4 were enriched in the screen, 
two of them showed decreased sensitivity to AG1478 and 3 of the enriched guide RNAs did 
target the BMP4 locus (GeCKOv2 library guide RNAs HGLibB_04605, HGLibB_04606 and 
HGLibB_04607). The validation of BMP4 demonstrates the ability of the screen assay to 
detect genes with a role in epidermal differentiation induced by AG1478.
BMP signaling seems essential for commitment to epidermal differentiation via 
BMP4
BMP signaling is linked to epidermal differentiation and different BMP ligands have shown 
to induce epidermal differentiation (van Eijl et al., 2018; Gosselet et al., 2007; Mulder et 
al., 2012). To demonstrate this for BMP4 and some other BMPs, we addressed the effect 
of 48 hours stimulation with recombinant BMP4, -5, -6 and -7 on the expression of late 
differentiation marker gene TGM1. This showed that BMP4 indeed induces TGM1 protein 
expression and even stronger TGM1 expression was induced by BMP7 (Figure 4d, S4b), 
confirming that BMP signaling is able to trigger differentiation with at least BMP4 and 7.
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Figure 3: Identification and validation of known and unknown differentiation regulators. (a) Log2 fold 
change and p-values calculated with MAGeCK are plotted per gene. Genes were filtered for a Log2 fold 
change ≥ 0.5, p-value ≤ 0.05 and a maximum of one good guide RNA in the negative selection analysis. 
Gene names are shown for Top ranked genes (Log2 fold change ≥ 0.9 and -log p-value ≥ 2.75) and as 
indicated from enriched Go terms (table 1) and the WNT signaling. (b) The Log2 fold changes of the 
indicated guide RNAs. Grey area represents the standard deviation calculated with all sgRNA counts. (c) 
Screen assay after 9 days AG1478, performed with individual guide RNAs of indicated genes. Confluency 
was measured and quantified for three biological replicates with DRAQ5 and the ratio was determined 
between day 0 and 9. Significance was calculated with two-sample T-test (*p<0.05, **p<0.005).
Based on our CRISPR screen, BMP4 seems to be the essential BMP ligand in AG1478 induced 
epidermal differentiation. To get a better understanding of other BMP ligands and receptors 
within our screen, we mined the data and found in addition to BMP4 its receptor BMPR2. 
For BMPR2, we observed two enriched guide RNAs with high count numbers similar like 
the 3 validated guide RNAs of BMP4 (Figure 4a). BMP4 needs a receptor to propagate its 
signal and it is therefore interesting to find BMPR2 as well. Another receptor, BMPR1A and a 
selection of other BMPs together showed only one guide RNA with a substantial fold change 
(Figure 4b). This BMP genes may therefore be less important in epidermal differentiation. 
Gene activity is essential for gene function and could explain why only BMP4 and BMPR2 
were found in the screen. To address the gene activities, we looked into published mRNA 
expression data from different time points during epidermal differentiation (Kretz et al., 
2012). Through this we observed expression for BMP4, BMPR2 and to a lesser extend 
BMPR1A before differentiation was initiated, whereas BMP2 and BMP6 started lower and 
increased during the onset of differentiation (Figure 4c, S4b). The later expression of BMP2 
and BMP6 makes their importance for commitment to differentiation less likely. Therefore, 
the mRNA expression analysis seems to indicate why BMP4 and its receptor BMPR2 scored 
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higher in the screen than the other BMP genes. Altogether, BMP signaling seems essential 
for AG1478 induced differentiation via BMP4. 
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Figure 4: BMP4 seems to be the most important BMP in epidermal differentiation. (a) Normalized sgRNA 
counts of baseline and 9 days AG1478 treated cells. Normalized counts of sgRNA with a fold change ≥ 
1.95 and ≤ 0.5 baseline and treatment are left out and the sgRNAs of BMP4 and BMPR2 are highlighted. 
(b) Log2 fold changes of sgRNAs of other BMP signaling factors are shown. Grey area represents the 
standard deviation calculated with all sgRNA counts. (c) Genome browser images displaying the mRNA 
expression of the indicated genes at 3 time points during differentiation. Data was used from Kretz et 
al., 2012. (d) TGM1 protein expression corrected for DRAQ5 upon 48 hour stimulation with recombinant 
BMPs. Expression was measured with in cell Western.
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Discussion
In this study, we aimed to construct a CRISPR screen in epidermal stem cells treated with 
AG1478 to generate potential hits in epidermal differentiation. This led to the development of 
a nine days AG1478 CRISPR screen assay in which cell proliferation is blocked, differentiation 
is induced with AG1478 and unintended differentiation is prevented. The screen showed 
a trend for positive selection based on GSEA which displayed enrichment of hits in two 
epithelial GO terms. Genes from these GO-terms were retrieved in a filtered list of top hits. 
In this list, we found known regulators and potentially unknown regulators in epidermal 
differentiation. Experimental validation of individual guide RNAs demonstrated GLIS3 
and WNT3a as interesting candidates for follow-up and with extra analysis and validation 
experiments, BMP4 was further established as regulator in epidermal differentiation. 
With our screening approach, we wondered if we would be able to find strong hits as we 
excluded cell harvest steps which had a prominent role in CRISPR drug screens performed 
in cancer cell lines (Peng et al., 2015; Ruiz et al., 2016; Shalem et al., 2014). In these 
screens, all cells were harvested and pooled at day 0, and from this pool, cells were collected 
for the baseline and seeded for the vehicle and drug treatment. Through this step, all 
screen conditions start with the same guide RNA library representation which allows proper 
comparison of the different treatments. With our primary epidermal stem cell model, we 
were not able to implement this step due to the effect on cell growth capacity which has the 
highest priority in CRISPR screening. Through the lack of this step, unequal distribution of 
guide RNAs between baseline and treatment condition at day 0 may introduce an increase 
of false positives. Unsuccessful validation of our strongest hit NRD1 could be an example of 
this. However, individually tested guide RNAs of three other candidates did show reduced 
AG1478 sensitivity, demonstrating the potential of the screen to generate actual hits.
Several BMPs can stimulate differentiation as confirmed by our stimulation experiment 
(Gosselet et al., 2007; Mulder et al., 2012). In our screen, we found BMP4, suggesting 
that BMP signaling is also essential for commitment towards differentiation. However, is 
only BMP4 essential for commitment to differentiation? To confirm this, effects on induced 
differentiation should be addressed upon knock-out of other BMPs such as BMP2 and BMP6. 
Another question is, do the BMPs act similar and If they do, is their function in epidermal 
differentiation simply based on the timing of their expression? Literature about BMP2 and 
BMP6 in terminal differentiation together with the mRNA expression analysis we did, would 
suggest that timing could play an important role (van Eijl et al., 2018; Gosselet et al., 2007). 
The question whether they act similar could be addressed with differential gene expression 
analysis upon stimulation with the different BMPs. Assuming they act similar and the timing 
of expression is important, their actions might be dose dependent during differentiation. This 
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would mean that only BMP4 is enough for commitment to differentiation and later on, it may 
be necessary to have the sum of multiple BMPs being expressed for terminal differentiation.
For WNT3a, two individual guide RNAs edited the WNT3a locus and they decreased the 
effect on proliferation by AG1478, which could indicate a role in epidermal differentiation. 
In contrast with this, WNT3a is often exemplified as ligand of the canonical WNT signaling 
(b-catenin dependent) which is thought to promote proliferation (Veltri et al., 2018). Evidence 
suggesting a role in differentiation is also present and is based on a study with WNT3a 
stimulation in human keratinocytes (Nam et al., 2014). Regarding BMP induced epidermal 
differentiation, BMP2 has been reported to induce expression of various WNT proteins (Yang 
et al., 2006). Moreover, BMP2 was able to stimulate TCF/LEF canonical WNT target gene 
expression similar like WNT3a conditioned medium. This would suggest that BMP2 induces 
differentiation while stimulating WNT gene expression and a prominent canonical WNT 
target gene. Regarding this, WNT3a induced differentiation seems possible and should be 
addressed in our epidermal cell culture model to validate WNT3a as regulator of epidermal 
differentiation. Unpublished work from the Mulder lab indeed showed decreased colony 
formation upon stimulation with WNT3a conditioned medium. These experiments were done 
in the presence of feeder cells thus their role in this WNT3a effect should be considered. 
Proper evidence for WNT3a induced epidermal differentiation in our model is therefore still 
lacking.
For GLIS3, an association with epidermal self-renewal and differentiation has not been 
described. GLIS3 belongs to the Gli similar protein family and represents a transcription 
factor with activator and repressor functions. GLIS3 is implicated in diverse processes 
representing thyroid hormone biosynthesis, pancreatic β cell generation and insulin 
expression and spermatogenesis (Jetten, 2018). Moreover, GLIS3 has been reported to 
promote osteoblast differentiation in vitro and in this process, GLIS3 was shown to act 
synergistically with BMP2 (Beak et al., 2007). After identification of GLIS3 in our screen, a 
potential role in epidermal differentiation seems interesting to look into as well. For this, 
more guide RNAs need to be confirmed for reduced sensitivity to AG1478 and editing of the 
GLIS3 locus. Ultimately, it would be important to address whether GLIS3 overexpression 
induces epidermal differentiation.
In conclusion, we report a genome-wide GeCKO screen in primary epidermal stem cell 
differentiation with the potential to find novel regulators in epidermal differentiation. It 
picked-up known epidermal differentiation regulators from the Notch and BMP signaling and 
with WNT3a as well as DVL1, we highlighted a potentially unknown role for WNT signaling. 
Furthermore, another potential candidate without background in epidermal differentiation 
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was validated with GLIS3, demonstrating the screen as resource for the discovery of novel 
regulators in epidermal differentiation.
Methods
Cell culture
Primary pooled human epidermal stem cells derived from foreskin were obtained from 
Lonza. Cells were cultured and expanded as previously reported (Gandarillas and Watt, 
1997). Briefly, cells were cultured on a feeder layer of Mitomycin C (SCBT) inactivated J2-
3T3 cells in FAD medium (Ham’s F12 medium/Dulbecco’s modified Eagle medium (DMEM) 
(1:3) supplemented with 10% batch tested fetal calf serum (FCS) and a cocktail of 0.5 µg/ml 
of hydrocortisone, 5 µg/ml of insulin, 0.1 nM cholera enterotoxin, and 10 ng/ml of epidermal 
growth factor) supplemented with Rock inhibitor (Y-27632, 10 µM). J2-3T3 cells were 
cultured in DMEM containing 10% bovine serum. For viral transduction and differentiation 
experiments, epidermal stem cells were transferred to Keratinocyte Serum Free Medium 
(KSFM) supplemented with 100ng/500ml Epidermal Growth Factor and 15mg/500ml bovine 
pituitary extract from Life Technology. HEK293T cells were cultured in DMEM supplied with 
10% fetal bovine serum. All media were supplemented with 1% penicillin/streptomycin 
antibiotics. Recombinant BMPs were obtained from R&D Systems and for stimulations a 
concentration of 200 ng/ml was applied.
In cell Western
Cells were washed with PBS and fixed by incubating 10 minutes with 4% paraformaldehyde 
(PFA) in PBS. PFA removal occurred with 3 PBS washes. Cell permeabilization was done in 20 
minutes with 0.1% Triton X-100 in PBS and blocking in 30-60 minutes with 1% BSA in PBS. 
Anti-TGM1 was produced from the BC.1 hybridoma cell line (van Buggenum et al., 2016) 
and used in the overnight primary stain (1:6000). After 3 washes, a secondary stain was 
performed with IR800 anti-mouse secondary antibodies (1:2000, LiCor) and a DNA stain, 
DRAQ5 (1:4000, Biostatus) for 1 hour at room temperature. After 3 PBS washes, plates 
were scanned and analyzed with the Odyssey system and software with consistent settings. 
TGM1 signal was corrected by dividing with DRAQ5 signals.
GeCKO library and cloning
The human GeCKOv2 library (A and B) was obtained from Addgene and  amplified in Stbl3 
chemically competent E.coli as described (Shalem et al., 2014). For the validation of sgRNAs 
of BMP4, oligo’s with sequences of the selected sgRNAs (HGLibB04605, HGLibB04606, 
HGLibB04607) were ordered from Biolegio with overhangs compatible for ligation into 
LentiCRISPRv2 (Addgene, 52961) after digestion with BsmBI (NEB). For efficient ligations, 
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phosphates were added to the oligo’s with an PNK (NEB) incubation upon annealing and 
phosphates were removed from the LentiCRISPRv2 backbone with Antarctic phosphatase 
(NEB). Identification of the correct constructs was achieved with a colony PCR in which the U6 
primer (5′-GAGGGCCTATTTCCCATG-3′) acted as forward primer and the reverse sgRNA oligo 
as reverse primer. Constructs were subsequently amplified in One Shot® TOP10 chemically 
competent E. coli at 30 °C to minimize the occurrence of recombination’s.
Lentivirus
Virus was produced in HEK293T cells from the GeCKO library (A and B) lentiCRISPRv2 
constructs using the second-generation packaging plasmids psPAX2 and pHDM-G. 
Lipofecatamin2000 was used for transfection and after 48 hours, medium containing 
released virus was collected 4x times in the next 36 hours following virus concentration 
with Lenti-X Concentrator (Clontech). One day after seeding, epidermal stem cells were 
transduced overnight. Puromycin selection was started 24 hours after transduction and 
performed for 3 days to preserve cells that incorporated the construct. A multiplicity of 
infection (M.O.I.) of 0.3 - 0.5 was applied in the screen assay and validation experiments 
and was determined as survival rate upon puromycin selection after transducing within a 
range of 0.1 - 50 ul/ml virus. Survival was determined through comparing confluency after 
puromycin selection compared to a no puromycin control. Confluency was measured with an 
in-cell-Western DRAQ5 stain. 
AG1478 screen and library preparation
The GeCKO screen was used as positive selection screen on cells treated with AG1478 
(Calbiochem) dissolved in DMSO (100 µM). Two replicate screens were performed 
simultaneously and per replicate 2.6x107 cells were seeded (1x106 cells/15cm dish). After 
puromycin selection, 50% of the cells were harvested for the baseline and after 9 days 
culture with AG1478 were the remaining cells collected for the treatment. Genomic DNA 
sequencing was performed as reported (Shalem et al., 2014). Briefly, two sequential PCR 
steps were done on genomic DNA (gDNA) using the same primers and Herculase II Fusion 
DNA Polymerase (Agilent). Extraction of gDNA was done with a kit from Zymo Research 
(D3110) after thawing frozen cell pellets which gave yields of 80-100 µg gDNA per duplicate. 
For the amplification of the sgRNAs in the first PCR, 18 cycles were run on 8-10 reactions 
of 100 ul with 10 µg gDNA input. To attach Illumina adaptors and sample barcodes in the 
second PCR, 15 cycles were applied on 100ul reactions with 5 ul of pooled PCR 1 product. 
Sequence libraries were purified with an E-gel and sequenced on the NextSeq. 
Analysis CRISPR screen
The MaGECK method version 0.5.6 was used to process and analyze the sequence data (Li et 
al., 2014) and R was used for visualization and additional calculations to determine, standard 
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deviations, correlations and fold changes. The number of sequenced reads ranged between 
10-15 million and a reasonable amount of 60-70% was mapped to the guide RNA sequences 
of the GeCKO library v2. Counts per guide RNA were generated from the replicates separately 
and to calculate Pearson correlations. The replicates were merged for the visualization of 
the individual sgRNA count data and for the MaGECK Test analysis. MaGECK test was run 
without zero counts and the non-targeting controls in the GeCKO library were used as 
control sgRNAs. Pathway gene lists (Ribosome, Proteasome, Spliceosome and Cell Cycle) 
were extracted from the KEGG pathway file c5.bp.v6.0.symbols.gmt downloaded from 
http://software.broadinstitute.org/gsea/msigdb. MaGECK was also applied to do Gene Set 
Enrichment Analysis (GSEA) on GO terms of biological processes (c5.bp.v6.0.symbols.gmt, 
downloaded from http://software.broadinstitute.org/gsea/msigdb) using the MaGECK test 
output table. From the MaGECK test output table, we also used the p-value and median Log2 
fold change of all guide RNAs per gene to filter genes with a significant increase of guide RNA 
counts in the treatment condition (positive selection analysis). After this selection, genes 
were excluded with more than one good guide RNA for negative selection. These are guide 
RNAs whose ranking is below the alpha cut off in the negative selection analysis. 
Genome browser tracks/RNA-seq analysis
Processed RNA-seq data from Kretz et al., (2012) was used. Tracks and images were 
generated in genome browser with bigwig files (GEO, GSE34767) .
T7E1 assay 
Genomic DNA was extracted from cells transduced with LentiCRISPRv2 constructs using the 
QIAquick PCR Purification Kit. The site of genomic editing was amplified from 30ng gDNA 
in a PCR with the Herculase II Fusion DNA Polymerase (Agilent) using primers flanking the 
sites targeted by the guide RNAs (Supplementary Table 1). Unpurified PCR products were 
denatured and re-hybridized in a Thermo cycler to form hetero-duplexes between edited 
and Wild-Type strands. Miss-matches in these hetero-duplexes around the target sites of 
the sgRNAs are targets for T7 endonuclease 1 (T7E1) and will lead to digestion. Upon 30 
minutes incubation with T7E1, samples were run on a 2% agarose gel to address whether 
digestions had occurred and as consequence of the CRISPR targeting.
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Supplementary figure 1: Raw data used for quantification of confluence and TGM1 expression upon 
AG1478 treatments. (a) Images of wells showing DRAQ5 signal upon 6 days treatment with different 
concentrations of AG1478. (b) Images of DRAQ5 and TGM1 staining upon 6 days treatment with different 
concentrations of AG1478.
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Supplementary figure 3:  T7E1 assays of indicated genes and guide RNAs. Lanes marked with an 
asterisk represent guide RNAs displaying targeting with the T7E1 assay.
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images displaying the mRNA expression of the indicated genes at 3 time points during differentiation. 
Data was used from Kretz et al., 2012.
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Table 1. Overview of primers for the T7E1 assay
Gene Guide RNA(s) Primer name Sequences (5’ - 3’) 
NRD1
B-32621
T7_fw_NRD1_1 TGCATCAAACCAAGGAGGGA
T7_rv_NRD1_1 CGCAGTTCTTCATCCACCCA
A-32665
T7_fw_NRD1_2 TTCTGATGTTTGGCTGGGGG
T7_rv_NRD1_2 CACTTTGCTGCTCCTCCTGA
GLIS3
B-19252
T7_fw_GLIS3_1 CCAGATGGCTCACGGTGAAT
T7_rv_GLIS3_1 CACCAGCCCACTATCAAGCA
A-19277
T7_fw_GLIS3_2 AACCACGGCTCTCAGAATGG
T7_rv_GLIS3_2 AGGCGTTCGGTCTTGAACAG
BMP4 A-04607/B-04605/ B-04606/B-04607
T7_fw_BMP4_1 TAACCTTCCACTCCCCTCCC
T7_rv_BMP4_1 GGGGCTTTGATGTAACCCGA
WNT3A
 A-54366
T7_fw_WNT3A_1 GCCATCGGTGACTTCCTCAA
T7_rv_WNT3A_1 AGACACTAGCTCCAGGGAGG
B-54302
T7_fw_WNT3A_2 CCTGGGCAACACAGTGAGAT
T7_rv_WNT3A_2 CCACCCCCATACCTTTGTCC
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Abstract
Multi-(phospho-)protein detection in single cells allows the study of cell signaling 
heterogeneity within a cell population. Previously, we developed a single cell multi-protein 
detection method that combines staining with (phospho-)antibody-DNA conjugates on cell 
populations with high-throughput sequencing as read-out (Immuno-Detection-Sequencing, 
scID-Seq). This method has a high resolution due to the PCR based amplification of the 
signal and allows multiplexing of antibodies. Here, we applied scID-Seq with a panel of 70 
(phospho-)antibodies on primary epidermal stem cells treated with kinase inhibitors against 
p90RSK (BI-D1870) and p70S6K (PF4708671). Both kinases phosphorylate Ribosomal S6 
and both can be stimulated with EGF, but via distinct pathways. Here, we provide novel 
insights on single cell level when a pathway is blocked and what it means for the activity 
of upstream factors and how this possibly leads to cross-talk with other pathways. Both 
kinase inhibitors led to decreased phosphorylation of downstream RPS6, and also increased 
signaling upstream and changed the phosphorylation level of components in other pathways 
of the EGF signaling network. We demonstrate here that a targeted drug treatment can 
induce changes that amount to much more than a block in the signaling cascade. These 
data provide a framework for future studies focused on targeted drug responses on multiple 
pathways in single cells.
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Introduction
The epidermis is the outer layer of the skin and forms the barrier with the outside 
environment to protect the body against pathogens and dehydration. The dermis is the 
layer underlying the epidermis and they are separated by the basement membrane. On 
the basement membrane reside the epidermal stem cells and they are important for 
maintaining the epidermis. Through tightly regulated processes, they divide and form new 
stem cells and/or differentiating cells. When the cells differentiate they disconnect from the 
basement membrane and migrate upwards as they maturate into terminally differentiated 
skin cells. The epidermis is renewed every 30 days and this ongoing process requires a 
fine balance between self-renewal and differentiation. When this balance is disturbed and 
skewed towards more self-renewal or differentiation, diseases can develop such as cancer 
or psoriasis (Blanpain and Fuchs, 2006). 
Epidermal Growth Factor (EGF) signaling activity is important for maintaining the epidermal 
stem cells in a self-renewing state and blocking the EGF signaling network with chemical EGFR 
inhibitors results in differentiation (Kolev et al., 2008; Mulder et al., 2012). In skin cancers, 
mutations are often found in the EGF receptor (EGFR) that lead to constitutive activity of 
the EGF signaling. Specific cancer drugs have also been developed to block the activity of 
the EGFR ( Cancer Genome Atlas Research Network, 2012; Scaltriti, 2006). However, EGF 
signaling constitutes a broad interconnected network of kinases and it contains multiple 
pathways with different functions, including PI3K/Akt/mTOR, RAS/ERK, JNK and p38 that can 
also be triggered by growth factor receptors other than EGFR (Gesser et al., 2011; Ito and 
Takeuchi, 2010; Manning and Toker, 2017; Mendoza et al., 2011). In addition, cross-talks 
have been described with other signaling pathways, including Wnt and Jak-STAT signaling, 
exemplified by the inactivating phosphorylation of Wnt component GSK3b by Akt (Manning 
and Toker, 2017; Mendoza et al., 2011; Wu and Pan, 2009), and activation of STAT3 via 
RAS/ERK signaling (Gough et al., 2013; Lim and Cao, 2001; Lo et al., 2003). Treating cancer 
with EGFR inhibitors often leads to severe cutaneous side-effects and at some point, cancer 
cells can also become resistant (Kalyankrishna and Grandis, 2006). They bypass the EGFR 
and have still active downstream signaling pathways that stimulate sustained cell growth. 
To overcome resistance, drugs that target signaling components downstream of the EGFR 
have been developed. Two major signaling pathways in the EGF signaling network are the 
Akt-mTOR and Ras/ERK (MAPK) signaling routes (Figure 1a). Both signaling routes lead 
to phosphorylation of RPS6, a protein important for the translation machinery of the cell 
(Meyuhas, 2015). The p90RSK kinase activates RPS6 via MAPK signaling component ERK1/2, 
whereas p70S6K phosphorylates RPS6 upon activation via the Akt-mTOR signaling(Mendoza 
et al., 2011). Both kinases are linked to cancer and small molecule inhibitors have been 
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developed to study their potential as targets for cancer therapies (Qiu et al., 2016; Tarng 
and Yang, 1989) (Fang et al. 2014; Qiu et al. 2016).
However, the effects of targeted drugs should be well addressed. In a recent report, 
optogenetic stimulation of the RAS/ERK pathway was used to quantitatively screen the 
effect of drug treatments on signal transmission. This demonstrated that targeted drugs can 
corrupt dynamic transmission properties in signaling pathways, shifting cellular response 
thresholds and changing cell decisions in a potentially pathological manner (Bugaj et al., 
2018). It is therefore of critical importance to understand how signaling activities change in 
response to targeted drugs which possibly affects other pathways as well. Here, we aimed to 
further look into the effects of targeted drugs on multiple pathways to answer the following 
questions: 1) How much is their effect limited to diminished downstream activity and does 
the block they introduce also lead to upstream accumulation of activity? 2) When activity 
does accumulate upstream the block, it would be important to know the consequences. Is 
the activity absorbed by the signaling network or is activity redirected to alternative signaling 
routes? To address these questions, a single cell approach is favored to address which 
pathways in a cell are active simultaneously and to determine cell population heterogeneity 
for a better interpretation of the drug response. Previously, the effect of increased abundance 
of specific pathway components has been demonstrated with mass cytometry detecting up 
to 35 epitopes including phospho-sites (Lun et al., 2017). A somewhat different strategy 
is based on DNA-antibody conjugates with high-throughput sequencing as read-out. Using 
this rationale, we recently reported single cell Immuno-detection-sequencing (scID-seq) 
measuring >70 (phospho-) proteins in single cells (van Eijl et al., 2018). In the present 
study, we applied scID-seq to investigate the effects on signaling pathway activity and cross-
talk in karyotypically normal epidermal stem cells treated with drugs targeting p70S6K and 
p90RSK downstream of EGFR. 
Results
Development of a barcoding strategy to multiplex scID-seq samples
To address the effect on the EGF signaling network and other pathways in single cells we 
aimed to apply our novel single cell ID-seq method with a panel of 70 antibodies barcoded 
with specific DNA sequences (van Buggenum et al., 2018; van Eijl et al., 2018). This 
panel contains antibodies detecting phosphorylated and non-phosphorylated components 
from the Akt-mTOR signaling and MAPK signaling as well as several other pathways and 
cellular processes such as the cell cycle and differentiation. To study the effects of short-
term RSK1/2/3/4 inhibition via the MAPK route and p70S6K via the Akt-mTOR route, cells 
were treated for 2 hours with the inhibitors BI-D1870, PF4708671 or vehicle (Figure 1a). 
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Subsequently, EGF was added to the medium to stimulate the EGFR for 30 minutes. The 
vehicle treatment was split into a condition with EGF stimulation and a condition without EGF 
stimulation as control for the 30 minutes EGF stimulation without inhibitors. 
To prevent batch-effect and minimize variation in staining efficiencies between samples, 
we designed a sample barcoding strategy that allows us to mix the different treatment 
groups prior to staining with our panel of 70 antibody-DNA conjugates. Moreover, this 
combined sample is used for FACS-based single-cell isolation into 96-well plates, effectively 
randomizing the treatment groups over the different independent sample preparations 
that are performed per plate. To achieve this, we implemented a pre-staining step with an 
antibody that is conjugated to four separate DNA barcodes, one for each sample (Figure 
1b), reminiscent of the cell-hashing approach (Stoeckius et al., 2017) In this pre-stain step, 
we used an antibody against the abundantly expressed ITGA6 protein to stain the different 
treatments with a sample-specific DNA barcode (Table 1). This enables computational 
classification of the cells to their respective treatments after sequencing. We developed a 
custom pipeline for data processing (Figure S2a) and identified high quality cells based on 
the number of counts per cell (van Eijl et al., 2018). We observed a bimodal distribution of 
high- and low-quality cells separated by a threshold of 25,000 counts per cell (Figure S2b). 
Next, we calculated the median count and variance of all antibodies. Sixty-nine antibodies 
with a median of >100 counts per cell were retained for further analyses. A higher variance 
was observed for each of the ITGA6 barcodes used for the sample barcoding which was 
expected as they should only have a high number of counts in approximately 25% of the 
cells (Figure S2c). Finally, we removed outlier cells that displayed extreme counts for one or 
more antibodies. After these filtering steps, raw UMI counts were normalized by subsampling 
and the cells were assigned to the treatment groups using the ITGA6 sample barcodes 
(Figure 1b). Cells from different treatment groups were relatively uniformly distributed over 
the different plates that underwent independent sample preparations (Figure S2d). The data 
was subsequently median-normalized per plate (Figure S3) and scaled (0-1 scaling) for 
further analysis (Figure S4).
S6 kinase inhibition leads to accumulation of phosphorylation of upstream 
regulators
To interpret inhibitor effects on EGF signaling we first looked at changes introduced by 30 
minutes EGF stimulation alone. Of all antibodies, a significant increase was only observed 
for NFKb-p65-p (Figure S4 and S5a), indicating that 30 minutes EGF stimulation leads to 
minimal changes. This can be explained by the presence of high expression levels for 5 
of the 7 known EGFR ligands in proliferating keratinocytes (Figure S6). For this reason, 
we only compared the inhibitor treatments with the EGF stimulated vehicle treatment. To 
determine biologically based differences, we applied multi-dimensional scaling on calculated 
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distances of antibodies that showed strong and significant dynamics (Figure S4, S5b and 
S5c). Through this, we observed a shift of the three different treatments based on biological 
differences already after two hours (Figure 1c), demonstrating the dynamic nature of our 
system and the robustness of scID-seq.
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Figure 1: Differently treated cells barcoded with antibody-DNA conjugates. a) Overview of EGF signaling 
network showing the targets of RPS6 kinase inhibitors BI-D1870 (RSK1/2/3/4) and PF4708671 (p70S6K). 
b) Experimental overview and result of the treatment barcoding with the ITGA6 antibody conjugated to 
DNA-barcode specific sequences. c) Multi-dimensional scaling (MDS) on calculated distances of scaled 
antibody counts. Antibodies used for MDS were selected based on strong significant changes between 
inhibitor treatments and vehicle.
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The kinases p70S6K and p90RSK both phosphorylate the downstream target RPS6. Generally, 
kinase inhibitors are used to block a kinase and downstream signaling. In line with this, we 
observed decreased RPS6 phosphorylation upon inhibition of p70S6K or p90RSK (Figure 
2a). We also measured two phosphorylation sites of p90RSK itself and observed decreased 
phosphorylation at the site targeted by ERK1/2 (T359) upon treatment with BI-D1870, 
suggesting that phosphorylation of this site is blocked (Ballif et al., 2005; Dalby et al., 
1998) (Figure 2a). These results indicate that p70S6K and p90RSK are both important for 
regulation of RPS6 phosphorylation which suggests that these two upstream kinases are 
rate limiting for RPS6 phosphorylation, as it scales with upstream kinase activity.
Next, we aimed to address what happens to the activity of the other canonical pathway 
proteins (Figure 1a).  Does activity dissipate or accumulate and can we observe this through 
increased phosphorylation of upstream signaling components. In the Akt-mTOR route, we 
observed more Akt1-p after p70S6K inhibition while in the MAPK route we observed a strong 
increase for ERK1/2-p upon p90RSK inhibition (Figure 2a), indicating that phosphorylation 
accumulates upstream in the canonical pathway. We did not observe global cross-talk 
between the Akt-mTOR and MAPK signaling routes upon inhibition (Figure 2b), suggesting 
that these signaling routes regulate RPS6 phosphorylation independently. 
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Figure 2: Inhibition of RPS6 kinases leads to accumulation of upstream phosphorylation. a) Scaled 
count frequency of cells treated with vehicle+EGF compared to treatment with BI-D1870+EGF or 
PF4708671+EGF. b) Log2 fold change and significance of antibody counts between vehicle and inhibitor 
treatments are visualized by the color and size of the nodes in a signaling context. The fold change was 
calculated using the median and the significance was determined with the Kolmogorov-Smirnov test.
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Known cross-talk of Akt1 with GSK3b is enhanced upon p70S6K inhibition
After observing the accumulation of upstream activity, we wondered where this activity 
is going? We hypothesize that 1) Activity accumulates and signals are absorbed by the 
network, or 2) Signal is redirected to specific alternative pathways. To identify possible 
cross-talks induced or enhanced by the inhibitors, we extended our scID-seq analysis to 
signaling components in other pathways including Jak-STAT, JNK, p38 and Wnt signaling. 
Cells treated with p70S6K inhibitor PF4708671 showed changed antibody levels for different 
components in the JNK, p38 and Wnt signaling (Figure 3a, S5b and S7). Phosphorylation 
of JNK signaling component cJun decreased, while the inactivating phosphorylation of Wnt 
signaling component GSK3b was enhanced as well as the activating phosphorylation sites 
of MAPK-p38 and downstream CREB (Reyskens and Arthur, 2016; Roux and Blenis, 2004). 
These changes show that drug treatments also affect the phosphorylation of components 
in other pathways and are limited and indicates that accumulated upstream activity may 
be redirected to alternative pathways. To interpret the possibility of enhanced cross-talk 
between pathways, we visualized all changes in a signaling network overview (Figure 3a). 
The inactivating Serine-9 phosphorylation site of GSK3b is a known target of Akt (Manning 
and Toker, 2017; Mendoza et al., 2011; Wu and Pan, 2009). In addition, inactivation of 
GSK3b has been shown to enhance phosphorylation of p38 signaling via MKK3/6 (Abell et 
al., 2007; Markussen et al., 2018)(Markussen et al. 2018; Abell et al. 2007). Therefore, the 
increased phosphorylation of Akt1 and GSK3b exemplifies cross-talk induced by p70S6K 
inhibition and enhanced GSK3b-p appears in turn to cause increased phosphorylation of 
multiple p38 signaling components (Figure 3a). 
The power of our approach is that we can determine whether these changes also occurred 
in the same single cell. We first compared the levels of GSK3b-p and Akt1-p in vehicle and 
PF4708671 treated cells. Indeed, cells with high Akt1-p also displayed elevated GSK3b-p 
levels (Figure 3b). To see if other global changes overlap with increased Akt1-p, we selected 
cells with high Akt1-p (Akt high > 0.5, 54 cells) to compare with the rest of the cells 
(Akt low). In line with the global observations, phosphorylation was significantly higher 
in Akt high cells for all measured p38 signaling components (MKK3/6, MAPK-p38 with two 
antibodies, MAPK-APK2 and CREB) (Figure 3c). Interestingly, phosphorylation of mTOR was 
not globally increased in PF4708671 treated cells compared to vehicle treated cell, but in the 
Akt high cells we did observe a significant increase of mTOR-p, indicating that accumulation 
of phosphorylation upstream p70S6K also occurred for mTOR-p in Akt high cells (Figure 3c). 
Through visualization of the levels of the Akt-GSK3b-p38 pathway between Akt high and Akt 
low cells in a heatmap, we observed that most cells with high Akt also have high MAPK-p38-p 
and high GSK3b-p (Figure 3d). Altogether, the results here show that p70S6K inhibition with 
PF4708671 leads to accumulated phosphorylation of two upstream components and seems 
to be redirected to GSK3b-p and subsequently to MAPK-p38 within an individual cell.
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Figure 3: Increased Akt1-p by p70S6K inhibition leads to enhanced known cross-talk in single cells. 
a) Log2 fold change and significance of antibody counts between vehicle and inhibitor treatment are 
visualized by the color and size of the nodes in a signaling context. The fold change was calculated using 
the median and the significance was determined with the Kolmogorov-Smirnov test. b) Separation of cells 
for low and high scaled counts of Akt1-p. c) Comparison of scaled counts of other antibodies between 
the Akt low and high cell populations from b. The p-value was calculated with the two-sample T-test. 
Heatmap visualizing scaled counts of all significant antibodies between Akt low and high cells. From the 
Akt low population 26 cells were subsampled. Significance was determined using the two-sample T-test 
and Benjamini-Hochberg multiple testing correction with a 1% FDR threshold.
RSKi induces multiple possible cross-talks and different responses for ERK and 
MAPK-APK2
To see if drug-induced redirection of signaling activity is specific for p70S6K inhibition or also 
applies for other drug treatments, we continued with the p90RSK inhibition data. Changes 
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in signal of all antibodies were addressed upon treatment with the p90RSK inhibitor to 
identify cross-talks possibly induced by increased ERK1/2-p. The strongest changes were 
observed for components in JNK, p38 and STAT signaling with increased phosphorylation of 
cJun, MAPK-APK2 and STAT3 and diminished phosphorylation of Jak1 and STAT1 (Figure S5c 
and S8). Phosphorylation of STAT3 by the MAPK signaling has been described previously as 
a known cross-talk (Gough et al. 2013; Jain et al. 1998), indicating that the accumulated 
upstream activity induced by p90RSK inhibition may be redirected to alternative pathways 
(Figure 4a). Surprisingly, upstream of MAPK-APK2-p, phosphorylation was also slightly 
increased for MAPK-p38, suggesting that the increase of MAPK-APK2-p occurred independent 
of ERK1/2-p. Similarly, JNK phosphorylation was increased upstream cJun-p. These results 
indicate that p90RSK inhibition with BI-D1870 leads to strong changes and possible cross-
talks via ERK and may also independent of ERK.
To see if these global observations occurred in the same cells, we addressed the strongest 
changes in single cells with respect to ERK1/2-p levels. We confirmed that RSK-p-T539 and 
RSP6-p levels were inversely correlated with ERK1/2-p within individual cells. Moreover, 
ERK1/2-p high cells display globally increased STAT3-p, cJun-p and MAPK-APK2-p (Figure 
S5c and S8b), indicating that these changes occur simultaneously in single cells. However, 
when focusing on ERK1/2-p and MAPK-APK2-p in BI-D1870 treated cells, we identified two 
apparent subpopulations, one with extra high MAPK-APK2-p and one with extra high ERK1/2-p 
(Figure 4b). This could indicate that these represent populations with distinct responses to 
BI-D1870. To determine the differences, we compared the two populations and used the 
third population with relatively low levels for ERK1/2-p and MAPK-APK2-p as reference. This 
showed more phosphorylation of cJun, Akt1, GSK3b and MKK3/6 in MAPK-APK2-p high cells 
(Figure 4c), indicating that MAPK-APK2-p high cells have a different signaling state then cells 
with extra high ERK1/2-p. Furthermore, we found elevated phosphorylation of histone 3 
(H3-p) in the MAPK-APK2-high cells (Figure 4d), which is a  marker for mitosis and increased 
condensation of the chromatin (Gurley et al., 1974; Sawicka and Seiser, 2014). In addition, 
a trend for decreased phosphorylation was observed for G1 to S-phase progression regulator 
Rb-p (Figure 4d). To see if H3-p is high and Rb-p is low in the same cells, we visualized their 
levels in single cells with respect to ERK1/2-p and MAPK-APK2-p. Indeed, we found that 
the trend of diminished Rb-p in combination with extra high MAPK-APK2-p and high H3-p 
is consistent in single cells (Figure 4e). This suggests that extra high MAPK-APK2-p and 
extra high ERK1/2-p are in a different cell cycle state, indicating that distinct responses in 
single cells to drug treatment are affected by or result in differences in their cell states (e.g. 
signaling and cell cycle). 
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Figure 4: BI-D1870 treatment leads to different responses representing cells with high ERK1/2-p or 
MAPK-APK2-p. a) Log2 fold change and significance of antibody counts between vehicle and inhibitor 
treatment are visualized by the color and size of the nodes in a signaling context. The fold change was 
calculated using the median and the significance was determined with the Kolmogorov-Smirnov test. b) 
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Scaled counts of MAPK-APK2-p and ERK1/2-p in BI-D1870 treated cells divided in MAPK-APK2-p high, 
ERK1/2-p high and low cells. c) Scaled counts of other antibodies measuring signaling components in cells 
of the indicated subpopulations from b. d) Scaled counts of other antibodies measuring cell cycle markers 
in cells of the indicated subpopulations from b. The p-value was calculated with the two-sample T-test. 
e) MAPK-APK2-p high and ERK1/2-p high cells with visualization of Rb-p and H3-p levels with grey-scale 
and dot sizes respectively. 
Discussion
In this study, we used single cell ID-seq as a method to address and compare the effects 
of drug treatments on signaling within individual cells. By measuring 69 proteins upon 
inhibition of RPS6 kinases p70S6K and p90RSK, we found that the effect of targeted drugs is 
not limited to a signaling cascade block Activity also accumulated upstream and was possibly 
redirected to alternative pathways as well. Inhibition of both kinases led to decreased 
phosphorylation of their target RPS6, but upstream phosphorylation accumulated for Akt1 
upon p70S6K inhibition and for ERK1/2 after p90RSK inhibition. Known targets of Akt1 and 
ERK in other pathways showed increased phosphorylation, indicating enhanced cross-talk 
via Akt1 and ERK1/2. Upon inhibition with BI-D1870, we also identified cells with either extra 
high ERK1/2-p or extra high MAPK-APK2-p with distinct levels for signaling components and 
cell cycle markers. This would suggest that the drug response can be heterogeneous due to 
the state of the cell.
Our observations for RPS6-p suggest that the Akt-mTOR and MAPK signaling routes 
independently phosphorylate a part of all RPS6 proteins in a cell. In line with this, partial 
phosphorylation of RPS6 by the MAPK route has been described (Roux et al., 2007). In 
contrast, ERK and p90RSK are also known to positively regulate p70S6K activity via mTOR 
(Mendoza et al., 2011; Romeo et al., 2012) and we indeed observed a slightly stronger 
reduction of RPS6-p after p70S6K inhibition, but we did not observe changed mTOR 
phosphorylation on population level. To confirm that both inhibitors partially reduce RPS6 
phosphorylation, an experiment with both inhibitors combined should show an even stronger 
decrease of RPS6-p compared to a total RPS6 measurement.
Beside an expected decrease of RPS6 phosphorylation downstream, we also observed 
accumulated phosphorylation of upstream pathway components. We proposed that this 
is caused by the block itself, but potentially also through diminished negative feedback 
downstream the block. Negative feedback loops have been described for both the RPS6 
kinases. P70S6K negatively regulates IRS1, a protein known to associate with growth factor 
receptors and important for the activation of pathways such as the AKT-mTOR signaling 
(Knowlden et al., 2008; Magnuson et al., 2012) and p90RSK inactivates SOS, a guanine-
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nucleotide-exchange factor for MAPK component Ras upstream of ERK (Douville and 
Downward, 1997). In addition, increased ERK1/2 activity has been reported in mice deficient 
for p90RSK2 and in a previous study with BI-D1870 (Dufresne et al., 2001; Sapkota et 
al., 2007). Therefore, the removal of these negative feedback loops could be an important 
reason for the accumulation of upstream phosphorylation. Enhanced phosphorylation of 
cJun and MAPK-APK2 by BI-D1870 may also be explained by the negative feedback loop 
with SOS, but via other downstream factors than Ras such as Rac1 (Hetmanski et al., 2016; 
Innocenti et al., 2002). This would suggest that p90RSK inhibition may also induced more 
p38 and JNK signaling stimulation via sustained SOS activity. In an experiment to verify 
the role of this negative feedback loop, BI-D1870 should be combined with an inhibitor 
upstream of ERK, STAT3, cJun or MAPK-APK2.
The inhibitors also induced changes in other pathways, and some of these indicate interesting 
examples of cross-talk enhanced by the upstream accumulation of activity. For example the 
increased GSK3b phosphorylation via accumulated Akt1-p and subsequent phosphorylation 
of multiple p38 signaling components after p70S6K inhibition (Abell et al., 2007; Manning 
and Toker, 2017; Markussen et al., 2018; Mendoza et al., 2011; Wu and Pan, 2009). With 
p90RSK inhibited, STAT3-p is probably increased via ERK1/2-p (Gough et al., 2013; Lim and 
Cao, 2001; Lo et al., 2003), suggesting that the inactivated negative feedback loop via SOS 
also increased STAT3 phosphorylation via the MAPK-signaling. 
Upon RSK inhibition with BI-D1870, we discovered a high MAPK-APK2-p and high ERK1/2-p 
subpopulation with distinct levels for components in signaling and cell cycle, indicating a 
difference in cell state. These different cell states may explain why these cells have either 
extra high MAPK-APK2-p or ERK1/2 in response to BI-D1870. In cell lines, distinct cell states 
and responses to inhibitors have been described. For instance, a study for sensitivity to 
MAPK inhibitors in melanoma cell lines with a specific mutation showed that distinct mRNA 
expression levels of two factors determined their sensitivity to the inhibitors (Konieczkowski 
et al., 2014). The power of our scID-seq approach is that we can look at single cells and 
determine heterogeneous drug responses within the population. Here, we report that within 
a population distinct response to a (kinase) inhibitor can be observed with scID-seq.
In conclusion, our scID-seq approach applied on epidermal stem cells treated with two 
S6 kinase inhibitors showed diminished phosphorylation of the downstream target RPS6. 
Through simultaneously measuring the levels of many other signaling components in single 
cells we also found that these inhibitors not only blocked the downstream signaling of a 
specific pathway, but also result in changed signaling upstream with subsequent cross-talk 
with other pathways as probable consequence. In addition, two subpopulations in BI-D1870 
treated cells were identified based on extra high ERK1/2-p levels or extra high MAPK-APK2-p 
levels displaying distinct cell states. Altogether, our approach demonstrates that (kinase) 
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inhibitor drugs can affect more than downstream signaling alone. In targeted therapies, 
it should therefore be well characterized how much the action of a drug is limited to the 
blocking of a specific pathway. In addition, with drug treatments, off target effects should be 
noted as well, which potentially could drive dynamics observed in other pathways as well. 
Analysis with scID-seq of other p70S6K/p90RSK inhibitors could be an approach to gain 
broader insight about inhibitory effects of these kinases. Our scID-seq method can cover 
many pathways and through its single cell application pathway activities and interactions 
may be better interpreted in response to a drug as well as the heterogeneity of the response 
within the complete cell population.
Methods
Cell culture
Primary pooled human epidermal stem cells derived from foreskin were obtained from 
Lonza. Cells were cultured and expanded as previously reported (Gandarillas and Watt, 
1997). Briefly, cells were cultured on a feeder layer of J2-3T3 cells in FAD medium (Ham’s 
F12 medium/Dulbecco’s modified Eagle medium (DMEM) (1:3) supplemented with 10% 
batch tested fetal calf serum (FCS) and a cocktail of 0.5 µg/ml of hydrocortisone, 5 µg/ml of 
insulin, 0.1 nM cholera enterotoxin, and 10 ng/ml of epidermal growth factor) supplemented 
with Rock inhibitor (Y-27632, 10 µM). J2-3T3 cells were cultured in DMEM containing 10% 
bovine serum and inactivated with Mitomycin C (SCBT) upon seeding the epidermal stem 
cells. For experiments epidermal stem cells were transferred to Keratinocyte Serum Free 
Medium (KSFM) supplemented with 0.2 ng/ml Epidermal Growth Factor (EGF) and 30 μg/ml 
bovine pituitary extract from Life Technology until 70% confluency. Cells were treated with 
RSK1/2/3/4 inhibitor BI-D1870 (10 μM, Sellekchem) or P70S6K inhibitor PF4708671 (10 
µM, Sellekchem). All media were supplemented with 1% penicillin/streptomycin antibiotics.
Antibody conjugation with dsDNA barcodes
Antibodies and dsDNA were functionalized and conjugated as described (van Buggenum et 
al., 2016). (Table 1). In short, antibodies were functionalized with NHS-s-s-PEG4-tetrazine 
(Jena Bioscience) in a ratio of 1:10 in 50 mM borate buffered Saline pH 8.4 (150 mM NaCl). 
Then, N3-dsDNA was produced and functionalized with DBCO-PEG12-TCO (Jena Bioscience) 
in a ratio of 1:25 (Table 1). Finally, purified functionalized antibodies were conjugated to 
purified functionalized DNA by 4-hour incubation at room temperature in borate buffered 
saline pH 8.4 in a ratio of 4:1 respectively. The reaction was quenched with an excess of 
3,6-diphenyl tetrazine. The conjugation efficiency and quality were checked on an agarose 
gel, confirming that a substantial amount of DNA conjugated with the antibody (Figure S1). 
Ultimately, conjugates were equally pooled for staining’s in scID-seq.
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Immuno-staining and single cell sorting 
Staining and sorting was performed as described previously. Briefly, Cells (> 3 x 106) were 
harvested with trypsin and cross-linked in suspension by incubating for 10 minutes with 
4% paraformaldehyde (PFA) in PBS following a quenching step of 5 minutes with 125 mM 
Glycine in PBS. Removal of PFA and Glycine occurred through washing twice with wash 
buffer (0.1x Pierce™ Protein-Free Blocking Buffer from Thermo in PBS). Then, cells were 
blocked in 500µl blocking buffer (0.5x 0.1x Pierce™ Protein-Free Blocking Buffer, 200 µg/ml 
boiled salmon sperm DNA, 0.1% Triton-X 100, in PBS) at room temperature for 30-60 min. 
Pre-stainings were performed at room temperature for 1-2 hours and staining with the 
conjugate mix occurred overnight at 4°C in 500 µl blocking buffer. After each staining, cells 
were washed 3x in 5ml wash buffer. Cells were sorted single cell with the BD FACSAria SORP 
flow cytometer (BD biosciences) in 96 well PCR plates containing 1µl release buffer (10 mM 
DTT in 15mM Tris, pH 8.8) and 7ul Vapor-lock (Qiagen).
Barcoding and library preparation for next generation sequencing
Library preparation was done as shown previously (van Eijl et al. 2018). Briefly, 3 PCR steps 
were performed to amplify the antibody barcodes and to add barcodes specific for the well 
and the plate of each cell (Overview of work flow). The barcoding occurred with the same 
sequences used in ID-seq (van Buggenum et al., 2018). For the first PCR step 15 cycles were 
run after adding to each well a 4 ul reaction mix containing the Herculase II Fusion DNA 
Polymerase (Agilent), dNTPs, 5x Herculase buffer and 0.1µM amplification primers. Directly 
after the first PCR step, 5 extra cycles were run after adding 1 ul mix containing Herculase 
buffer 0.2 µM forward amplification primer and 0.2 µM reverse well barcoding primer. Then 
all material was pooled per plate, Vapor-lock was removed and a clean-up was performed 
with the QIAquick PCR Purification Kit, an EXO1 treatment to degrade remaining primers 
followed by another purification. Another 5 cycles were run in PCR 3 with a 20 ul reaction 
containing pooled and purified plate sample and 0.1 µM plate barcoding primers. After 
repeating the clean-up, the libraries were checked on agarose gel and with the Bioanalyzer 
(Agilent) to confirm the size of the DNA fragments (expected size around 185 bp).     
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Data analysis
Sequence data from the NextSeq500 (Illumina) was de-multiplexed using bcl2fastq software 
(Illumina). Then, all reads were processed using our dedicated IDseq R-package (van 
Buggenum et al., 2018). In short, the sequencing reads were split using a common “anchor 
sequence” identifying the position of the Unique Molecular Identifier (UMI) sequence, 
Barcode 1 (antibody specific) and Barcode 2 (well specific) sequence. After removing all 
duplicate reads, the number of UMI sequences were counted per barcode 1 and 2. Finally, 
barcode 1 (“antibody)” and barcode 2 (‘well’) sequences were matched to the corresponding 
antibody and well information.
Using R-code, further processing was done to remove cells with low counts, cells with 
Antibody outliers, antibodies with low counts, subsampling, indexing of treatments, 
correction of plate effects (Figure S2). For removal of low count cells, a threshold was set 
based on the difference of total UMI count per well between high UMI count cells and low 
UMI count wells. Cells were also removed if one or more antibodies had a higher UMI count 
than 5 times the standard deviation of the total UMI count. Antibodies with a median UMI 
count <40 were removed. Cells were normalized through subsampling without replacement 
with the number of counts equal to the total count of the cell with the lowest total count 
number. The treatments pre-stained with 4 specific antibody-barcodes were indexed 
through determining the enriched pre-stain barcode per cell. A treatment barcode making 
up >40% of all treatment barcodes was defined as enriched. Plate effects were corrected 
per antibody by taking the median count per plate and subtract all counts of a plate with 
the difference between the plate median and the lowest plate median. Phospho-antibodies 
marked with a (*) were corrected by dividing corrected counts of the phospho-antibody with 
normalised counts of the non-phospho-antibody. The significance of changes in antibody 
signal between different treatments were determined with the Kolmogorov-Smirnov test. 
The log2 fold change between treatments was calculated with the mean of normalized and 
scaled antibody counts. 
Genome browser tracks/RNA-seq analysis 
For analysis of RNA expression of specific genes in proliferating keratinocytes we used the 
processed RNA-seq data from Kretz et al., (2012) downloaded from GEO, GSE34767. Tracks 
and images were generated in genome browser using their bigwig files.
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Supplementary figure 1: Overview of antibody-DNA conjugations loaded on 1% agarose gels stained 
with sybr green. A DNA-band-shift can be observed upon conjugation with the indicated antibodies.
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Supplementary figure 2: Overview of data processing and data quality. a) Data processing scheme. 
b) Visualization of UMI (unique molecular identifier) count frequencies with a clear separation between 
low quality or empty wells compared to good wells based on UMI counts per cell. Red line indicates the 
UMI count threshold of 25,000 for good cells. c) Variance and median count of all antibody-barcodes with 
high variation for the treatment barcodes 94-97. Dashed-line indicates the minimum UMI count threshold 
(40 UMI counts) for the antibodies. d) Distribution of the cells from different treatments over the plates.
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Supplementary figure 3: Distribution of normalized counts per plate after plate correction.
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Supplementary figure 4: Scaled counts of all measured antibodies per treatment.
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Supplementary figure 5: Antibody level changes between the different treatments. The fold change 
was calculated using the median and the significance was determined with the Kolmogorov-Smirnov test 
between vehicle +/- EGF (a) and vehicle + EGF compared to the inhibitor treatments (b, c). 
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Supplementary figure 6: Most EGFR ligands have high mRNA expression in epidermal stem cells. RNA-
seq tracks of self-renewing epidermal stem cells. 
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Supplementary figure 7: Changes between Vehicle+EGF and PF4708671+EGF Frequency histograms 
of signaling components significant with the Kolmogorov-Smirnov test. Frequency represents density of 
scaled counts. 
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Supplementary figure 8: Changes between Vehicle+EGF and BI-D1870+EGF. a) The fold change was 
calculated using the median and the significance was determined with the Kolmogorov-Smirnov test. 
b) Frequency histograms of signaling components significant with the Kolmogorov-Smirnov test. c) 
ERK1/2-p scaled counts against the most significantly changed signaling components.
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Table 1: Overview of Antibody-DNA conjugate panel
Barcode_1 Ab_barcode_
nr
Ab_name Antibody info
GTATCGTCGT 1 Akt-p-S473 Cell Signaling Technology, 4060
GTGTATGCGT 2 Akt1/2/3-p-S473 / S474 / S472 R&D systems, AF887
TGCTCGTAGT 3 Akt2 R&D systems, MAB23152
GTCGTCGTCT 4 BMP2/4 R&D systems, AF355
GTGCGTGTGT 5 BMPRII R&D systems, AF811
GCGTCGTGTA 6 Cdc2-p-Y15 Cell Signalling Technology, 4539
GTCGTGTACT 7 cMyc R&D systems, AF3696
GATGTAGCGT 8 CREB-p-S133 Cell Signaling Technology, 9198
GAGTGATCGT 9 EGFR-p-Y1045 Cell Signaling Technology, 2237BF
CGCTATCAGT 10 Ephrin-B3 R&D systems, AF395
CGCTGTAGTC 11 x  
GCTAGTGAGT 12 ERK1-2 R&D systems, MAB1576
GAGCTAGTGA 13 Fak R&D systems, MAB4467
CGTGCTGTCA 14 Fak-p-Y397 R&D systems, AF4528
GATCGTCTCT 15 Frizzled3 R&D systems, AF1001
GTGCTGTCGT 16 GAPDH R&D systems, MAB5718
TGAGCGTGCT 17 GSK3b-p-S9 Cell Signaling Technology, 5558
CATGTCGTCA 18 H2A-p-S139 Cell Signaling Technology, 9718BF
TCAGTGTCTC 19 IGFBP-3 R&D systems, MAB305
GTGCTCATGT 20 IKB-a R&D systems, AF4299
CGTATCTCGA 21 x  
GTCATGCGTC 22 x  
CTATGCGATC 23 IKB-a-p-S32/S36 R&D systems, AF4809
TGCTATGCTG 24 Jagged1 R&D systems, AF1277
TGTGTGCATG 25 Jak1 R&D systems, MAB4260
GAGTGTCACT 26 x  
CTAGTCTCGT 27 x  
GAGTGCATCT 28 x  
TGCGTAGTCG 29 x  
CTGTGTCGTC 30 x  
CTGTAGTGCG 31 Jak1-p-Y1022/Y1023 R&D systems, AF4510
GTGCGCTAGT 32 JNK R&D systems, AF1387
TGTGCTCGCA 33 JNK-p-T183/Y185 R&D systems, AF1205
GATGCGAGCT 34 x  
CTGTACGTGA 35 x  
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GCGATGATGA 36 x  
TGTCGAGTCA 37 x  
GTCTACTGTC 38 x  
CAGTCAGAGT 39 x  
CGCAGTCTAT 40 x  
GTATGAGCAC 41 x  
CGAGTGCTGT 42 x  
TATAGCACGC 43 x  
TCATGCGCGA 44 x  
TATGCGCTGC 45 x  
TCTCTGTGCA 46 x  
CTATCGCGTG 47 x  
TACGCTGCTG 48 x  
GTATCTCTCG 49 KLF4 R&D systems, AF3640
CGCGTATCAT 50 Kallikrein-6 R&D systems, AF2008
CTGCATGATC 51 x  
GCTCATATGC 52 MAPK-p38-p-T180/Y182 Cell Signaling Technology, 4511
CACTATGTCG 53 MAPK-p38-p2-T180 / Y182 R&D systems, AF869
TAGCGCGTAG 54 MKK3/6-p-3: S189/6: S207 Cell Signaling Technology, 12280BF
CGTCACAGTA 55 mTOR-p-S2448 Cell Signaling Technology, 5536
TCGCGTGAGA 56 NFκB p65/RelA R&D systems, MAB5078
TACATCGCTG 57 NFκB p65/RelA-p-S536 R&D systems, MAB7226
GTGAGAGACA 58 Notch-2 R&D systems, AF3735
GACTGTACGT 59 x  
GCACGTAGCT 60 Notch-3 R&D systems, MAB1559
TCACGCTATG 61 TP63 R&D systems, AF1916
CGTACTACGT 62 PLC-g1-p-Y783 Cell Signaling Technology, 14008
CAGCTGAGTA 63 PLC-g2-p-Y753 R&D systems, MAB37161
GAGATCAGTC 64 Rb-p-S807/S811 Cell Signaling Technology, 8516
TACTGAGCTG 65 Ribosomal-S6-p-S240/S244 Cell Signaling Technology, 5364
TAGTAGCGCG 66 RNAPOL2 DSHB, 8GW16
GACGTCTGCT 67 RSK-p-S380 R&D systems, AF889
GTACTCGCGA 68 RSK-p90-p-T359 Cell Signaling Technology, 8753BF
TCTGAGCGCA 69 smad1 R&D systems, AF2039
TAGACGTGCT 70 smad1/5-p-S463/S465 Cell Signaling Technology, 9516
GTGACTCGTC 71
Smad1/5/9-p-
S463/465;S465/467 Cell Signaling Technology, 13820
TCGAGTAGCG 72
smad2/3-p-S465/S467;S423/
S425 Cell Signaling Technology, 8828
CGTATGATGT 73 smad3 R&D systems, MAB34038
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TAGTCTGTCA 74 Src R&D systems, AF3389
TGTCTCTATC 75 Src-p-Y419 R&D systems, AF2685
CTAGAGTATC 76 Cdc2 Thermo Scientific, MA1-21453
TATCATGTGC 77 STAT3-p-S727 R&D systems, MAB4934
CATGAGTGTA 78 STAT5-p-Y694 Cell Signaling Technology, 9314
TGTCGTCATA 79 TGM1 BC1 hybdridoma, Dr. R. Rice
TATCTCATGC 80 CDK4 Thermo Scientific, MA1-12299
TGTGTCACTA 81 cJun-p-S73 Cell Signaling Technology, 3270
TATCGATGCT 82 Cyclin-E Thermo Scientific, MA1-12295
TAGAGTCTGT 83 H3-p-S10 Cell Signaling Technology, 3377
CATGCATCAT 84 LRP6-p-S1490 Cell Signaling Technology, 2568
TGATCAGTCA 85 MAPK-APK2-p-T334 Cell Signaling Technology, 3007
CGTCTATGAT 86 NFKB-p65-p-S536 Cell Signaling Technology, 3033
GTGATACTGA 87 NICD Cell Signaling Technology, 4147
CTAGATCTGA 88 STAT1 R&D systems, PAF-ST1
TATCAGTCTG 89 cFos-p-S32 Cell Signaling Technology, 5348BF
TCAGATGCTA 90 x  
TATGTACGTG 91 Cyclin-B1 R&D systems, AF6000
CTATACAGTG 92 EGFR-p-Y1173 R&D systems, AF1095
TGATACTCTG 93 ERK1/2-p-T202/Y204/T185/Y187 R&D systems, AF1018
TCAGCGATAT 94 ITGA6_Veh_EGF_treated_cells DSHB, P5G10
CTACTGATGA 95 ITGA6_Veh_treated_cells DSHB, P5G10
GTAGTACACA 96
ITGA6_BI-D1870_EGF_treated_
cells  
TGCTACATCA 97
ITGA6_PF4708671_EGF_
treated_cells DSHB, P5G10
AGTGTGTCTA 98 ITGB1 DSHB, P4C10
TCATATCGCG 99 Notch-1 R&D systems, AF5317
TACGTATAGC 100 STAT1-p-Y701 R&D systems, AF2894
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Abstract
In this study, we originally aimed to characterize the potential role of Argonaute 2 
(AGO2) in the nucleus, a key protein of the miRNA machinery. We combined Chromatin 
Immunoprecipitation (ChIP) with high throughput sequencing (ChIP-seq) and quantitative 
mass spectrometry (ChIP-MS) using the broadly used AGO2 11A9 antibody to determine 
interactions with chromatin and nuclear proteins. We found a previously described interaction 
between AGO2 and SWI/SNF on chromatin with ChIP-MS and observed enrichment at 
enhancers and transcription start sites using ChIP-seq. For validation of these findings, 
we developed a CRISPR/Cas9 engineered AGO2-/- HEK293T cell line. ChIP-qPCR and 
immunoprecipitation combined with MS (IP-MS) showed that the 11A9 antibody associates 
with chromatin and SWI/SNF in the absence of AGO2. Furthermore, stoichiometry, IP-MS 
and co-IP analysis suggests a direct interaction of this antibody with SMARCC1, a component 
of the SWI/SNF complex. For this reason, particular care should be taken in performing and 
interpreting experiments in which the 11A9 antibody is used to study a nuclear role of AGO2.
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Introduction
MicroRNAs (miRNAs) are known for their role in fine tuning the expression of genes through 
modulation of mRNA levels and protein translation (Meister and Tuschi, 2004). Classical 
miRNA action takes place in the cytoplasm involving sequence specific targeting of mRNAs 
leading to degradation and/or inhibition of translation (Winter et al., 2009). AGO2 is a key 
protein of the cytoplasmic RNAi machinery and directly binds the miRNAs. 
Apart from a cytoplasmic function, RNAi machinery components are also found in the nucleus 
of mammalian cells (Chu et al., 2010; Rüdel et al., 2008; Tan et al., 2009). It is shown that 
AGO2 can shuttle between the nucleus and the cytoplasm in association with small RNAs 
and most proteins of the cytoplasmic RNAi machinery (Ahlenstiel et al., 2012; Gagnon et 
al., 2014; Kalantari et al., 2016a; Nishi et al., 2013). In addition, AGO2 has been reported 
to stabilize small RNAs in the nucleus and most of these small RNAs were end-processed by 
DICER, which supports the idea that miRNAs are transported back into the nucleus by the 
RNAi machinery (Zamudio et al., 2014). In other species than mammalian, there is more 
evidence for a nuclear RNAi mechanism (Malone and Hannon, 2009; Moazed, 2009; Zhang 
and Rossi, 2011) and in Drosophila, AGO2 association with specific genomic binding sites 
has been reported as well (Moshkovich et al., 2011). Recently, the potential role of AGO2 
in the nucleus has gained more attention and different nuclear mechanisms in mammalian 
cells involving AGO1 and AGO2 have been described and reviewed (Kalantari et al., 2016b). 
These mechanisms include transcriptional gene silencing (Cho et al., 2014; Hawkins et al., 
2009; Kim et al., 2006, 2008), gene activation (Matsui et al., 2010, 2013; Morris et al., 
2008; Schwartz et al., 2008) and alternative splicing (Allo et al., 2014; Ameyar-Zazoua et 
al., 2012). In particular, one report described an interaction of AGO2 with the chromatin 
remodelling complex SWI/SNF (Carissimi et al., 2015). However, this interaction is somewhat 
controversial, as conflicting results have been reported (Kalantari et al., 2016a).
Based on the published literature, it seems probable that AGO2 associates with chromatin, 
yet it remains unclear how and where on the genome it is bound. Our study originally 
aimed to further investigate this by combining Chromatin Immunoprecipitation (ChIP) with 
quantitative MS and high-throughput sequencing (Mohammed et al., 2013) in primary 
human epidermal stem cells and the HEK293T cell line. Using this approach, we chose the 
rat monoclonal 11A9 antibody against human AGO2 which is commonly used and shown 
to be non-reactive with other Argonaute proteins (Rüdel et al., 2008). Applications for 
which this antibody has been used, include immunofluorescence (Rüdel et al., 2008), co-
immunoprecipitation (IP) (Rüdel et al., 2008), nuclear IP combined with quantitative Mass 
spectrometry (MS) (Carissimi et al., 2015),  Chromatin Immunoprecipitation (ChIP) with 
qPCR (Ameyar-Zazoua et al., 2012) and RNA-IP for AGO2 associated RNAs (AGO2-RIP) 
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(Ameyar-Zazoua et al., 2012; Ender et al., 2008). The diverse uses of this antibody and 
especially the use in our strategy requires good characterization. Although this may seem 
obvious, no in-depth characterisation of this antibody has been described, especially for non-
standard applications such as ChIP-seq and ChIP/IP-MS. We used the AGO2 11A9 antibody 
in ChIP-MS and identified the previously reported interaction between AGO2 and members 
of the SWI/SNF complex. Furthermore, we performed ChIP-seq analysis in parallel that 
revealed genomic sites presumably enriched AGO2 occupancy. To rigorously validate these 
observations, we engineered a CRISPR/Cas9 mediated AGO2-/- HEK293T line. We found that 
the 11A9 antibody strongly enriched for SWI/SNF factors with IP-MS, even in the absence 
of AGO2 protein. Furthermore, ChIP-qPCR analysis of loci enriched in our ChIP-seq dataset 
indicated that this signal was independent of AGO2. Moreover, stoichiometry analysis in 
combination with IP-MS of the SWI/SNF complex, as well as reciprocal co-IPs from WT and 
AGO2-/- lysates, identify a likely cross-reactivity of the 11A9 antibody with the SWI/SNF 
component SMARCC1. 
Results
ChIP-MS using anti-AGO2 11A9 suggests interactions between AGO2 and SWI/
SNF factors.
To investigate a potential nuclear role of AGO2 in epidermal stem cells, we aimed to identify 
novel physical interactions within this cellular compartment. To allow identification of potential 
AGO2 interactors on chromatin and to stabilize transient protein-protein interactions, we 
combined formaldehyde cross-linking and chromatin immunoprecipitation (ChIP) using 
the anti-AGO2 11A9 antibody with quantitative mass spectrometry (MS) (Mohammed et 
al., 2013). Using stable isotope labelling by amino acids in cell culture (SILAC), we found 
that components of the SWI/SNF complex, including SMARCA4, SMARCC1, SMARCD1 and 
SMARCE1 co-purified with AGO2 (Figure 1A). These results were confirmed with a second 
quantitative MS technique using dimethyl-labelling (Boersema et al., 2009) (Figure 1B). 
These findings are in line with previous observations (Carissimi et al., 2015) and suggest 
that AGO2 may interact with chromatin and the SWI/SNF complex.
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Figure 1: Anti-AGO2 ChIP-MS in epidermal stem cells suggests AGO2 interaction with SWI/SNF complex 
proteins. (A) ChIP-MS with SILAC labeling of AGO2 11A9 antibody and anti-FLAG control. (B) ChIP-MS 
with dimethyl-labeling of AGO2 11A9 antibody and IgG isotype control. In red anti-AGO2 11A9 antigen 
AGO2 and in blue SWI/SNF complex proteins.
In parallel with the quantitative MS analysis in epidermal stem cells, AGO2 association 
with chromatin was investigated with Chromatin Immunoprecipitation followed by high-
throughput sequencing (ChIP-seq). We identified 379 high confidence peaks (MACS p<10-8), 
most of which were located in close proximity to known genes. To investigate their genomic 
distribution, we aligned the peaks with a chromatin state track generated in normal human 
epidermal keratinocytes (NHEK) from the ENCODE project (Ernst et al., 2011). This revealed 
that 42% of the peaks overlap with active enhancer regions and 41% with active promoters, 
suggesting a potential role for AGO2 in transcriptional gene regulation (Figure 2A). The 
HNRNPA2B1, DICER1 and GSK3β loci are examples of peaks at transcription start sites 
(TSSs) representing a range of occupancy levels (Figure 2B-D, note the differences in scales 
on Y-axes). We confirmed enrichment at these sites in independent duplicate ChIP-qPCR 
experiments (Figure 2F). Moreover, Meis1 is an active locus based on H3K4me3 enrichment 
(500-fold over background, data not shown), but negative for AGO2 (Figure 2E and 2F). 
This shows that the AGO2 11A9 antibody does not simply enrich for active, more accessible 
loci. Furthermore, ChIP with non-specific IgGs did not show enrichment at any of the loci, 
indicating that the enrichments are indeed specific for the AGO2 11A9 antibody.
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Figure 2: Chromatin immunoprecipitation with anti-AGO2 11A9 enriches promoters and enhancers in 
epidermal stem cells. (A) Alignment with promoters/enhancers regions with 379 best peaks obtained with 
MACS peak calling. (B-E) ChIP-seq in epidermal stem cells at the transcription start site of the indicated 
loci. (F) ChIP-qPCR in epidermal stem cells at the indicated loci. Meis1 is a negative region and occupancy 
represents enrichment over a heterochromatic region. A and B represent biological replicates and error 
bars represent standard deviations of 3 technical replicates.
Furthermore, the same loci were enriched in an 11A9 ChIP in HEK293T cells, showing that 
the AGO2 11A9 ChIP enrichments were not cell-type specific (Figure 3A). Next, we tested 
two other antibodies against AGO2 (4F9 and ab57113) in ChIP-qPCR (Figure 3B). This 
showed that the enrichment at the HNRNPA2B1 locus was exclusively found using the 11A9 
antibody. This could mean that this antibody is the only one of the three suitable for ChIP 
enrichment of AGO2. Alternatively, it could be that the enrichment we observed is the result 
of cross-reactivity with a chromatin-bound factor, independent of AGO2. This prompted 
us to generate an AGO2 genetic knock-out cell line, to discriminate between these two 
possibilities.
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Figure 3: The anti-AGO2 11A9 ChIP enriched loci seem not cell type specific or AGO2 specific. (A) ChIP-
qPCR in HEK293T cells at the same loci as in figure 1F. Meis1 is a negative region. (B) ChIP-qPCR in 
epidermal stem cells with anti-IgG and 3 different AGO2 antibodies at the HNRNPA2B1 locus. Occupancy 
represents enrichment over a heterochromatic region, A and B represent biological replicates and error 
bars represent standard deviations of 3 technical replicates.
Generation of a CRISPR/Cas9 engineered AGO2-/- clone to validate anti-AGO2 
11A9. 
In the literature, conflicting results have been reported for the interaction between AGO2 
and SWI/SNF using quantitative IP-MS and co-IPs. One report identified the interaction, as 
did we, using the 11A9 antibody, although another report did not observe this interaction 
using the AGO2 ab57113 antibody in co-IP experiments (Carissimi et al., 2015; Kalantari 
et al., 2016a). To validate the use of the AGO2 11A9 antibody in our experiments, we 
engineered a CRISPR/Cas9 mediated AGO2 knock-out in HEK293T cells. The start of exon 
2 AGO2 encodes 8 of the 15 amino acids (MYSGAGPALAPPAPP) of the AGO2 11A9 antibody 
epitope (Rüdel et al., 2008). To disrupt this epitope sequence, we designed and cloned two 
CRISPR/Cas9 constructs to delete the beginning of exon 2. Single-cell derived HEK293T 
clones transfected with these constructs were screened for deletions using a genotyping PCR 
(Figure 4A). Two rounds of transfections were necessary to obtain a clone with a deletion 
in both the AGO2 alleles (AGO2-/-). These deletions were further characterized with Sanger 
sequencing (Figure 4B), which showed a 58 base pairs (bp) frameshift mutation that were 
identical in both alleles. Most likely, this occurred through homologous directed repair (HDR) 
induced by CRISPR/Cas9 in the second round of targeting where the first mutated allele 
was used as a repair template. Western blot analysis confirmed that the AGO2 protein 
was no longer expressed in the AGO2-/- clone (Figure 4C). AGO2 plays an important role 
in RNA interference (RNAi) using small interfering RNAs (siRNAs) by degrading the target 
mRNAs via its unique slicer activity. When AGO2 is absent, the introduction of siRNAs into 
the cell should not lead to degradation of target mRNA and subsequent knock-down of the 
corresponding protein. To determine whether the AGO2-/- clone constitutes a full functional 
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knock-out, we transfected the AGO2-/- clone and wild-type (WT) HEK293T cells with control 
or GAPDH directed siRNAs. Upon transfection with GAPDH siRNAs, Western blot analysis 
showed a decrease of GAPDH protein in WT cells and not in AGO2-/- cells. This indicates 
that the AGO2-/- clone is indeed a functional AGO2 knock-out (Fig. 4D). Taken together, 
we created an AGO2-/- clone that can be used to verify our findings with the AGO2 11A9 
antibody.
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Figure 4: AGO2 11A9 antibody validation with CRISPR/Cas9 introduced AGO2 knock-out. (A) Agarose 
gel showing the genotyping PCR products amplified from the CRISPR/Cas9 targeted region. (B) Overview 
figure displaying the deletion by CRISPR/Cas9 determined with Sanger sequencing. The AGO2 exon2 bar 
corresponds with the underlying sequence and in red the sequence encoding the epitope of anti-AGO2 
11A9. (C) AGO2 11A9 stained Western blot loaded with whole cell lysates from wild type and AGO2 knock-
out HEK293T cells. GAPDH was stained as loading control. (D) Western blot of siRNA treated wild-type 
and AGO2 knock-out HEK293T extracts. ATP synthase-β was used as a loading control. Uncropped images 
are shown in the supplementary.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 127
127
Antibody characterization with CRISPR-Cas9 engineered knock-out
5
The 11A9 antibody enriches SWI/SNF factors and chromatin in the absence of 
AGO2.
To verify the interaction of AGO2 with SWI/SNF factors we performed label-free quantitative 
(LFQ) IP-MS on WT and AGO2-/- HEK293T lysates using 11A9 and IgG antibodies. These 
experiments were performed in triplicate to allow outlier identification via statistical analysis. 
In accordance with the ChIP-MS experiments in epidermal stem cells, we enriched AGO2 
and eight SWI/SNF factors from WT lysates using the 11A9 antibody. We also enriched three 
known interactors of AGO2: TNRC6A, B and C (Figure 5A). As expected, AGO2, TNRC6A, B 
and C were not identified with IP-MS on AGO2-/- lysates, confirming the specificity of these 
common interactors and the known affinity of the 11A9 antibody for AGO2 (Figure 5B). 
Surprisingly, SWI/SNF factors were still enriched in the IP-MS on AGO2-/- lysates (Figure 5B), 
suggesting cross-reactivity of the 11A9 antibody with one or more of the SWI/SNF factors. 
The raw LFQ signals of AGO2-/- lysates compared to WT lysates show a strong decrease of 
signal for AGO2 and its common interactors and no decrease for the SWI/SNF factors (Figure 
5C). Please note that the low LFQ signal for AGO2, TNRC6A, B and C in AGO2-/- lysates are 
a result of an imputation step included in the data analysis procedure. To verify whether 
the 11A9 antibody specifically enriches AGO2 on chromatin, we performed ChIP-qPCR using 
WT and AGO2-/- HEK293T cells to assess the association with the HNRNPA2B1 and GSK3β 
loci, representing different occupancy levels in our original ChIP-seq dataset. Enrichment at 
these sites was observed in WT as well as AGO2-/- cells compared to the negative control, 
indicating that the 11A9 antibody binds chromatin at these loci in the absence of AGO2 
(Figure 5D). Together, these results suggest that the 11A9 antibody binds other proteins 
than AGO2 on chromatin. 
The AGO2 11A9 antibody cross-reacts with SWI/SNF component SMARCC1/
BAF155.
After observing that the 11A9 antibody associated with SWI/SNF factors in the absence 
of AGO2, we mined the IP-MS data to further investigate this cross-reactivity. We applied 
a previously described method (Smits et al., 2013) to determine the stoichiometry of the 
interactors of the 11A9 antibody, including the bait AGO2 and the SWI/SNF factors that 
we quantified in our IP-MS experiment. This allowed us to estimate the relative number 
of interactor protein molecules associated with the 11A9 antibody for each AGO2 protein 
molecule (Figure 6A). The known AGO2 interactors TRNC6A, B and C associated with a 
stoichiometry of 0.1 - 0.2 per AGO2 molecule, in line with their presumed mutually exclusive 
interaction with AGO2. In contrast, 15 to 16 copies of the SWI/SNF component SMARCC1 
were identified for each AGO2 protein, suggesting that SMARCC1 might be interacting 
with the 11A9 antibody directly. This high recovery of SMARCC1 with the 11A9 antibody 
compared to AGO2 itself could potentially also be partially explained by a high abundance of 
SMARCC1 protein in the lysate. For this reason we looked into the PaxDB protein abundance 
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Figure 5: The 11A9 antibody enriches SWI/SNF factors in the absence of AGO2. (A,B) Label-free 
quantification of 11A9 antibody associated proteins compared to IgG isotype control. IP-MS experiments 
were performed in triplicate in wild type and AGO2 knock-out HEK293T cells. For the analysis a two-sample 
t-test was applied. (C) Table with mean Maxquant derived label free quantification (LFQ) intensities (x10 
) of 3 IP-MS experiments for 11A9 and IgG with HEK293T wild-type and AGO2 knock-out lysates. AGO2 
TRNC6A, B and C signals in AGO2 knock-out extracts are the result form imputation. CV represents 
coefficient of variation. (D) ChIP-qPCR in wild type and knock-out HEK293T cells. The control region 
(heterochromatic site) and Meis1 locus represent negative sites.
database for the abundance of AGO2 and SMARCC1 in HEK293T cells (Geiger et al., 2012; 
Wang et al., 2012). Both proteins had a similarly high abundance based on their number 
of proteins per million (145 and 169, respectively). According to our stoichiometry analysis 
and the minor difference in total abundance of both proteins, SMARCC1 seems to bind the 
AGO2 11A9 antibody more efficiently than AGO2 itself, either directly or indirectly. This is 
in line with the proposed cross-reaction interaction between SWI/SNF factors and the 11A9 
antibody, rather than a bona fide protein-protein interaction. 
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To get an overview of the proteins that are immuno-precipitated by the SMARCC1 antibody, 
we performed an IP-MS experiment in HEK293T cells. Multiple SWI/SNF factors and other 
proteins were enriched as interactors (Figure 6B). Notably, AGO2 was not enriched in these 
samples. Also note that the number of interacting proteins is rather high due to the use 
of low stringency buffer conditions in the SMARCC1 IP-MS experiment. Nonetheless, the 
highest LFQ value was measured for SMARCC1 (Figure 6C).  Ultimately, to see how the 
SMARCC1 IP-MS relates to the AGO2 11A9 IP, we compared the quantified interactors and 
the stoichiometry of SMARCC1. These experiments had 30 quantified interactors in common, 
suggesting that these proteins are identified through an interaction with SMARCC1, rather 
than with AGO2 (Figure 6D). In the SMARCC1 IP, the SWI/SNF factors associated with a 
stoichiometry of 0.2 - 0.7 per SMARCC1 protein (Fig. 6E), indicating that we purified an 
intact SWI/SNF complex and that the majority of cellular SMARCC1 resides in this complex 
and not as a free monomer. In contrast, SMARCC1 was substantially more over-represented 
in the 11A9 IP-MS experiments (15-16 fold, Figure 6A). This may be due to the more 
stringent buffer conditions in the 11A9 IP resulting in lower amounts of co-purified proteins 
that bind the antibody through protein-protein interactions. This explanation also supports 
the possibility that SMARCC1 directly interacts with the 11A9 antibody. Finally, we performed 
reciprocal co-IPs for AGO2 and SMARCC1 in WT and AGO2-/- HEK293T cells (Figure 6B). In 
accordance with our previous findings (Figure 5B, C and 6A), SMARCC1 was detected in 11A9 
WT and AGO2 KO immuno-precipitates. This provides further proof that the enrichment of 
SMARCC1 by the 11A9 antibody does not require the presence of AGO2. In line with this, we 
could not find AGO2 in the reciprocal IPs with a SMARCC1 antibody (Figure 6F).
Together, the results presented here show that SMARCC1 cross-reacts directly, or indirectly, 
with the 11A9 antibody, which may lead to erroneous conclusions when using this antibody 
for nuclear IP-MS or ChIP experiments to investigate AGO2.
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Figure 6: The 11A9 antibody may cross-react with SWI/SNF component SMARCC1/BAF155. (A) 
Stoichiometry analysis in HEK293T with iBAQ values generated with Maxquant normalized with the IgG 
isotype control. AGO2 is the bait and set at 1 as we used anti-AGO2 (11A9) for the IP. Error bars represent 
standard deviations of 3 individual IPs. (B) Label-free quantification of BAF155 A301-019A associated 
proteins compared to IgG control. Experiment was performed in triplicate in HEK293T cells. For the 
analysis a two sample T-test was applied. (C) Table with average Maxquant derived label free quantification 
intensities of 3 IP-MS experiments for BAF155 A301-019A and IgG with HEK293T wild type lysates. Mean 
LFQ values are times 10 billion and signals from AGO2 knock-out come from imputation. CV represents 
coefficient of variation. (D) Venn diagram representing the number of quantified and significant proteins 
in the SMARCC1 IP-MS and the AGO2 11A9 IP-MS and proteins that were quantified and significant in 
both experiments. (E) Stoichiometry analysis as in A with SMARCC1 as bait. SMARCC1 was set at 1 as 
we used anti-BAF155 (A301-019A) for the IP. Error bars represent standard deviations of 3 individual 
IPs. (F) Reciprocal co-IPs with AGO2 11A9 and BAF155 antibodies with anti-IgG as negative control in 
Wildtype and AGO2 knock-out HEK293T cells. All samples were loaded on the same gel and transferred to 
the same blot on which both the staining’s were performed with different detection methods. Uncropped 
images are shown in the supplementary.
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 131
131
Antibody characterization with CRISPR-Cas9 engineered knock-out
5
Discussion
In this study, we aimed to address the nuclear role of AGO2 in epidermal stem cells through 
ChIP-sequencing and MS using the 11A9 antibody. This antibody showed enrichment at 
enhancer/promoter regions with ChIP-seq and enriched AGO2, SMARCC1 and other SWI/
SNF factors with ChIP-MS. The observed interaction between AGO2 and SMARCC1 is in 
accordance with a previous report in which the interaction was shown using the same 
antibody (Carissimi et al., 2015). We confirmed these results in HEK293T cells as well. 
However, by using a CRISPR/Cas9 engineered AGO2-/- HEK293T line, we demonstrated that 
this interaction does not depend on the presence of AGO2. Indeed, we still observed a strong 
enrichment for SWI/SNF factors using IP-MS in AGO2 knock-out cells. In addition, ChIP-
qPCR enrichment at two representative promoter regions was essentially unaffected after 
knocking-out AGO2. Recently, the interaction between AGO2 and SMARCC1 has been tested 
with a different AGO2 antibody. With this antibody, no interaction was observed between 
AGO2 and SMARCC1 supporting the idea that SMARCC1 represents an unintended binder of 
the AGO2 11A9 antibody (Kalantari et al., 2016a). 
Our stoichiometry analysis for 11A9 antibody interacting proteins showed that SWI/SNF factor 
SMARCC1 associated 15.5 times more frequent than AGO2. This suggests that SMARCC1 is a 
likely candidate as direct interactor of the 11A9 antibody. In line with this, we noted that the 
peptide epitope used to generate the 11A9 antibody is proline rich and that the C-terminus 
of SMARCC1 contains a very similar, and proline-rich, sequence (QPPPPPPADGVPPPPAPGP). 
In addition, Rüdel et al. (2008) showed an unidentified band on an 11A9 probed Western blot 
loaded with nuclear extract. Although cross-reactivity on a Western blot is not necessarily 
representative of cross-reactivity in an immunoprecipitation approach, our data strongly 
argue that this reported band represents SMARCC1. To determine if SMARCC1 indeed directly 
binds the 11A9 antibody allowing re-interpretation of our ChIP data, we applied CRISPR/
Cas9 on the SMARCC1 locus as well. However, we were not able to engineer a SMARCC1 
knock-out line despite repeated attempts and only obtained cell lines with in-frame deletions 
(data not shown). This might suggest that SMARCC1 knock-out has a negative effect on cell 
survival or proliferation in HEK293T cells. Therefore, we cannot formally exclude that the 
SWI/SNF and ChIP-qPCR enrichments we observed in our experiments can be explained by 
other proteins than SMARCC1 associating with the AGO2 11A9 antibody. 
Taken together, our data indicate that the AGO2 11A9 antibody associates with SMARCC1 in 
IP-MS aproaches using whole lysates or nuclear extracts. Therefore, we strongly recommend 
verifying nuclear AGO2 interactions identified with this antibody using an AGO2 knock-out 
line or with a tagged-AGO2 protein.
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Materials and Methods
Cell culture, transfection, clonal selection and knock-down
Primary pooled human epidermal stem cells derived from foreskin were obtained from 
Lonza. Cells were cultured and expanded as previously reported (Gandarillas and Watt, 
1997). Briefly, cells were seeded on a feeder layer of J2-3T3 cells in FAD medium (Ham’s F12 
medium/Dulbecco’s modified Eagle medium (DMEM) (1:3) supplemented with 10% batch 
tested fetal calf serum (FCS) and a cocktail of 0.5 µg/ml of hydrocortisone, 5 µg/ml of 
insulin, 0.1 nM cholera enterotoxin, and 10 ng/ml of epidermal growth factor. J2-3T3 cells 
were cultured in DMEM containing 10% bovine serum. HEK293T cells were cultured in DMEM 
supplied with 10% fetal bovine serum. All media were supplemented with 1% penicillin/
streptomycin antibiotics.  
For transfections HEK293T cells were incubated 4 hours in 6 well-plates with Lipofectamine2000 
from Life Technologies and 2µg CRISPR/Cas9 plasmids (expressing gRNA 1 and 2) or 2µl 
siRNA (20µM stock) [negative control (#4390844) and GAPDH (#4390849) from Ambion] 
in DMEM. 
CRIPSR/Cas9 transfected cells were harvested after 72 hours and seeded in low numbers 
for clonal growth. Clones were picked and scaled-up to 6 well-plate size for subsequent 
genotyping. A genotyping PCR was performed with primers (5’-GACACTTTTGGGCTCTTTGC-3’, 
5’-AACTCTCCTCGGGCACTTCT-3’) flanking the region in which both gRNAs target on 
genomic DNA which was extracted using the QIAquick PCR Purification Kit (Table 1). A 
smaller amplicon due to an introduced deletion was distinguished from wild type alleles with 
electrophoresis using a 2% agarose gel. Clones with heterozygous deletions were retargeted 
by repeating the transfection and cloning procedure to increase the chance for clones with 
homozygous deletions. Sanger sequencing was applied to determine the exact deletions on 
sequence level.
For transfections with siRNAs, cells were lysed after 48 hours for Western blot analysis with 
RIPA buffer (Tris HCl pH 8.0 10 mM, EDTA 1 mM, EGTA 0.5 mM, SDS 0.1%, deoxycholic acid 
0.1%, NaCl 140 mM, Triton X-100 1%, 1x PIC).
Stable isotope labelling by amino acids in cell culture (SILAC)
For SILAC experiments, epidermal stem cells were cultured for 6 days in R/K-deficient SILAC 
FAD medium (DMEM:F12 for SILAC, Thermo Scientific #88215 mixed 1:1 with R/K-deficient 
DMEM, Gibco A14431-01) supplemented with 10% dialyzed serum (Sigma-Aldrich, F0392) 
and 800 mM L-Lysine 13C6 15N2Hydrochloride and 482 mM L-Arginine 13C6 15N4 hydrochloride 
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(Sigma-Aldrich) for ‘‘heavy’’-labeled media or 800 mM L-Lysine 12C6 14N2-Hydrochloride and 
482 mM L-Arginine 12C6 14N4 hydrochloride for ‘‘light’’-labeled media(Mohammed et al., 2013).
Antibodies
AGO2 was detected with anti-AGO2 clone 11A9 (#SAB4200085, Sigma-Aldrich), anti-AGO2 
(#Abcam571130), anti-AGO2 (4FG, sc-53521)  and as negative control antibodies were 
used anti-FLAG (f1804, Sigma-aldrich) and rat IgG isotype 2a (#54447, Novus biologicals). 
For loading controls, GAPDH and ATP synthase β were used with anti-GAPDH (Abcam8245) 
and anti-ATP synthase β in the same dilution as described (Simonnet et al., 2002). H3K4me3 
on chromatin was detected with anti-H3K4me3 (Abcam8580). SMARCC1/BAF155 detection 
occurred with anti-BAF155 from Bethyl laboratories (#A301-019A). Purified Rabbit IgG 
antibody (#P120-101, Bethyl laboratories) was used as negative control. For detection 
on Western blot, secondary antibodies were used from Licor (IRDye 800CW Goat-anti-Rat 
Antibody, IRDye 800CW Goat-anti-Rabbit Antibody and IRDye 680RD Goat-anti-Mouse 
Antibody) and from Dako (rabbit anti-rat immunoglobulins/HRP, #P0450).
ChIP-qPCR and ChIP-MS  
Cells (7.5 x 107) were cross-linked in suspension with 1% formaldehyde in PBS for 10 
minutes, quenched for 5 minutes with 1.25 M glycine in PBS and washed in PBS. Cross-
linked cells were incubated 4 hours in lysis buffer (5 mM Tris-HCl pH 8.0, 85mM NaCl, 
0.5% NP40, 1X PIC) on ice, following 50 strokes with a dounce homogenizer to enrich for 
nuclei. Nuclei were sonicated in sonication buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 
0.1% SDS, 150mM NaCl and 0.5% deoxycholic acid) to get an average chromatin fragment 
length of 500 bp. Overnight, 15 µg antibody was incubated following a bead capture step 
of 4 hours with 100 µl protein G-coated magnetic beads (life Technology). Subsequently, 
beads were washed 5X in RIPA buffer. From this point, the sample was prepared for qPCR 
and next-generation-sequencing or quantitative mass spectrometry (described below). 
For sequencing and qPCR, chromatin was reverse cross-linked overnight at 65°C followed 
by a 1 hour incubation step with proteinase K (1µg/µl) and RNAse A (1µg/µl) at 37°C 
with. The DNA was purified with the Qiaguick PCR purification kit upon. Quantitative 
PCR was performed with Sybr green (Bio-Rad) and custom primers around the negative 
control region (5’-ATATCAAGGGCTCAGTGTTGGT-3’, 5’-GTGGAGGGATGGAGGTTATACA-3’) 
and the transcription start sites of HNRNPA2B1 (5’-CGCAAGGCAGGTGAGAAAC-3’, 
5’-CGGAAAACAAAAAGGGAAGG-3’), DICER1 (5’-GCCTCCATTGTTGCTCCTT-3’, 
5’-GCGGAAGTGGGTGTTTGTT-3’), GSK3β1 (5’-GCTGGCTGGAGGAGACATT-3’, 
5’-TTCACCAATCACCGAAGGA-3’) and Meis1 (5’-GCCTCCTGAACCTTCTTTCTCT-3’, 
5’-AATGGGGTAGATCGTCGTACTG-3’).
Next-generation-sequencing and analysis
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Using the KAPA Biosystems kit (#KK8504), between 0.5 and 5ng ChIP-derived DNA was 
trimmed, A-tailed, provided with Nextflex adaptors and amplified with 10 PCR cycles. 
Subsequently, DNA was size-selected with the E-Gel® iBaseTM Power System (Invitrogen) to 
purify for fragments between 300 and 400bp. The libraries were quantified on the Agilent 
2100 Bioanalyzer and evaluated by qPCR to confirm representation of enrichments at 
specific loci. The libraries were sequenced with the Nextseq500 to generate 25 - 45 million 
reads which were aligned to the human hg19 genome with the Burrows-Wheeler Alignment 
tool (BWA) (Li and Durbin, 2009) and processed with SAMtools (Li et al., 2009) to generate 
BAM files. Peaks were called from BAM files using “Model-based analysis of ChIP-Seq version 
1.4” (MACS14) (Zhang et al., 2008) with a P-value cut-off of 1x10-8. The called peaks were 
manually checked with BigWig tracks in IGV from Broad institute and visualized with UCSC 
genome browser. Overlaps with specific chromatin states of the normal human epidermal 
keratinocyte (NHEK) genome were analyzed with BEDtools (Afgan et al., 2016) using the 
wgEncodeBroadHmmNhekHMM.bed file from ENCODE (Ernst et al., 2011). 
Immunoprecipitation, sample preparation and quantitative mass spectrometry
Cells were washed with PBS and lysed on 15cm plates with 1.5ml RIPA buffer. When 
indicated in the results section a less stringent lysis buffer was used (Tris HCl pH 7.5 50 
mM, Triton X-100 0.25%, glycerol 10%, NaCl 150 mM, 1x PIC). Lysate was centrifuged 10’ 
at 17,000g to remove precipitates. Overnight, 1ml lysate was immuno-precipitated with 
either 6µg anti-AGO2 11A9, 1µg anti-BAF155 A301-019A, 6µ anti-IgG (rat) or 1µg anti- IgG 
(rabbit). Antibody precipitates were captured with 50 µl protein G-coated magnetic beads 
(life Technology) for 4 hours and subsequently washed 5X in RIPA buffer or the less stringent 
lysis buffer when indicated.
Beads loaded with immuno-precipitates from (Ch)IP experiments were washed 2X with 
100mM NH 4HCO3. Heavy and light labeled SILAC samples of different ChIP experiments 
were combined after the first wash step. Proteins were on bead digested with 15ul trypsin 
(10µg/ml in 100mM NH 4HCO3) overnight. Supernatant was taken and the digestion was 
stopped by adding up to 100µl with triethylammonium bicarbonate (100mM) including 5% 
formic acid. For quantification with dimethyl-labeling, light- or intermediate dimethyl labels 
were added at this point (Boersema et al., 2009). Briefly, 4µl of 4% label and 4µl of 0.6M 
NaBH2CN were added and incubated for 1 hour. Before merging heavy and light labelled 
samples, 16µl 1% ammonia was added and after merging 10ul of 100% trifluoric acid. 
Before sending the samples for Mass spectrometry analysis, a purification was applied on 
StageTips (Rappsilber et al., 2007). Peptides were loaded onto a pulled fused silica column 
(New Objectives) packed in house with 1.8 μm Reprosil-Pur C18-AQ (Dr. Maisch, 9852). 
Using the Easy-nLC 1000 (Thermo Fisher Scientific), peptides were separated in a 120 
minutes gradient and directly injected into a QExactive mass spectrometer (Thermo Fisher 
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Scientific). The mass spectrometer was operated in TOP10 data dependent acquisition. Full 
MS were recorded at a resolution of 70,000 at m/z = 400 and a scan range of 300-1,650 
m/z. MS/MS spectra were recorded at a resolution of 17,500. 
Mass spectrometry data analysis
Raw mass spectrometry data analysis was analysed with the MaxQuant software package, 
version 1.3.5.7, using standard settings with the additional option “match between runs” 
(Cox and Mann, 2008). For label free quantification, LFQ and iBAQ were selected. The 
output proteingroupst.txt table was filtered for contaminants, reverse hits, number of 
unique peptides (>0) and number of peptides (>1) in Perseus (MaxQuant package) and 
R as described. For Label dependent quantification, the ‘ratio H(eavy)/L(ight) normalized’ 
was taken from two replicate experiments (reverse and forward labelled) and plotted in 
Excel to visualize fold enrichments. For label free interactor identification, IPs were applied 
in triplicate to allow t-test based statistics on LFQ values and stoichiometry analysis on 
iBAQ as described earlier (Smits et al., 2013). In Perseus, the option imputation of missing 
values was applied by normal distribution with default settings. Statistical outliers for the 
pull down of AGO2 11A9 or BAF155 A301-019A were determined with a two-tailed t-test and 
multiple testing correction was done with a permutation based false discovery rate method 
in Perseus. Stoichiometry analysis of AGO2 and SMARCC1 was determined by comparing the 
relative abundance of the identified interactors as measured by the iBAQ values. The iBAQ 
values of the proteins in the IgG IP (control) samples were used as background binding level 
and were subtracted from iBAQ values from the bait IP samples. The relative abundance 
value of each interactor was scaled to the bait protein which was set at 1.
Western blot
Beads loaded with immuno-precipitates from IP experiments were incubated 10 minutes 
at 95°C in 100 µl 1X Sample buffer (1% SDS, 40 mM TrisHCl pH 6.8, 5% glycerol, 0,25% 
β-ME, BPB) to release and denature the proteins. Whole cell lysates were incubated with 
4X Sample buffer. Proteins were separated on standard 4-15% gradient gels (Bio-Rad) and 
blotted on a PVDF membrane using the Bio-Rad Trans-Blot® TurboTM RTA Transfer Kit. Blots 
were blocked 30 minutes. with 3.5% milk in PBS (w/v) and stained with primary antibody 
in blocking buffer overnight at 4°C (AGO2 11A9 1:500, BAF155 A301-019A 1:500, GAPDH 
Abcam8245 1:2500 and ATP synthase β 1:10,000). After primary antibody incubation, 
blots were washed 3X with TBST, stained with secondary antibodies for 1 hour at room 
temperature and washed again 3X with TBST. Detection occurred using the Odyssey CLx or 
the LAS4000. 
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Cloning CRISPR/Cas9 constructs
PX330 based constructs were generated as described(Ran et al., 2013). Briefly, 
guide RNAs (gRNAs) were designed to target the anti-AGO2 11A9 epitope-encoding 
region of AGO2 with the online Zhang lab CRISPR design tool (http://tools.
genome-engineering.org). Oligo’s encoding the gRNAs were obtained from Biolegio 
(Nijmegen, The Netherlands), representing the forward and reverse sequences 
5’-CACCGGCGCCGCCGCCCCCCATCCA-3’ and 5’-AAACTGGATGGGGGGCGGCGGCGCC-3’ for 
gRNA1 and 5’-CACCGAGAGAGAACACCCATTAACG-3’ and 5’-AAACCGTTAATGGGTGTTCTCT
CTC-3’ for gRNA2. Top and bottom oligo’s were annealed and ligated into BbsI digested 
pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene #42230) upon poly nucleotide kinase 
and Antarctic phosphatase treatment of the annealed oligo’s and backbone respectively. 
Identification of the correct constructs was achieved with a colony PCR in which the U6 
primer (5’-GAGGGCCTATTTCCCATG-3’) acted as forward primer and the reverse gRNA oligo 
as reverse primer. Constructs were subsequently amplified in E. coli strain DH5α.
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Supplementary Figures: Non-cropped images of gels and Western blots. (A) Uncropped agarose gel 
image of figure 4A showing the CRISPR-Cas9 targeted cells. (B) Uncropped Western blot of figure 4C 
stained with anti-AGO2 11A9 (rat) and anti-GAPDH (mouse) loaded with WT and AGO2 knock-out HEK293T 
cells. (C) Uncropped Western blot from figure 4D in colour (distinguishing GAPDH and ATP synthase β) 
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and grey as in figure 4D. The western blot was loaded with lysates derived from WT and AGO2 knock-out 
HEK293T cells treated with siRNAs. (D) Western blot from figure 6F loaded with Immuno-precipitates 
stained with anti-AGO2 11A9 and anti-BAF155. To allow detection of both proteins separately on the same 
Western blot, detection of anti-AGO2 was performed on the LAS4000 (chemiluminescence) and detection 
of BAF155 on the Odyssey CLx (near-infrared fluorescence).
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The regulation of epidermal tissue maintenance requires a balance between self-renewal 
and differentiation (Blanpain and Fuchs, 2006). Basal cells are on the self-renewal side 
of this balance which can be moved towards the differentiation side in various ways. 
This includes an EGF signaling blockade, down-regulation of integrins or increased notch 
signaling (Kolev et al., 2008; Mulder et al., 2012; Williams et al., 2011). In our experiments 
we applied this knowledge to study differentiation. With the CRISPR screen described in 
Chapter 3, differentiation was induced with EGFR inhibition and with the identification of 
Notch signaling related genes, we had a good indication that the screen identified growth 
arrest and differentiation associated genes. In Chapter 2, scID-seq was demonstrated to 
measure 70 (phospho-) proteins in single cells and was used to study signaling during 
differentiation. The simultaneous measurement of NICD (marker for active Notch) together 
with other self-renewal and differentiation markers allowed us to create a differentiation 
pseudotime for cells sorted based on ITGB1 self-renewal marker expression. Along this 
differentiation trajectory, several pathways showed remarkable dynamics, including the 
BMP and Wnt signaling, of which components were also identified in the CRISPR screen 
in Chapter 3. In Chapter 2, the increased activity of BMP signaling during differentiation 
was further addressed to gain insight in its contribution to this process. We found that 
BMP signaling targets the MAF/MAFB transcription factors which are regulators of a gene 
expression program important during differentiation. This indicated that BMP signaling 
contributes to differentiation through driving an important transcription program. For 
maintaining self-renewal, EGF signaling activity is important. In Chapter 4, we applied 
scID-seq to analyse dynamics introduced by drugs targeting kinases downstream of EGFR. 
Thought this, we were able to observe changes in the EGF signaling network within single 
cells as well as the heterogeneity of these changes on the population level. A surprising 
observation was the increased phosphorylation upstream the targeted kinases and, in these 
cells, we also observed changes in other pathways. This demonstrated the power of scID-
seq to detect multiple targeted drug effects that are not necessarily restricted to decreased 
phosphorylation downstream the signaling block. Altogether, for Chapters 2, 3 and 4, 
innovative and novel techniques were developed and applied which provided new insights 
about signaling and transcription in epidermal cells. Therefore, I will further elaborate on 
signaling with respect to transcription and other cellular events during differentiation as well 
as the consequences of signaling perturbations with drugs.  
Signaling routes that drive differentiation
The studies in Chapter 2 and 3 both pointed towards the importance of BMP signaling in 
differentiation and indicated a potential role for (canonical) Wnt signaling. Wnt signaling 
has different routes which are known to have varying outcomes such as proliferation or 
differentiation. The direction of the Wnt signaling can depend on the amount of stimulation 
by the ligand or the combination of cooperating Wnt receptors that pass on the signal 
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(Veltri et al., 2018). In hair follicle stem cell differentiation, BMP signaling and canonical 
Wnt signaling are thought to have reciprocal roles with a self-renewal function for canonical 
Wnt (Veltri et al., 2018; Zhu et al., 2014). The role of canonical Wnt signaling in basal cell 
differentiation is still unclear, but results from Chapter 2 and 3 suggest an active role for 
Wnt. WNT3a and DVL1 were identified with the CRISPR screen in Chapter 3 and in Chapter 
2, differentiating ITGB1 low cells showed increased activity for WNT receptors Fzd3 and 
LRP6 together with increased inactivation of Wnt repressor GSK3b. Although it is known 
that these proteins act in the canonical Wnt signaling, the hallmark of active canonical Wnt 
signaling is represented by nuclear activity of b-catenin (Veltri et al., 2018). This gene has 
not been addressed in our studies. Therefore, it is possible that the canonical Wnt signaling 
components for which we found dynamics in epidermal differentiation act in alternative Wnt 
signaling routes during differentiation. To improve our knowledge, scID-seq would be an 
interesting tool to measure the dynamics of many Wnt signaling molecules from the different 
signaling routes during epidermal differentiation.
BMP signaling has been described well in relation to the skin. Mouse studies demonstrated a 
role in skin development and hair follicle differentiation (Botchkarev and Sharov, 2004; Mou 
et al., 2016; Zhu et al., 2014). Furthermore, BMP4 is used in the process of keratinocyte 
differentiation from human induced pluripotent cells (iPSCs) and recombinant BMP2, -4, -6 
and -7 were shown to induce growth arrest and terminal differentiation in human epidermal 
stem cells (Fessing et al., 2010; Gosselet et al., 2007; Mulder et al., 2012; Pattison et al., 
2018). The knowledge about the actual contribution of BMP signaling in human basal cell 
differentiation was still unclear and has been further expanded in this thesis. In Chapter 
3, the CRISPR screen and subsequent validation, demonstrated an essential role for BMP4 
in AG1478 induced growth arrest/differentiation and in Chapter 2, scID-seq revealed an 
increasing BMP signaling activity along the differentiation trajectory. In addition, BMP2 
mRNA expression increased over time upon AG1478 treatment. Through this we show that 
BMP signaling clearly contributes to the differentiation of basal cells. It seems an important 
pathway for differentiation and together with the increasing activity along the differentiation 
trajectory, BMP signaling is already active early on in the differentiation process (Figure 1A). 
Connection between signaling and transcription in epidermal differentiation 
In epidermal differentiation, Notch signaling is the most prominent and established pathway. 
Its activity has been shown at the start of differentiation. Notch remains active in the 
suprabasal layer through stimulation by JAG1 expressed on the surface of neighboring 
cells (Hsu et al., 2014; Williams et al., 2011). In line with this, JAG1 was identified in 
the CRISPR screen in Chapter 3. For differentiation progression, signaling has to initiate 
the transcription and expression of genes that push the differentiation process. Various 
transcription factors active in epidermal differentiation are regulated by Notch (Watt et al., 
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 147
147
Discussion
6
2008) and of these genes, the CRISPR screen identified and highlighted the importance of 
Hes1 and IRF6 in differentiation (Figure 1B). Hes1 induces the expression of spinous layer 
genes encoding differentiation specific proteins such as Keratin-1 and -10 (Blanpain et al., 
2006). IRF6 acts independent of the Hey/Hes genes. It downregulates the self-renewal 
associated transcriptional regulator TP63 and activates other transcription factors associated 
with epidermal differentiation including GRHL3 and Ovol1 (Huynh et al., 2017; Kwa et al., 
2014; Lee and Dai, 2013).  
Chapter 2 was further focused on how BMP signaling contributes to differentiation. Previously 
and also in Chapter 2, several transcription factors including the Id proteins and DLX3 were 
demonstrated as BMP signaling targets (Fessing et al., 2010; Park, 2002). Beside these 
genes, other target genes were discovered in Chapter 2. They were found based on their 
differential expression upon BMP signaling inhibition with DMH1 during AG1478 induced 
differentiation and through addressing the active transcription mark H3K4me3 occupancy at 
transcription start sites upon BMP stimulation. This showed that the downstream Notch/IRF6 
targets Ovol1 and GRHL3 are also regulated by BMP signaling. This overlap in targets of the 
BMP and Notch signaling indicates the possibility of cooperation between the two pathways 
for the regulation of transcriptional events during differentiation. Other BMP targets were 
identified as well. Of these targets the MAF/MAFB transcription factors are interesting as 
their regulation was not linked to a signaling pathway yet and more importantly, they 
regulate many epidermal differentiation genes including the transcription factors ZNF750, 
KLF4, GRHL3 and PRDM1 (Lopez-Pajares et al., 2015). Furthermore, we showed that BMP 
stimulation quickly induced MAF/MAFB mRNA expression within 2 hours, indicating that they 
are most likely direct targets of the BMP signaling. Through this (direct) link to an important 
transcription program for differentiation progression, we enlarged our understanding about 
the contribution of BMP signaling to epidermal differentiation. 
To place this link in a context, a network of genes was previously constructed upon discovery 
of the MAF/MAFB master regulatory role in epidermal differentiation (Klein and Andersen, 
2015; Lopez-Pajares et al., 2015). The authors also demonstrated the lncRNAs ANCR and 
TINCR as regulators of MAF/MAFB. ANCR together with chromatin factor EZH2 is thought 
to maintain low activity of MAF/MAFB in basal cells whereas TINCR was shown to positively 
regulate the MAF transcription factors. Furthermore, they suggested a positive upstream 
regulation by TP63 based on increased expression of MAF/MAFB upon overexpression of 
TP63. However, this is not in line with the idea that TP63 is highest in basal cells and decreases 
during epidermal differentiation what we also demonstrated in Chapter 2 (Kouwenhoven et 
al., 2010; Truong et al., 2006). It is therefore uncertain whether endogenous TP63 drives 
MAF/MAFB expression during epidermal differentiation. With the dynamics and the direct 
regulatory link of BMP signaling towards MAF/MAFB demonstrated in Chapter 2, BMP 
530821-L-bw-Eijl
Processed on: 21-5-2019 PDF page: 148
148
Chapter 6
signaling can be considered as one of the main drivers of MAF/MAFB (Figure 1B). For further 
research on the regulation of MAF/MAFB in epidermal differentiation, it would be interesting 
to investigate the relation between BMP signaling, TP63 and the lncRNAs ANCR and TINCR. 
Figure 1: Epidermal differentiation regulated on signaling and transcription level. (A) The different layers 
of the epidermis with indicated the activity of different factors and pathways. (B) Factors and pathways 
driving transcriptional regulation during epidermal differentiation. GRHL3 and OVOL1 are highlighted 
with grey indicating they are regulated by the MAFs and IRF6 and the dashed lines indicate potential 
interactions. This Illustration is based on the figure from Klein and Andersen, 2015.
Single cell analysis: Does EGFR contribute to differentiation upon loss of 
integrins?
In the previous sections, the BMP signaling and Notch signaling have been discussed and 
mentioned for their prominent role in epidermal differentiation. Both pathways have a 
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significant role in differentiation and are activated in vivo (Botchkarev and Sharov, 2004; 
Watt et al., 2008) and in vitro as demonstrated by our approach in Chapter 2. In addition, 
we showed that BMP signaling is activated by AG1478 induced differentiation in vitro 
and others previously showed this with Notch signaling (Kolev et al., 2008). As AG1478 
represents an EGFR inhibitor, EGFR signaling seems important for the negative regulation 
of Notch and BMP. Downstream of EGFR, it has indeed been shown that the MAPK signaling 
component ERK has an essential role in the negative regulation of Notch activity (Kolev et 
al., 2008) and similarly, antagonistic effects have been shown with BMP. Very simplified, this 
could mean that EGF signaling stimulates cell cycle progression whereas pathways such as 
BMP and Notch push the cell towards cell cycle arrest. What the cell decides will therefore 
be influenced by the balance in activity of these pathways (Botchkarev and Sharov, 2004). 
However, there is also a phenomenon called endoreplication, which is thought to be the 
result of accelerated cell cycle progression leading to duplication of the nucleus, but not the 
cell itself (Zielke et al., 2013). Through this, stimuli that promote proliferation can contribute 
to differentiation as well.
Endoreplication is a phenomenon seen in various tissues including the epidermis. In this 
tissue, a role has been proposed for the oncogene Myc as driver of the accelerated cell 
cycle progression (Gandarillas, 2012; Zielke et al., 2013). Although Myc is an oncogene 
and associated with proliferation, there is also evidence for its activity during epidermal 
differentiation (Eilers and Eisenman, 2008; Gandarillas and Watt, 1997). In Chapter 2, 
Myc was also measured with scID-seq and showed increased levels in differentiating ITGB1 
low cells. Endoreplication is thought to be important to increase the cell size. This requires 
enhanced protein production which can be accomplished easier when cells are multinucleated. 
In Myc deficient mice, differentiation was not impaired, but the differentiated cells were 
smaller and the skin was less functional as skin ripped off in areas of mechanical tension, 
and wound healing was inefficient (Zanet et al., 2005). In addition, they showed that less 
cells had multiple copies of their DNA, suggesting that a lower number of cells underwent 
endoreplication. This indicates that Myc is dispensable for differentiation, but it is necessary 
for proper function of the epidermis through regulating cell size via endoreplication. 
However, it remains unclear how Myc is stimulated as inducer of endoreplication. A known 
stimulator of Myc is the MAPK signaling which is driven by EGF in epidermal cells (Sears et 
al., 2000). However, based on the fact that EGFR inhibition induces differentiation, a role of 
EGF in this seems controversial. On the other hand, Myc is also dispensable for epidermal 
differentiation (Zanet et al., 2005), and non-discussed supplementary data from Chapter 
2 showed increased phosphorylation of EGFR and ERK in ITGB1 low cells. This supports 
the possibility of Myc stimulation via EGFR and along the pseudotimed differentiation 
trajectory demonstrated in Chapter 2, levels clearly increase for two EGFR phospho-sites, 
phosphorylated ERK and Myc (Figure 2A).
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Endoreplication has previously been studied in human epidermis and consistently showed 
a link between differentiation and cycling cells unable to divide due to a block in mitosis 
(Zanet et al., 2010). During the cell cycle, cyclins play an important role for the transition 
of cells through the different cell cycle phases which represent the: resting phase G1/G0, 
DNA replication phase S, DNA repair phase G2  and division phase mitosis (Gandarillas, 
2012). Of these cyclins, Cyclin E is required for transition to the S-phase and was shown to 
increase in the suprabasal layers while other cyclins or cell cycle regulators such as Cyclin A 
and phosphorylated Rb were absent or only active in cells near the basal layer (Zanet et al., 
2010). This is in agreement with our data in Chapter 2 showing increased Cyclin E along 
the pseudotimed differentiation trajectory while protein expression diminished for Rb-p and 
Cdc2, a protein associated with mitosis progression (Figure 2B) (Jorrit and Richard, 2010). 
Interestingly, Cyclin B1 also increased, which is a regulator of mitosis entry (Peter et al., 
2002). However, Cyclin B1 dependents for this action on unphosphorylated Cdc2 which 
was diminished in these cells (Jorrit and Richard, 2010; Peter et al., 2002) (Figure 2B), 
indicating that ITGB1 low cells have a mitotic block. The accelerated cell cycle involves 
intensive replication of DNA during the S-phase. A major consequence of this is DNA damage 
and this consequence is also considered to be the main trigger of an irreversible mitotic 
block (Gandarillas, 2012; Zanet et al., 2010). Therefore, we also visualized phosphorylation 
of the DNA repair marker yH2A.X along our pseudotimed differentiation trajectory. This 
showed increased yH2A.X together with Cyclin E and Cyclin B1 (Figure 2B), suggesting 
enhanced DNA damage and repair. 
Altogether, we demonstrated increased Myc, Cyclin E and Cyclin B1 in differentiating cells 
low in ITGB1, indicating an accelerated cell cycle. Simultaneously, we saw low Rb-p and 
Cdc2 indicative for a mitosis block which seems a likely consequence of enhanced DNA 
damage and repair based on increased yH2A.X-p levels. These observations contribute 
well to the idea previously proposed about accelerated cell cycle induced endoreplication 
during epidermal differentiation (Figure 2C) (Gandarillas, 2012). In addition to this idea, we 
showed increasing EGF-ERK activity in differentiating ITGB1 low cells, suggesting a potential 
role for EGF signaling in accelerating the cell cycle possibly via Myc. However, this enhanced 
EGFR/ERK activity could be an artefact of our in vitro model in which cells are cultured in 
medium supplemented with EGF. On the other hand, publicly available RNA-seq data from 
different time points during epidermal differentiation does contain evidence for increased 
EGFR ligand expression by the cells themselves (Lopez-Pajares et al., 2015). Moreover, 
with EGF signaling activated during differentiation, loss of integrin expression seems the 
strongest initiator of differentiation. Through this, pathways driving differentiation such as 
BMP and Notch may also be activated independent of EGF signaling inactivation. Although 
speculative, in the absence of integrin signaling and presence of BMP and Notch pathway 
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activity, increased EGF signaling activity maybe focused on activation of Myc and subsequent 
acceleration of the cell cycle leading to endoreplication.
Figure 2: Active EGF signaling, accelerated cell cycle and mitosis block during epidermal differentiation. 
(A, B) Scaled antibody count data of EGF signaling components and cell cycle regulators from Chapter 2, 
visualized along the differentiation trajectory pseudotime as in Chapter 2, figure 2D-F. Dots represent bins 
of 10 cells and the average scaled antibody count per bin (C) Schematic overview of the accelerated cell 
cycle model inducing an irreversible mitosis block with EGF signaling as suggested driver. The illustration 
is based on a previously proposed model (Gandarillas, 2012).
Accumulating phosphorylation upstream drug induced signaling blocks
Signaling pathways are considered to have specific roles. In cancer therapies, drugs 
have been developed to block proliferation through targeting specific pathways such as 
the EGFR signaling. However, pathways are also interconnected. Targeting one pathway 
could therefore affect another pathway too. When cells all respond similarly and with the 
same pace, it is sufficient to look at the average drug response of a cell population, but 
practically there is always heterogeneity in how cells respond. Looking at the average result 
could be misleading and therefore requires single cell analysis. In Chapter 4, scID-seq 
was used to look at the effects of signaling blocks induced by two distinct drugs targeting 
the kinases p70S6K and p90RSK respectively. Both kinases phosphorylate RPS6 and they 
are both regulated by EGFR. A remarkable observation with both drug treatments was the 
accumulation of phosphorylation upstream the targeted kinases. The single cell analysis 
demonstrated that not all cells responded identically. Upon p70S6K inhibition, only a 
subpopulation showed increased upstream Akt phosphorylation and this were also the cells 
showing dynamics in other pathways. The inhibition of p90RSK showed a strong increase of 
upstream ERK phosphorylation as well as MAPK-APK2 phosphorylation in all cells. However, 
some cells had extra high ERK-p and other cells had extra high MAPK-APK2-p, indicating 
distinct drug responses within the cell population. These findings clearly demonstrate that 
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signaling blocks can affect upstream signaling that in turn, affect other pathways in the 
signaling network as discussed in Chapter 4.
In the normal situation without drugs, a kinase such as Akt or ERK is subject to a balance 
between phosphorylation and phosphate removal by phosphatases. After a stimulus, the 
phosphorylated form of the kinase will increase. The stimulus type, length and strength will 
determine how far the signal will reach and how the cell responds (Manning and Toker, 2017; 
Shaul and Seger, 2007). For instance, in the neuron like PC12 cell line, EGF stimulation of 
EGFR leads to transient but strong activation of ERK and facilitates proliferation. However, 
when EGF stimulation is prolonged, differentiation is induced. This effect is comparable 
with nerve growth factor (NGF) stimulation which is shown to induce differentiation via 
a sustained activation of ERK (Shaul and Seger, 2007; Traverse et al., 1994). Therefore, 
mutants in the signaling cascade or drug treatments can have an enormous impact on the 
response of a stimulus. A recent study with the RAS-ERK pathway demonstrated that slowed 
inactivation of mutated Raf upstream ERK led to a 10 times longer increased phosphorylation 
of ERK (Bugaj et al., 2018). This indicates that the mutant will transmit one stimulus for 20 
minutes while normal cells are able to distinguish and transmit stimuli every 2 minutes. This 
shows how a mutation and subsequent longer activation affects the signaling resolution of 
a pathway and therefore the downstream processes such as transcription. In Chapter 4, 
p90RSK inhibition with the BI-D1870 drug also induced enhanced ERK phosphorylation. In 
the discussion of Chapter 4 and in previous reports, inactivation of a negative feedback loop 
via p90RSK inhibition was suggested as explanation for this inhibitory effect (Dufresne et al., 
2001; Sapkota et al., 2007). This abrogated feedback effect via upstream Sos is not present 
in each cell line/type and is most likely depended on the p90RSK baseline levels (Sapkota et 
al., 2007). Furthermore, in BI-D1870 responsive Rat-2-cells, ERK phosphorylation was still 
enhanced after 160 minutes preceded by a peak around 80 minutes (Sapkota et al., 2007), 
indicating that p90RSK inhibition induces a prolonged ERK phosphorylation. As Inhibition of 
p70S6K with PF4708671 led to increased phosphorylation of upstream Akt, an inactivated 
negative feedback loop via p70S6K inhibition was suggested as well. The phosphorylation 
of p70S6K by Akt goes via mTOR. Inhibition of mTOR with Rapamycin also enhances Akt 
phosphorylation and was shown to depend on the regulation of IRS1/2 upstream of Akt 
(Badalà et al., 2014; Wang et al., 2017). Similarly, Akt phosphorylation may be enhanced 
by p70S6K inhibition. 
Abrogated negative feedback is a likely explanation for the accumulation of upstream 
activity shown in Chapter 4. To confirm this, activity of factors upstream Akt and ERK, such 
as IRS1/2 and Sos should be measured. However, it could be that the abrogated negative 
feedback may not be the reason, or only reason of the accumulating activity upstream. It 
is known that unphosphorylated ERK is already in complex with p90RSK (Ballif et al., 2005; 
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Roux and Blenis, 2004). Upon phosphorylation of ERK by MEK, a series of phosphates is 
added to p90RSK which fully activates p90RSK resulting in the release of ERK (Ballif et 
al., 2005; Roux and Blenis, 2004). The question is, does this release of ERK mediate its 
dephosphorylation? This would mean that ERK phosphorylated in the absence of p90RSK 
has a longer life-time leading to accumulation of ERK-p. A possible mechanism, as described 
here, could imply that accumulating upstream activity may not only rely on abrogated 
negative feedback to upstream signaling components. 
Both drugs tested in Chapter 4 were developed as potential drug in cancer treatment and 
long term treatment previously showed that they both induce cell arrest and differentiation 
in epidermal stem cells from healthy donors (van Buggenum et al., 2018). With scID-seq we 
were able to show how these cells individually respond on the signaling level after 2 hours. 
Given the cell arrest on the long term, it would be interesting to investigate how signaling is 
affected by longer treatment with these drugs. In cancer cells, cell arrest induced by drugs is 
a desired outcome. As these cells are deregulated compared to healthy cells, scID-seq would 
be an interesting tool to address signaling differences between cancer cells and healthy cells 
in response to drugs.
Concluding remarks and future perspectives
This thesis described the development and application of CRISPR screening and Single cell 
Immuno Detection by sequencing applied on epidermal stem cells to study their signaling, 
transcription and differentiation. In Chapter 2, scID-seq demonstrated activity dynamics of 
several differentiation associated pathways such as Notch and BMP signaling, but also activity 
of Wnt signaling and EGF signaling as well as dynamics of cell cycle regulators and a marker 
for DNA repair. In Chapter 3, components of Notch, BMP and Wnt signaling were also found 
with the genome-wide CRISPR screen applied on differentiating epidermal cells. In Chapter 
2, BMP signaling was further addressed during differentiation and led to new insights about 
the timing of BMP activity and its role in regulating the MAF/MAFB transcriptions factors 
which are responsible for an important transcription program in epidermal differentiation. 
In addition, further interpretation of the scID-seq data from Chapter 2 led to supporting 
evidence for the idea about the accelerated cell cycle activity via Myc and Cyclin E. This is 
thought to drive endoreplication, a process that may be important for cell size expansion 
and enhanced barrier protein production (Gandarillas, 2012). Although important for the 
epidermis function, this process seems dispensable for epidermal stem cell differentiation. 
Therefore, EGF signaling activity could be important in this while EGFR inhibition is also 
a trigger for epidermal stem cell differentiation. Moreover, EGF signaling is an intensively 
studied pathway as target for cancer drug therapies and led to development of drugs 
targeting the receptor or downstream kinases in the cell. As demonstrated in Chapter 4, 
scID-seq also represents a powerful approach to address the effects as well as side-effects 
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of targeted drug treatments in single cells. Beside downstream inactivation of the pathway, 
targeting p70S6K and p90RSK showed in many cells increased phosphorylation for upstream 
pathway components and in these cells, other pathways were affected as well. With scID-
seq we demonstrated an interesting tool, to address these generally unwanted/unexpected 
drug treatment effects.
The effect on signaling by kinase inhibitors was demonstrated with scID-seq in epidermal 
stem cells from healthy human donors. Through this we gained information about the 
signaling response in healthy cells. In malignant cells, signaling is generally deregulated 
compared to the healthy cells. Assessment of drug responses in cancer lines would be the 
next step to take. Through this, the difference in response by cancer cells can be addressed 
compared to healthy cells as reference. This could demonstrate that different pathways are 
affected, but it can also tell how heterogeneous cancer cells respond to a drug. Generally, 
cancer drugs are meant to stop proliferation. It is therefore beneficial if the effect of a 
drug on cancer cell growth may be linked to particular differences in signaling compared 
to healthy cells. For this, specific measurement of many (phospho-)proteins in single cells 
is essential which is possible with the scID-seq method developed and demonstrated in 
Chapter 2 and 4. Similarly, the CRISPR screen in Chapter 3 was conducted on healthy 
epidermal stem cells treated with an EGFR inhibitor drug. Applying this screen on cancer 
cells could for instance tell whether different genes are important in these cells for AG1478 
sensitivity. In addition, instead of positive selection screening, a negative selection screen 
can be applied when cancer cells are resistant to EGFR inhibition. This could tell which genes 
have become important for the proliferative capacity instead of the genes that depend for 
this on the EGFR in cells sensitive for EGFR inhibition.   
In this thesis, I also discussed a potential paradox about the role of EGF signaling in epidermal 
differentiation. EGFR inhibition was used as robust trigger for differentiation, but we also 
showed increased phosphorylation of EGFR and ERK within differentiating ITGB1 low cells. 
In addition, the contribution of an accelerated cell cycle was described and demonstrated 
to occur in these cells as well. As EGF signaling is known to promote proliferation and thus 
cell cycle progression, I argued that the co-occurrence of EGF signaling activity and an 
accelerated cell cycle are possibly linked. However, further research should demonstrate 
that increased EGF activity is not an artefact of our in vitro model, but indeed a driver of an 
accelerated cell cycle during epidermal differentiation. An interesting experiment would be 
the application of scID-seq on AG1478 treated cells. This would demonstrate inactivation of 
the EGF signaling and how this possibly affects cell cycle acceleration within individual cells. 
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SUMMARY
Self-renewal and differentiation constitute a balanced process essential for tissue 
maintenance. In the epidermis, basal cells represent the stem cells responsible for the 
maintenance. They have a unidirectional differentiation path which makes them an interesting 
and facile differentiation model. The work in this thesis involved the use of this model 
and the development of innovative and novel techniques. This led to interesting concepts 
about epidermal signaling, transcription and differentiation. In Chapter 2, we developed 
the scID-seq method and observed dynamics in multiple pathways along a pseudotimed 
differentiation trajectory which was created using information from single cells about the 
expression of self-renewal and differentiation makers. BMP signaling activity increased at 
different levels (ligand, receptor and intracellular signaling), indicating the activation of 
a (potentially autocrine) signaling loops. Further investigation established the MAF/MAFB 
transcription factors as BMP signaling targets, which connects the BMP signaling with a 
prominent transcription program in epidermal differentiation. The findings in this chapter 
present BMP signaling as a (potentially) self-sustaining driver of epidermal differentiation. 
In Chapter 3, AG1478 was used to inhibit EGFR for the development of a differentiation 
screen assay tailored for genome-wide CRISPR screening. This enabled the discovery of 
genes important for the growth arrest as well as the initiation of differentiation triggered 
by AG1478. With genes from the Notch and BMP signaling, known regulators of epidermal 
differentiation were found in a list of selected hits together with multiple other genes that 
possibly act on growth arrest and/or differentiation such as canonical Wnt genes. The data 
of this screen is therefore an interesting resource for the discovery of novel genes important 
for AG1478 sensitivity in epidermal stem cells. In Chapter 4, we applied our scID-seq 
method to address the effects on signaling introduced by drug treatments targeting the 
EGF regulated RPS6 kinases p70S6K and p90RSK in single cells. As expected, downstream 
RPS6 phosphorylation diminished, but upstream phosphorylation was increased and other 
pathways were affected as well. This indicates how pathways are connected, but more 
importantly, it shows how targeted drug therapies unintentionally affect other pathways 
that are not necessarily downstream the inhibited signaling molecule. In Chapter 5, we 
demonstrate CRISPR-cas9 as a great tool for characterizing antibody specificity, as non-
specific binders can be demonstrated best through the removal of the antigen. For the 
widely used AGO2 11A9 antibody, we therefore genetically deleted the antigen with CRIPSR-
Cas9. Through this approach, we revealed cross-reactivity with other proteins than AGO2. 
This included strong interactions with SWI/SNF which forces the field to reinterpret previous 
findings with this antibody. Altogether, this thesis involved the development of an innovative 
CRISPR screening approach and a novel scID-seq method which provided new insights about 
signaling and transcription in epidermal self-renewal and differentiation. 
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SAMENVATTING
De huid beschermd ons tegen de buiten wereld en bestaat uit verschillende lagen 
van weefsels waarvan de epidermis de bovenste laag is. Voor het in standhouden van 
de epidermis spelen epidermale stamcellen een belangrijke rol. Zij kunnen zichzelf 
vermenigvuldigen wat proliferatie heet, maar ze kunnen er ook voor kiezen om één van 
de twee gevormde cellen uit te laten rijpen met een specifieke functie in het weefsel. Dit 
proces heet differentiatie. De balans tussen proliferatie en differentiatie is erg belangrijk, 
want als deze verloren gaat kunnen ziektes ontstaan zoals kanker en psoriasis. Voor dit 
proefschrift is gebruik gemaakt van epidermale stamcellen als model om de regulatie van 
proliferatie en differentiatie te onderzoeken op het moleculaire niveau. Op dit niveau is 
gekeken naar DNA-, RNA- en eiwitmoleculen. Het DNA is opgebouwd uit hele lange ketens 
bestaande uit vier verschillende bouwstenen met een eigen base: Adenine (A), Cytosine 
(C), Guanine (G) en Thymine (T). Hierdoor vormen de bouwstenen sequenties en delen 
daarvan coderen voor onze genen. In totaal bevat het DNA in een menselijke cel ongeveer 
18000 genen. De combinatie van actieve genen bepalen de vorm en functie van een cel. 
Bij gen activatie worden RNA-moleculen gevormd op basis van de DNA-code. Dit proces 
heet transcriptie. RNA functioneert als blauwdruk voor de productie van eiwitten met een 
specifieke functie in de cel. Dit kunnen allerlei functies zijn. Op de cel zitten bijvoorbeeld 
heleboel receptoreiwitten. Deze kunnen actief worden door binding met specifieke eiwitten 
buiten de cel wat binnen in de cel vervolgens leidt tot activatie van signaal eiwitten. Vaak 
wordt in serie een hele reeks eiwitten geactiveerd. Dit heet een signaleringsroute. Deze 
routes kunnen weer eiwitten met een transcriptie functie regulieren waardoor specifieke 
genen worden geactiveerd of juist geïnactiveerd. Signalen van buiten de cel kunnen daarom 
invloed hebben op de keuze van de stamcel om te gaan prolifereren of differentiëren. Om 
dit te bestuderen hebben we single cell ID-seq opgezet, een techniek waarmee heleboel 
eiwitten tegelijk meetbaar zijn in één cel. De techniek gebruikt antilichamen die specifiek 
binden aan een (actief) eiwit. Om deze binding te meten is elk antilichaam gekoppeld aan 
een synthetisch DNA-molecuul met een specifieke code die kan worden afgelezen met 
een sequence instrument. Dit instrument kan veel DNA-codes tegelijk lezen en daarnaast 
bijhouden hoe vaak een DNA-code gelezen wordt per cel. Een ideale techniek om veel 
(actieve) signaleringseiwitten te meten. In Hoofdstuk 2 hebben we met deze techniek 
verschillende signaleringsroutes in proliferatieve en differentiërende cellen bekeken en in 
Hoofdstuk 4 hebben we twee drugs bestudeerd die signaleringseiwitten blokkeren in twee 
routes die belangrijk zijn voor cel proliferatie. In Hoofdstuk 3 en 5 is gebruik gemaakt van 
een andere techniek, namelijk de recent ontwikkelde CRISPR-Cas9 technologie waarmee 
specifieke DNA-codes verandert kunnen worden in een cel. Op deze manier kan een gen 
worden gemuteerd en geïnactiveerd door de code te veranderen. In Hoofdstuk 5 is het 
AGO2 gen op deze manier gemuteerd om bevindingen met een antilichaam tegen het AGO2 
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eiwit in niet gemuteerde cellen op juistheid te controleren. In Hoofdstuk 3 is CRISPR 
Cas9 grootschalig toegepast om te zoeken naar genen belangrijk voor cel differentiatie. In 
miljoenen epidermale stamcellen werd willekeurig één van de 18000 genen gemuteerd met 
CRISPR-Cas9 en vervolgens hebben we de cellen gestimuleerd om te differentiëren. Met deze 
screen aanpak konden we naderhand zien welke CRISPR-Cas9 afhankelijke gen mutaties 
correleerde met aanhoudende cel proliferatie ondanks de stimulatie om te differentiëren. 
Dit leverde bekende differentiatie genen op maar ook genen die nog niet eerder in verband 
waren gebracht met epidermale stamcel differentiatie. Samengevat, beschrijft dit proefschrift 
de ontwikkeling en toepassingen van nieuwe moleculaire technieken die een breder inzicht 
hebben opgeleverd over genen belangrijk voor signalering en transcriptie in epidermale 
stamcel proliferatie en differentiatie.  
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met het lab. Voor verschillende projecten heb ik ook ondersteuning gehad van studenten. 
Teun, Mehdjabin en Yan-Ting, graag wil ik jullie bedanken voor jullie inzet en ondersteuning. 
Alles bij elkaar was het Mulderlab een hele prettige werkomgeving waarin ik veel plezier en 
support heb ervaren. Ik kijk terug op een hele leuke periode!
When I started my PhD in the molecular (developmental) biology department, many other 
people started a PhD or Postdoc as well. Getting to know each other was very easy by the 
Friday Afternoon borrels and the many social activities. I really enjoyed the barbecues, 
parties, 4daagse feesten, bowling, and all the other fun activities.  George, Matteo, Boris, 
Bowon, Jakob, Guido, Ila, Georgina, Naomi, Bilge, Menno, Rik, Lisa, Ino, Matthew, Cristina, 
Federica and all the other people that I have not listed here, I would like to thank you for 
the great time that we have spent together. It created a very good working atmosphere! 
To all colleagues in the department I would like to say: thank you for your support during my 
PhD and the social/scientific interactions we had in the lab, in front of the coffee machine or 
during the borrels. The feedback I received on my research during the Wednesday morning 
meetings was very helpful and from many people I received support during my work in 
the lab. Voor hulp bij problemen in het lab en technische vragen wil ik Siebe graag in het 
bijzonder bedanken en voor alle sequence gerelateerde experimenten was Eva van grote 
waarde. In het begin heb ik ook veel gehad aan de hulp van Luan en Nina met de Mass spec 
experimenten waarvoor ik ook regelmatig support heb gekregen van het Vermeulen lab. 
Marion, jou wil ik graag bedanken voor de antwoorden op vele uiteenlopende vragen en voor 
je betrokkenheid. Natuurlijk ook veel dank voor Maria, Anita, Josephine en Lidwien voor het 
regelen van een heleboel zaken zoals bestellingen, declaraties, problemen met accounts en 
nog veel meer.
Guido, Jakob, Matteo, Boris and George, during our time together in Nijmegen, a nice group 
of friends developed. It was nice to share with you the successes and also the struggles 
during the PhD. I enjoyed the lunches, dinners (including countless times at Stoom), beers, 
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and many other activities and events. Highlights were of course Jakob’s bachelor weekend 
and the wintersport in Mayrhofen. Thanks for all the good fun and support!  
Guido en Jakob, ik ben blij dat jullie na deze leuke maar ook zeker inspannende tijd nu ook 
mijn paranimfen zijn. Guido, vanaf het begin hadden we een goede klik. We zochten elkaar 
vaak op en ik vond het erg fijn om dingen met jou te kunnen bespreken. Voor de sportieve 
ontspanning vond ik de potjes squashs ook erg geslaagd, al worden de keren dat ik win 
wel een beetje schaars de laatste tijd… Gelukkig kunnen we ook andere sporten doen zoals 
boulderen of gewoon een biertje drinken. Jakob, in de korte tijd dat we samen in het lab 
hebben gezeten heb ik een beroep op jouw bioinformatica skills gedaan toen ik met (ChIP-)
sequencing data te maken kreeg waar ik nog nooit meegewerkt had laat staan werken 
met command lines in Linux. It was really helpful that you and later on George, could help 
me out with solving the difficulties that I encountered while looking at a black screen with 
command lines. Buiten het lab zorgde jij ook voor leuke experimenten zoals het cider maken 
en bierbrouwen. Nu we toewerken naar onze verdedigingen, vind ik het leuk dat we nog 
regelmatig afspreken voor een lunch, een hapje of een drankje. 
Lieve familie, vrienden en oud-studiegenoten die ik niet heb genoemd. Ik wil jullie bedanken 
voor jullie steun. Voor de ontspanning was het ook erg fijn om naast mijn promotieonderzoek 
leuke dingen te beleven met jullie! 
Lieve mama, je bent een fantastische moeder. Ik wil jou in het bijzonder bedanken voor 
de steun, liefde en belangstelling die je me in de jaren hebt gegeven. Sinds het overlijden 
van papa halverwege mijn masterstudie heb je dit helaas zonder hem moeten doen, maar 
door alle mogelijkheden die je samen met papa hebt gegeven, heb ik wel dit punt kunnen 
bereiken. Lieve papa, helaas ben je niet meer bij ons, maar ik weet zeker dat je heel erg 
trots op me zou zijn.
Timothy, het is super fijn om een broer te hebben zoals jij waarmee ik alles kan bespreken 
en die mij begrijpt. Het is jammer dat we nu wat verder uit elkaar wonen, des te specialer 
is het om af en toe weer samen te zijn om leuke dingen te doen, te sporten of lekker te 
eten. Niken, we zijn tegelijkertijd aan ons PhD avontuur begonnen. Het was erg leuk om 
ervaringen en successen te delen. Ik wil je ook bedanken voor de momenten dat je samen 
met Timothy support hebt geboden en dat ik altijd terecht kan voor advies, feedback of 
bijvoorbeeld de proof-reading van mijn thesis. Jullie zijn erg belangrijk voor mij!
Sanne al vroeg tijdens het promotieonderzoek kwam jij in mijn leven. Je zorgde voor rust en 
het is heel fijn om met jou samen te zijn. Bij stressvolle momenten had je veel geduld met 
mij en wist je me vaak te motiveren. Jouw steun en vertrouwen in mijn kunnen zijn heel 
belangrijk voor mij en ik voel me heel vertrouwd bij jou. Ik hou van jou!
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